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INTRODUCTION
Retinoblastoma is rare but also the most common malignant intra-ocular tumor in young 
children. The incidence is one in 17,000 births in the Netherlands, comparable to incidences 
in other countries such as the United States, United Kingdom, Northern Europe and Singapore 
1;2. In 90%-95% of patients with retinoblastoma, the tumor is diagnosed before the age of 5 
years, and rarely in utero 3 as the immature retina is still developing in these young patients. 
Retinoblastoma has very rarely been reported in older children or young adults 4;5. The disease 
could involve one eye (unilateral retinoblastoma) or both eyes (bilateral retinoblastoma). The 
age at diagnosis is younger for patients with bilateral retinoblastoma as explained below. The 
mean age at presentation for bilateral tumors is 12 months, while that for unilateral tumors is 
24 months 6. 
Genetics 
Retinoblastoma shows a hereditary and non-hereditary form. In 1971, Knudson proposed the 
two-hit hypothesis that retinoblastoma is a neoplasm caused by loss or mutation of both alleles 
of the Rb1-gene, localized on chromosome 13q14 7. In the heritable form, the first hit is a 
germ cell mutation. Every cell in the body already has the first hit. The second hit occurs in a 
particular retinal cell. When only one more hit is necessary to cause neoplastic transformation, 
it is likely that more than one cell, out of millions of cells in the developing retina, will become 
capable of neoplastic growth. In these hereditary patients indeed, more often multiple tumors 
are seen. In contrast, no germline mutation is present in non-hereditary retinoblastoma (60% of 
all retinoblastoma cases) and two independent mutations or hits must occur in the same retinal 
cell to develop a neoplasm. Because it is less likely that two hits in the same cell occur, non-
hereditary retinoblastoma more often presents at a later age and as a solitary tumor and always 
unilateral. Approximately 40% of patients with retinoblastoma have the hereditary form, which 
can be divided into a familial and sporadic hereditary form. The familial hereditary form involves 
a parent or family member with retinoblastoma, proving that one of the parents was the carrier 
of the Rb1 gene. In the sporadic form of hereditary retinoblastoma, the patient is the first person 
in the first generation in the family with retinoblastoma. All bilateral cases of retinoblastoma 
and 15% of the unilateral cases are related to a constitutional (hereditary or de novo) mutation 
of the Rb-1 gene 8. In hereditary retinoblastoma, the germline mutation is highly penetrant 
(90%) and shows an autosomal dominant transmission with a 45% risk of retinoblastoma in 
the offspring. In patients with 13q deletion syndrome with loss of parts of chromosome 13q14 
carrying Rb1 genetic material, retinoblastoma could also develop. Recently, a new form of non-
hereditary retinoblastoma was discovered. These patients present with unilateral retinoblastoma 
at a very young age. This particular form of retinoblastoma develops by amplifications in the 
MYCN-oncogene in the presence of non-mutated RB1-genes9.
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Clinical features and diagnosis
Clinical symptoms of retinoblastoma depend on tumor size, the site of origin and on its growth 
pattern. The most frequent presenting sign of retinoblastoma is a white pupil reflex (leukocoria). 
Strabismus could be a very early sign when a small tumor arises in the macula. Red eye, orbital 
cellulitis, hazy cornea, hyphema (blood in the anterior chamber), discolorization of the iris and 
glaucoma are less common symptoms 10 and are associated with a poor prognosis for globe salvage 
and vision11. In some cases however, other conditions could cause confusion in retinoblastoma 
diagnosis, like Coats’ disease, congenital cataract, persistent hyperplastic primary vitreous, 
retinal detachment, retinopathy or prematurity, toxocariosis, and other 12. In most cases, careful 
clinical examination can differentiate these conditions from retinoblastoma. The diagnosis 
of retinoblastoma is made on clinical grounds with fundoscopy and ultrasound examination, 
which detect the majority of the cases. On fundoscopy, retinoblastoma appears as a white mass. 
Ocular ultrasound demonstrates a echogenic mass in contrast to vitreous, with fine calcifications 
12. In addition, detailed history, physical examination, imaging, DNA analyses and sometimes 
fluorescein angiography are obtained to complete the diagnosis.
Biopsy should be avoided in retinoblastoma because of the risk for extraocular disease 
dissemination13.
Staging
Two classifications are used to stage retinoblastoma; 1) The Reese-Ellsworth classification 
(REC) and 2) the International Classification of Retinoblastoma (ICRB). The REC (table 1) 
was designed to predict outcome from treatment with external beam radiation therapy (EBRT), 
used internationally as the primary eye salvage treatment in the 1980s until introduction of 
chemotherapy 14. The ICRB system (table 2) was developed to predict outcome from combination 
chemotherapy and focal therapy. This system is more relevant to modern therapies than the REC 
and became the standard staging system globally in the early 2000 for tumors contained in the 
eye(s) 15. 
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Table 1: Reese-Ellsworth Classification for Retinoblastoma
Group 1: Very favourable for maintenance of sight:
a Solitary tumour, smaller than 4 disc diameters (DD), at or behind the equator
b Multiple tumours, none larger than 4 DD, all at or behind the equator
Group 2: Favourable for maintenance of sight:
a Solitary tumour, 4 to 10 DD at or behind the equator
b Multiple tumours, 4 to 10 DD behind the equator
Group 3: Possible for maintenance of sight:
a Any lesion anterior to the equator
b Solitary tumour, larger than 10 DD behind the equator
Group 4: Unfavourable for maintenance of sight:
a Multiple tumours, some larger than 10 DD
b Any lesion extending anteriorly to the ora serrata
Group 5: Very unfavourable for maintenance of sight:
a Massive tumours involving more than one half the retina
b Vitreous seeding
DD = disc diameter
Table 2: International Classification of Intraocular Retinoblastoma
Group Characteristics
A Very low risk Small tumors away from macula and optic disc
     Tumors < 3 mm in greatest dimension confined to the retina and
     Located at least 3 mm from macula and 1.5 mm from the optic disc
B Low risk All remaining tumors confined to the retina
     All other tumors confined to retina not in group A
     Subretinal fluid (without seeding) < 3 mm from the base of tumor
C Moderate risk Local subretinal fluid or vitreous seeding
     Local subretinal fluid alone > 3 to < 6 mm from tumor
     Vitreous seeding or subretinal seeding < 3 mm from the tumor
D High risk Diffuse subretinal fluid or seeding
     Subretinal fluid alone > 6 mm from tumor
     Vitreous seeding or subretinal seeding > 3 mm from the tumor
E Very high risk Presence of any one or more of  poor prognostic features
     More than two thirds of globe filled with tumor
     Tumor in anterior segment or ciliary body
     Iris neovascularization, neovascular glaucoma
     Tumor necrosis, phthisis bulbi
Histopathology
Retinoblastoma appears macroscopically as single or multiple white nodules within the retina. 
The tumor may grow endophytically from the inner retinal surface, through the internal 
limiting membrane of the retina towards the center of the globe and spread into the vitreous. 
Retinoblastoma can shed vitreous seedings, which are characterized by clumps of tumor cells 
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floating within the vitreous cavity. Alternatively, the tumor may grow exophytically behind 
the retina and in some cases even results in retinal detachment or subretinal hemorrhage. In 
advanced stages, the tumor may breach the Bruch membrane to invade the choroid. In rare cases, 
retinoblastoma can present as diffuse infiltration of the retina without a specific tumor mass 
16. This form of retinoblastoma, which is more common in older patients can pretend to be an 
intraocular infection of inflammation because of the absence of a mass and the low incidence of 
characteristic calcifications 17. 
Microscopically, retinoblastoma shows a monomorphous mass of small tumor cells with 
a high nuclear-to-cytoplasmic ratio imparting a blue color quality on histologic sections 
stained with hematoxylin and eosin. This sea of small blue cells is sometimes interrupted by 
strands of fibrous ensheated blood vessels and doughnutlike structures formed by the tumor 
cells with a central lumen, the so-called Flexner-Wintersteiner rosettes (or retinoblastomatous 
rosettes). Although characteristic for retinoblastoma, this cell is also seen in pineoblastomas 
and medulloepitheliomas18. A second specialized structure found within retinoblastoma is the 
fleurette in few retinoblastoma tumors 17. A minority of retinoblastoma may also contain Homer-
Wright rosettes, similar to the Flexner-Wintersteiner rosettes but without a central lumen. The 
frequent presence of Flexner-Wintersteiner rosettes characterizes well-differentiated tumors, 
whereas Homer-Wright rosettes may occur in both well- and poor-differentiated retinoblastoma.
  
Prognostic risk factors and local recurrences
Retinoblastoma spreads either by haematogenous metastases or by direct extension through 
the optic nerve and in its meningeal sheath to cerebrospinal fluid 19. Pathology is the golden 
standard to evaluate metastatic risk factors in retinoblastoma. Current pathological risk factors 
include invasion of the anterior eye segment, choroid, sclera and optic nerve behind the lamina 
cribrosa (post-laminar optic nerve invasion, furthermore tumor angiogenesis, extensive tumor 
necrosis and massive choroidal invasion 9;19-23. Children with postlaminar optic nerve invasion and 
massive choroidal invasion require adjuvant chemotherapy to reduce the risk of metastatic spread 
8. Because currently possibilities in non-operative management of retinoblastoma are increasing, 
non-invasive evaluation of these risk factors by imaging is becoming more and more important.
Diagnostic imaging
Fundoscopy under general anesthesia in combination with ultrasound examinations, enables 
detection of more than 91%-95% of the retinoblastomas and are the most important sources for 
diagnosis 24. Only in cases with unclear ocular medium, such as corneal haze, anterior chamber 
hemorrhage or vitreous hemorrhage, the ability of ultrasound to detect small calcifications is 
limited. CT used to be the standard imaging technique to detect calcifications in retinoblastoma 
in about 81%-96% of the tumors 24-26. Owing to the suspected raised radiosensitivity of 
patients with the hereditary form of the disease, CT has been progressively replaced by MRI in 
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detection of tumor extent and tumor staging and is not recommended anymore 27. In suspected 
retinoblastomas, MRI however could be a technique to confirm the diagnosis by detection of 
calcification with T2*-WI. Although this technique seems promising, its diagnostic accuracy 
must be determined 28. 
For evaluation of tumor risk factors, in particular invasion in ocular coats and optic nerve and 
extraocular extension, MRI with its superior contrast resolution is generally recommended as 
diagnostic method in retinoblastoma 24;26. 
Imaging of risk factors 
Pre-treatment staging is important to guide conservative treatment options and determine the 
surgical approach for enucleation in order to prevent postoperative residual intraorbital tumor 
tissue. Children with histopathological risk factors need adjuvant chemotherapy to reduce 
the risk for metastatic spread 13;19;29;30. Despite the fact that pathology is the golden standard 
for evaluation of metastatic risk factors, MRI showed its potential in detecting these tumor 
parameters in vivo 8;31-35. The use of orbital surface coils during imaging instead of head coils is 
generally recommended on 1.5T MR machines, since it increases both the signal-to-noise ratio 
and the spatial resolution 19;22;24;26;36. 
Evaluation of post-laminar optic nerve invasion, massive choroidal invasion, tumor 
angiogenesis and extensive tumor necrosis on MRI, has shown promising results 19;25;31;32;37. 
Interruption of the normal linear enhancement at the optic nerve disc on MRI is suggestive 
for optic onerve invasion 32. Histopathological proven optic nerve invasion is associated with a 
significant increase of metastatic disease and mortality rate 19;22;38. In retinoblastoma with post-
laminar optic nerve invasion, leptomeningeal metastases should be suspected 8. Focal choroidal 
thickening on MRI is a sign of massive choroidal invasion which in itself is a significant predictor 
of metastases 38. 
Tumor angiogenesis is a histopathological risk factor that helps to identify retinoblastoma 
patients at high risk for disease dissemination after enucleation 21. Currently, the degree of 
angiogenesis can only be assessed in vitro on histopathological angiogenic markers, such as 
microvessel density or VEGF expression and its receptors 21;39. Angiogenesis-related risk for tumor 
progression on MRI in retinoblastoma is only described as anterior eye segment enhancement, 
which reflects angiogenesis in the iris and correlates with tumor volume and optic nerve invasion 
33. So far, no evidence for in-vivo evaluation on MRI of angiogenesis in the tumor itself is 
available. A potential MRI application to evaluate tumor angiogenesis non-invasively is dynamic 
contrast enhanced MR imaging (DCE-MRI). The change of signal intensity (SI) over time reflects 
the delivery of the contrast into the tumor interstitial space. The rates of contrast washin and 
subsequent washout from the tumor are related to tissue vascularization and perfusion, capillary 
permeability and composition of the interstitial space and could be a potential non-invasive 
method to evaluate angiogenesis in retinoblastoma 40.
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Extensive tumor necrosis in vitro is significantly associated with high risk prognostic factors 
post-laminar optic nerve invasion and choroidal invasion 20. Although recently, the diffusion 
weighted MRI technique showed adequate differentiation between viable and necrotic tissue 34, 
no imaging method has been described to evaluate the degree of tumor necrosis. 
Depiction of these histopathological risk factors with MRI is not optimal yet. Despite 
relatively high values of specificity for optic nerve and choroidal invasion, variable values for 
sensitivity were assessed due to differences in MRI protocols and rather small patient populations 
with secondarily low incidences of risk factors8;13;23;25;31;33;41.
Retinoblastoma associated intracranial abnormalities
Trilateral retinoblastoma is a primary intra-cranial primitive neuro-ectodermal tumor in a patient 
with intra-ocular retinoblastoma occurring in the pineal gland or suprasellar region. Pineal tissue 
has the same origin as the retina, resulting in histological similar tumors 42. The risk of trilateral 
retinoblastoma depends on the hereditary aspect of the disease and varies from 0,5% - 15% 
43. Trilateral retinoblastoma usually presents with symptoms of intracranial hypertension and 
prognosis is very poor 44-46. Therefore, in every new retinoblastoma patient the brain is imaged for 
analysis of the midline structures to depict trilateral retinoblastoma. The incidence of trilateral 
retinoblastoma at diagnosis of retinoblastoma is unknown, because in the majority of cases 
described in literature no imaging of the brain was performed.
Besides malignant tumors, benign intracranial abnormalities are also reported in retinoblastoma 
patients. Benign pineal cysts are possibly associated with retinoblastoma although the presence of 
these cysts is quite common in the general population 47-50. 
Treatment
The aims of the treatment of retinoblastoma are curing the disease and preservation of life, 
vision and eye. The most radical approach is surgical treatment and is preferred in unilateral 
retinoblastoma diagnosed in an advanced stage with an eye full of tumor and without functional 
vision. 
For a long time radiotherapy (external beam radiation therapy (EBRT) and radioactive plaque 
therapy) was the main conservative treatment as the tumor was rarely reachable for laser ablation 
therapy 51.The late complications of EBRT however were a major concern in the treatment of 
especially hereditary retinoblastoma patients because of its long-term risks 52-54. The increased use 
of focal treatment and chemotherapy was mainly developed to avoid the use of EBRT. Numerous 
conservative treatment options are now available for intraocular retinoblastoma: laser ablation, 
systemic chemotherapy with or without a combination with laser photocoagulation or radioactive 
plaque therapy and in lesser extent EBRT for advanced forms or after failure of other treatments 
55-63. Recently the use of intra-arterial and intra-vitreal chemotherapy, a technique with infusion 
of small doses (but locally very high concentrations) of chemotherapy via the ophthalmic artery, 
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seems promising in retinoblastoma treatment with minimal systemic effect64;65. In most cases, the 
current treatment strategy need a combination of several of the therapeutic modalities indicated 
above. 
Whereas small tumors without extensive vitreous seedings are generally effectively treated with 
focal treatment strategies such as laser ablation, large advanced tumors require tumor reduction 
with intravenous chemotherapy and to a lesser extent radiation or both, to avoid enucleation 66. 
Intra-arterial chemotherapy can be performed repeatedly in young children without significant 
systemic or local side effects and is effective in preventing progression to clinical metastases 
in >95% of the cases67-69. Intravitreal chemotherapy is a recent upcoming treatment strategy 
for retinoblastoma with extensive vitreous seedings70. Preliminary studies show that intravitreal 
melphalan injection for persistent or recurrent vitreous seedings  can provide tumor control 
with minimal toxicity and complications71. Therefore, non-invasive tumor characterization and 
monitoring of treatment response must be evaluated. 
Follow-up of retinoblastoma survivors
Hereditary retinoblastoma survivors have an increased risk for developing second primary tumors 
(SPT)72. Radiation therapy increases this risk with a cumulative incidence of 28% to 36% in 
irradiated patients at 30 to 40 years after diagnosis of retinoblastoma 73;74. In non-hereditary 
retinoblastoma, no increased risk for SPT was found. Chemotherapy containing alkylating agents, 
alone or in combination with radiotherapy, also seems to be involved in the development of 
SPT 75. Osteosarcomas and soft tissue sarcomas are the most well-known SPTs in retinoblastoma 
survivors, particularly in younger individuals 76;77. Radical resection remains the main primary 
therapeutic method for optimal tumor control and cure, but despite aggressive treatment, 
mortality is still very high. 
Other complications from radiation include damage to the optic nerve, cataract (radiation 
damage to the lens of the eye causes a cataract), chronic keratitis and photophobia because of 
dryness due to irradiation of the lacrimal gland, abnormal orbital bone development (midfacial 
hypoplasia) and vitreous hemorrhage, due to radiation retinopathy52;53;63;78. 
European Retinoblastoma Imaging Collaboration (ERIC)
Retinoblastoma is a very rare disease. All retinoblastoma patients in the Netherlands are referred 
to the VU University Medical Center with an incidence of 12 – 15 new patients a year. Because of 
the infrequency of retinoblastoma, we started a European retinoblastoma imaging collaboration 
in 2008 with 4 other participating retinoblastoma reference centers from Paris, Essen, Siena and 
Lausanne. In this collaboration experienced radiologists come to an agreement regarding research 
questions, imaging protocols, and data management for a larger retinoblastoma population to 
stimulate retinoblastoma research. Part of the studies in this thesis were initiated from this 
collaboration. 
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PURPOSE AND OUTLINE OF THE THESIS
The aim of this thesis is firstly to evaluate the potential of different advanced MRI techniques 
to evaluate imaging features involving prognostic factors and treatment response such as 
angiogenesis and tumor necrosis. Secondly, this thesis focused on broader aspects related to 
imaging of retinoblastoma patients. Imaging of potentially related structural brain abnormalities, 
trilateral retinoblastoma and radiation induced second cancers in retinoblastoma survivors.
Imaging is becoming more and more important in the diagnosis of retinoblastoma and is a 
significant factor in the choice of treatment nowadays. Because of the lack of standardization it 
is important to formulate minimal required sequences in retinoblastoma imaging. Due to the 
low incidence of the disease, uniformity of retinoblastoma imaging protocols is also necessary in 
order to stimulate research by multi-institutional international imaging collaboration. In chapter 
2 the minimal protocol requirements formulated by the European Retinoblastoma Imaging 
Collaboration (ERIC) are discussed for retinoblastoma diagnosis, tumor extent and the detection 
of associated neoplasms.
Advanced MRI techniques 
In chapter 3 and 4 the role of advanced imaging techniques for lesion characterization with 
T2*WI and noninvasive evaluation of treatment response and prognostic factors by dynamic 
contrast enhanced imaging are discussed. Calcifications are characteristic for retinoblastoma. 
Chapter 3 describes the ability of T2*WI in visualization of retinoblastoma calcifications. This 
advanced technique is compared with ex-vivo CT scans of enucleated eyes. Although imaging 
with CT is the golden standard in detecting calcifications, avoiding radiation risk by replacing 
CT with MRI is preferable in hereditary retinoblastoma. 
Upcoming conservative treatment options require additional non-invasive imaging parameters 
for assessment of treatment response and prognosis. Histopathological parameters as tumor 
angiogenesis and necrosis are well known parameters in ex-vivo eyes. Chapter 4 describes the 
necessity of noninvasive evaluation of these parameters. The role of dynamic contrast enhanced 
imaging is discussed.
Retinoblastoma associated abnormalities and neoplasms 
Chapter 5 describes structural brain abnormalities and pineal gland lesions associated with 
retinoblastoma in a large group of patients. The results of this study led to the question whether 
specific morphologic characteristics in the brain could be indicative for the development of 
trilateral retinoblastoma. Because trilateral retinoblastoma is very rare, this research question 
could only be answered within the multicenter ERIC collaboration. Chapter 6 discusses the 
clinical findings and MRI characteristics of associated intracranial tumors in retinoblastoma 
patients. 
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Second primary tumors are the leading cause of death in hereditary retinoblastoma survivors in 
the western world. External beam radiation therapy increases this risk. To obtain more insight in 
the presentation and outcomes, imaging characteristics of cranio-facial second primary tumors in 
irradiated hereditary retinoblastoma survivors will be discussed in chapter 7. 
GENERAL DISCUSSION AND CONCLUSION
Chapter 8 summarizes the results of the studies presented in this thesis and discusses the clinical 
implications and suggestions for future research.
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ABSTRACT
Retinoblastoma is the most common intraocular tumor in children. The diagnosis is usually 
established by the ophthalmologist on the basis of fundoscopy and US. Together with US, high-
resolution MRI has emerged as an important imaging modality for pretreatment assessment, i.e. 
for diagnostic confirmation, detection of local tumor extent, detection of associated developmental 
malformation of the brain and detection of associated intracranial primitive neuroectodermal 
tumor (trilateral retinoblastoma). Minimum requirements for pretreatment diagnostic evaluation 
of retinoblastoma or mimicking lesions are presented, based on consensus among members of the 
European Retinoblastoma Imaging Collaboration (ERIC). The most appropriate techniques for 
imaging in a child with leukocoria are reviewed. CT is no longer recommended. Implementation 
of a standardized MRI protocol for retinoblastoma in clinical practice may benefit children 
worldwide, especially those with hereditary retinoblastoma, since a decreased use of CT reduces 
the exposure to ionizing radiation. 
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INTRODUCTION
Retinoblastoma is the most common intraocular tumor in children. The incidence is one in 
17,000 births. Mean age at clinical presentation is 2 years in unilateral forms (60% of cases) and 
1 year in bilateral forms [1, 2]. All bilateral forms, as well as 15% of unilateral forms are related 
to a constitutional (hereditary or de novo) mutation of the RB-1 gene, localized on chromosome 
13q14 [2]. Usually the patients present with leukocoria (white pupil reflection) or a squint. 
Retinoblastoma is curable. If detected while still confined to the globe and if there are no 
metastatic risk factors, the child will nearly always survive following appropriate treatment [3,4]. 
The preservation of visual function depends on ocular preservation, initial tumor volume, the 
anatomical relationships of the tumors to the macula and optic disk and the adverse effects of 
the treatments (cataracts, vitreous hemorrhage) [5]. In the presence of metastatic risk factors, 
adjuvant treatment regimens are usually applied to prevent life-threatening relapse [6,7]. 
Diagnosis of retinoblastoma is usually made by fundoscopy (Fig. 1) (under general anesthesia) 
and US. The ophthalmologist usually performs both investigations. In almost all cases classic 
intratumoral calcifications can be detected by US providing high confidence rate regarding 
diagnosis. Various tumor parameters (laterality; number, location and size of tumors; tumor 
seeding to vitreous, subretinal space or anterior segment) can be evaluated with these techniques. 
These are important for grouping the retinoblastoma and to guide therapeutic decisions. 
Further diagnostic imaging plays a crucial role in determining the local extent and for detecting 
associated brain abnormalities, i.e. intracranial tumor extension, possible midline intracranial 
primitive neuroectodermal tumor (PNET) and brain malformations in patients with 13q deletion 
syndrome [8–10]. 
PNETs are associated with hereditary retinoblastoma, a combination known as trilateral 
retinoblastoma, which occurs in 5–15% of children in the hereditary subgroup [10,11]. Besides 
the pineal region (pineoblastoma), tumors may also occur in the suprasellar or parasellar regions. 
Trilateral retinoblastoma has been lethal in virtually all cases reported in literature; however, 
early detection and intensive (chemo-)therapy may be lifesaving for some patients [10,12,13]. 
Conservative treatment strategies (avoidance of enucleation and external beam radiation 
therapy) can be successful in the early stages of retinoblastoma and in some patients with 
advanced intraocular disease [14]. The options for eye-preserving therapy have significantly 
improved during recent years and are mainly based on tumor reduction with chemotherapy, 
and are usually combined with laser coagulation, cryotherapy or radioactive plaque. Recently, 
selective ophthalmic artery infusion of a chemotherapeutic agent became available as an additional 
treatment option for locally advanced disease [15]. As a consequence, more children are treated 
without histopathological confirmation and, what is more important, without assessment of risk 
factors for disease dissemination and prognosis. Therefore, imaging is very important in local 
staging. 
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Whereas imaging is increasingly used for diagnosis and as a basis for treatment decisions 
in retinoblastoma, there is a lack of standardization for choosing among modalities and for the 
minimum quality of MRI. The purpose of this report is to present a guideline for diagnostic 
imaging of retinoblastoma including a standardized MRI protocol using conventional pulse 
sequences. The potential role of advanced imaging techniques for lesion characterization and 
detection of tumor extent (such as 3D T1W sequences, diffusion-weighted imaging, diffusion 
tensor imaging and MR-spectroscopy) is beyond the scope of this guideline. 
44 
 
 
  
Risk factors for metastasis and local recurrence
Retinoblastoma may spread either by hematogenous dissemination or by direct extension either 
through the bulbar wall into the orbit or via the optic nerve and its meningeal sheath [16]. 
Therefore, current risk factors for metastasis and local recurrence include invasion of the optic 
nerve posterior to the lamina cribrosa (in particular if there is tumor at the surgical resection 
margin), anterior eye segment (AES), or extensive invasion of the ocular coats (massive choroidal 
and scleral invasion) [17–20]. Pathology remains the gold standard to assess high-risk features 
of retinoblastoma. The rate of postlaminar optic nerve invasion in patients treated by primary 
enucleation has been estimated at 7–8% [21,22]. Choroidal invasion is present in 23–42% of 
enucleated eyes, out of which the invasion is massive in about 9–11% [19,23–25]. The exact 
incidence of massive choroidal invasion is unknown, especially since the definition of “massive” 
differs among pathologists. Recently, new consensus criteria were proposed by a worldwide 
collaboration of pathologists and pediatric oncologists [26]. Tumor invasion into the AES is very 
rare, being present in approximately 2% of primary enucleated eyes [24,27–30]. Children with 
histopathological risk factors for metastatic disease require adjuvant chemotherapy to reduce the 
risk of relapse [18–20,31].
Radiation exposure and second primary malignancies in hereditary retinoblastoma
Unlike survivors of non-hereditary retinoblastoma, survivors of hereditary retinoblastoma have an 
elevated risk of developing second (or even more) malignancies with a cumulative mortality rate 
of 17% [32–34]. In patients with hereditary retinoblastoma, the cumulative incidence of a second 
Fig. 1 Fundus photograph shows two tumors. The large white 
mass with prominent feeder vessels is located at the macula 
causing reduced visual acuity. A smaller tumor is located in the 
inferolateral part of the retina. Image courtesy Annette C. Moll, 
Amsterdam
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primary malignancy within 40 years of the initial retinoblastoma is 28% [34]. Chemotherapy has 
been reported to increase the risk of leukemia in survivors of retinoblastoma [35]. Radiotherapy is 
associated with an increased risk of soft-tissue sarcomas in survivors of hereditary retinoblastoma, 
with a reported significant association of radiation dose with the risk of second primary (or more) 
cancers [34,36]. Assuming a linear relation between radiation dose and stochastic risk, several 
studies have demonstrated a theoretical increased risk of CT-associated radiation-induced fatal 
cancers in children [37]. Although low, this risk is likely to be further increased in patients with 
hereditary retinoblastoma, who are known to be genetically unstable, due to the inherited germ 
cell mutation in the RB-1 tumor-suppressor gene. To minimize the development of subsequent 
cancers, survivors of retinoblastoma are advised to avoid unnecessary radiation. Furthermore, 
children undergoing radiotherapy for retinoblastoma may experience abnormalities in the growth 
and maturation of their craniofacial skeleton, resulting in mid-face deformities [38]. For these 
reasons, external beam radiotherapy was dramatically reduced for the conservative treatment 
options, and the principle of minimizing the exposure to ionizing radiation should also be 
applied to imaging. US and MRI should be used instead of CT. The radiation from interventional 
procedures, e.g., selective ophthalmic artery chemotherapy infusion, is also important [39]. The 
radiation dose should be optimized, precisely measured and clearly reported in future publications 
to facilitate balancing risks and benefits both in imaging and therapy. 
CHOICE OF IMAGING MODALITY
US, CT and MRI are the mainstay for imaging of head and neck tumors in children. US is 
particularly useful for examining superficial masses, such as retinoblastoma, whereas CT and MRI 
are used to delineate deeper lesions, particularly those involving the skull base and the central 
nervous system. Nowadays, diagnostic evaluation of retinoblastoma consists primarily of US and 
MRI. Positron emission tomography has become an important modality for cancer imaging in 
general; however, its value in retinoblastoma imaging is currently limited [40]. 
US
The human eye, with its superficial position and its fluid-filled structures, is ideally suited for 
US. Ocular US is usually performed by the ophthalmologist while the child is under general 
anesthesia, but can also quite easily be performed without sedation. In retinoblastoma, US 
demonstrates an irregular mass, more echogenic than the vitreous body, with fine calcifications 
(highly reflective foci mostly with characteristic acoustic shadowing) [41] (Fig. 2). Histologically, 
there is calcification present in approximately 95% of tumors [42]. Calcification is key to 
differentiating retinoblastoma from other mass lesions in a young child. US detects calcifications 
in 92–95% of cases where it is present histopathologically [42, 43]. Retinal detachment may also 
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be observed, which is an important feature to define tumor growth pattern, either endophytic 
or exophytic, or a combination of both. Endophytic tumors arise from the inner layers of the 
retina and grow into the vitreous body. Frequently, small clusters of tumor cells detach from an 
endophytic mass, producing multiple floating tumor islands; this process is known as vitreous 
seeding. Exophytic tumors originate in the outer layers and grow in the subretinal space, which 
causes retinal detachment with subretinal exudate and possible subretinal tumor seeding. Tumors 
with exophytic growth more frequently have choroidal infiltration compared to endophytic 
tumors [44]. Diffusely infiltrating retinoblastoma is a rare histological form characterized by 
diffuse infiltration of the retina without a tumor mass [45]. Tumor height and diameter are 
usually measured at US, as these measurements are used for choice of treatment. Color Doppler 
can be useful for differentiating a vascularized tumor mass from echogenic effusions and for 
differentiation against developmental abnormalities such as persistent hyperplastic primary 
vitreous (PHPV; also known as persistent fetal vasculature, PFV), with the characteristic 
persisting hyaloid artery.
US is not the imaging modality of choice for direct evaluation of metastatic risk factors. Tumoral 
calcifications commonly obscure visualization of the optic nerve [41]. Indirect detection of 
optic nerve invasion by measurement of optic nerve diameter with a 3D-US technique has been 
reported in a single case report [46], hence its value remains unknown. 
44 
 
 
  CT
On CT, retinoblastoma is typically a mass of high density compared with the vitreous body, 
usually calcified and moderately enhancing after iodinated contrast medium administration. CT 
detection of calcifications in retinoblastoma has a sensitivity of 81–96%, and an even higher 
specificity [47]. However, delineation of intraocular soft-tissue detail is limited. The evidence 
from surveys suggests that CT is still regarded an obligatory imaging tool for evaluation of 
Fig. 2 US reveals a hyperechoic tumor occupying the posterior 
segment of the globe. Calcium deposits, seen as highly reflective foci 
(arrows), are pathognomonic for retinoblastoma in a young child
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leukocoria, primarily because CT is supposed to be the best imaging modality for detection 
of intraocular calcifications [47–49]. However, justification of the irradiation of a large group 
of retinoblastoma patients requires a base of evidence of the procedure’s clinical effectiveness 
and possibly also radiation-effectiveness [50] for supplying (1) valuable additional information 
leading toward the diagnosis of retinoblastoma and (2) valuable additional information, compared 
to non-ionizing radiation modalities in detection of tumor extent. 
CT was the first imaging modality used to detect optic nerve invasion [51–53] and is historically 
assumed to be precise in detection of tumor extent [54–56]. However, this assumption is based on 
conflicting outdated literature, without thorough evidence by radiologic-pathologic correlation 
studies. The sensitivity of CT in detection of optic nerve invasion is actually very low, even in 
patients with extensive optic nerve invasion (length of invaded nerve segment > 2 mm) [21, 
51, 53]. The specificity, accuracy and negative predictive value of CT remain artificially high 
because of the relatively low incidence of optic nerve invasion in normal-size nerves. An enlarged 
nerve due to massive tumor infiltration is rare in developed countries. Assuming retinoblastoma 
invasion into the optic nerve produces distortion of the anastomotic vascular network in the 
anterior optic nerve region, Jacquemin and Karcioglu [52] considered that non-visualization of 
the central retinal vessels is a reliable indicator of optic nerve invasion. However, these results 
were not confirmed by other studies [21]. 
MRI
Diagnostic MRI evaluation of a suspected retinoblastoma requires much more than performing 
a routine MR imaging examination of the orbit. High-resolution contrast-enhanced MRI is the 
technique of choice and should be used whenever possible to answer the key clinical questions (to 
evaluate an intraocular mass and to determine disease extent; Fig. 3). MRI has proved to be the 
most sensitive technique for evaluating retinoblastoma, especially regarding tumor infiltration of 
the optic nerve, extraocular extension and intracranial disease [21,22,44,57,58]. A major factor 
influencing the success of MRI is the use of appropriate hardware and optimized pulse sequences 
with appropriate spatial resolution for ocular MRI [21, 22, 44, 57–61]. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
34  |  Chapter 2
45 
 
 
Fig. 3 Transaxial T2-weighted (TR/TE, 3,460/116 ms) (a) and T1-weighted (TR/TE, 374/14 ms) Precontrast 
(b) and postcontrast (c) MRI of exophytically growing retinoblastoma with secondary retinal detachment. 
Retinoblastoma typically has low signal intensity Fig. 3 Transaxial T2-weighted (TR/TE, 3,460/116 ms) (a) 
and T1-weighted (TR/TE, 374/14 ms) precontrast (b) and postcontrast (c) MRI of exophytically growing 
retinoblastoma with secondary retinal detachment. Retinoblastoma typically has low signal intensity
IMAGING STRATEGY
Diagnosis of retinoblastoma
Examination under general anesthesia with fundoscopy and US almost inevitably leads to the 
diagnosis. As US detects foci of calcification in almost all retinoblastomas, there is now little 
benefit of routine CT for detection of calcifications in suspected retinoblastoma. Due to technical 
development, US and MRI are currently almost as accurate as CT for detection of calcifications. 
Recently, Galluzzi et al. [42] showed that when data from ophthalmoscopy, US and MRI are put 
together, no calcifications detected on CT were missed. A high-resolution gradient-echo T2W 
sequence showed promising results regarding detection of calcifications and has been shown to be 
more effective than spin-echo techniques [42, 44]. 
The differential diagnosis of retinoblastoma includes several non-neoplastic lesions that also cause 
leukocoria. After retinoblastoma, which accounts for 47–58% of cases of leukocoria in children, 
other causes in decreasing order of frequency include PHPV, Coats disease, larval granulomatosis 
(Toxocara canis), retinopathy of prematurity, and retinal astrocytic hamartoma [48]. Calcification 
is the most important differentiating feature of retinoblastoma. However, when clinical diagnosis 
remains uncertain, US and MRI help characterize and differentiate intraocular abnormalities, 
especially when ophthalmological evaluation is limited due to opaque ocular refractive media, 
as may occur in all of these conditions. The role of CT in the detection of (sometimes subtle) 
characteristic findings is limited due to its low soft-tissue contrast [48, 55]. 
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Detection of tumor extent
In the past, CT was used to determine tumor size, retro-orbital spread and intracranial growth; 
however, spread within the optic nerve past the cribriform lamina, and infiltration of choroid and 
sclera, which are important prognostic factors, are not reliably assessed with CT [51, 53]. Because 
of its superior soft-tissue contrast, MRI is more sensitive and specific than CT in detection of 
tumor extent and metastatic risk factors. MR imaging using high-resolution protocols is currently 
considered to be the most accurate and valuable tool in pretreatment staging of retinoblastoma, 
without known biological side effects. 
Standardized retinoblastoma MRI protocol
Although individual examinations should always be tailored to the specific queries in individual 
patients (laterality, disease extent, therapy options), there are general recommendations for 
MRI in retinoblastoma. In the following paragraphs we discuss the minimum requirements 
for diagnostic evaluation of retinoblastoma or mimicking lesions according to the consensus 
reached among members of the European Retinoblastoma Imaging Collaboration (ERIC). If 
these recommendations cannot be followed because of technical limitation, ERIC members 
recommend to refer the patient to the nearest (or national) reference center for retinoblastoma, 
where a multidisciplinary team of specialized physicians (ophthalmology, pediatric oncology, 
radiology, pathology, radiotherapy, clinical genetics, psychology) and specialized nurses will 
ensure that practice conforms to the best standards of care. 
Patient handling
Although the technical success of MRI usually depends on the cooperation of the patient, in 
retinoblastoma appropriate sedation techniques or general anesthesia are nowadays widely 
used, with a high yield of diagnostic scans. Nevertheless, in our experience the success rate 
of intravenous sedation is highly dependent on the presence of trained anesthetists and of the 
choice of radiofrequency coils. Especially, the use of small surface coils decreases the success rate, 
because these coils need to be accurately positioned close to the eye. The depth of sedation may 
be insufficient for accurate patient positioning. Therefore, general anesthesia is recommended for 
MRI in children with retinoblastoma. Another advantage of general anesthesia is the possibility 
to ensure that the eyelids are fully closed and to avoid uncontrolled eye movements by putting 
pads (fixed with tape) on the closed eyelids. Thereby susceptibility artifacts caused by air-tissue 
interface or by air bubbles under the eyelids is avoided, which is favorable for the image quality 
in the anterior eye segment. If possible, the MR examination can be combined with fundoscopy 
and US under the same general anesthetic. 
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Hardware
Clinical MRI of orbit and eyes is mostly acquired using the current standard field strengths 
up to 1.5  T. Since adequate imaging of retinoblastoma requires high spatial resolution, the 
field strength of the MR system should be at least 1.5 T. The performance of scans at 1.5 T 
using a head coil is the most practical approach for evaluation of retinoblastoma. However, this 
combination usually gives insufficient signal-to-noise ratio (SNR) at required in-plane image 
resolution and section thickness. Therefore, scanning at 1.5 T should always be performed with 
one or two small surface coils (diameter ≤ 5 cm) to reliably detect small lesions and metastatic risk 
factors (Fig. 4). Indeed, the use of surface coils in ocular tumors has been reported to increase the 
diagnostic accuracy [44, 62]. The main advantage of higher field strengths (3 T) is the increased 
SNR. Publications on ocular 3-T MRI are still limited [63, 64]. At 3 T with multi-channel head 
coil or surface coils one can achieve high-resolution images similar to those obtained at 1.5 T 
with surface coils (Fig. 5). We think the diagnostic accuracy for detection of tumor extent might 
improve, but there is currently no published evidence for this.
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Fig. 5 Transaxial contrast-enhanced T1-weighted (TR/TE, 722/14 ms) image obtained at 3.0 T using 
a 32-channel head coil shows an exophytic retinoblastoma with secondary total retinal detachment and 
proteinacious subretinal effusion
Fig. 4 High-resolution MRI in retinoblastoma. The child is under 
general anesthesia. A small circular surface coil (arrow) is accurately 
positioned close to the affected eye
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Imaging protocol
MRI protocols vary because of differences in available equipment and individual preferences. 
However, despite differences, certain basic elements are common to most imaging protocols 
for retinoblastoma. The minimal requirements for diagnostic evaluation of retinoblastoma 
or mimicking lesions according to the consensus reached among members of the European 
Retinoblastoma Imaging Collaboration (ERIC) are presented below and summarized in Table 1. 
A typical MR imaging protocol for retinoblastoma should always include high-resolution 
imaging of the affected eye(s) and imaging of the entire brain.
Table 1 MRI protocol in Retinoblastoma*
Requirements
Scanner and coils
Field strength above 1 T
1.5 T system combined with one or two small surface coils (< 5 cm diameter)
3.0 T system combined with multichannel head coil
Sequences (minimal 
requirements)
Orbits
Transverse T2-W  (slice thickness ≤ 2 mm) 
Optional: Transverse CISS (Siemens) / FIESTA (GE) / DRIVE (Philips)
Eye(s) and optic nerve(s)
Inplane pixel size < 0.5 x 0.5 mm; slice thickness ≤ 2 mm
Unilateral disease (or bilateral disease with only one eye strongly affected)
     Precontrast   T1-W; at least one plane (transverse or oblique-sagittal)     
                          T2-W; at least one plane (transverse or oblique-sagittal) 
     Postcontrast  T1-W, no FS; two planes (transverse and oblique-sagittal) 
Bilateral disease (both eyes strongly affected)
     Precontrast   T1-W (transverse)    
                         T2-W (transverse) 
     Postcontrast  T1-W, no FS; two planes (oblique-sagittal on both eyes and  
     transverse) 
Brain
Transverse T2-W (slice thickness ≤ 4 mm)
Postcontrast T1-W (2D SE with slice thickness ≤ 3 mm or 3D GRE ≤ 1 mm) 
FS fat-saturation, SE spin-echo, GRE gradient-echo
* consensus among members of the European Retinoblastoma Imaging Collaboration (ERIC)
Orbits
Regardless of laterality, at least one transaxial thin-slice (≤ 2 mm) T2W sequence should cover 
both orbits. For T2W imaging based on a (fast) spin-echo technique, it is recommended to use 
a long TE (heavily T2-weighted; TE ≥ 120 ms) for generating the image contrast necessary to 
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provide an optimal differentiation of retinoblastoma and surrounding vitreous or subretinal fluid 
(Fig. 6). Fat saturation combined with T2W imaging is not recommended. When fat suppression 
is used, the resulting loss in SNR should be compensated (e.g., by increasing the number of 
acquisitions). 
T2W spin-echo may be replaced by gradient-echo T2W sequences such as 3D steady-state 
free precession sequences with slice thickness ≤ 1 mm (Fig. 6; vendor-specific acronyms: CISS 
[Constructive Interference in Steady State, Siemens], FIESTA [Fast Imaging Employing Steady 
State Acquisition, GE Healthcare]; DRIVE [Driven Equilibrium, Philips]) (slice thickness, 
≤ 1  mm). These pulse sequences provide detailed images of both orbits and eyes, and allow 
accurate comparison of eye size, anterior chamber depth and laterality. Very small tumors can be 
depicted with these techniques. 
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Eye and distal optic nerve
Increased spatial resolution will improve the accuracy of MRI in assessing the anatomical details 
of the papilla, lamina cribrosa and pre- and postlaminar segments of the optic nerve [65]. The 
continuous improvement of MR units and the use of small fields-of-view with either multi-
channel head coils or surface coils now allows much higher image resolution. High spatial 
resolution means section thickness ≤ 2 mm and in-plane pixel size ≤ 0.5 × 0.5 mm. For optimal 
detection of optic nerve invasion, the image plane through the orbit (transaxial and sagittal 
oblique) should align with the orientation of the distal (1 cm) end of the nerve, just posterior to 
the lamina cribrosa (Fig. 7). One section in each of these sequences should be precisely aligned 
within the distal part of the optic nerve at the level of the middle of the optic disk. Although the 
use of the fat-saturation technique is highly recommended for contrast-enhanced MR imaging in 
orbital pathology, its use in high-resolution contrast-enhanced T1W MRI in retinoblastoma is 
Fig. 6 a Thin-slice transaxial T2-weighted (TR/
TE, 4,430/102 ms; section thickness, 2 mm) image 
demonstrates retinoblastoma of the right eye with 
secondary retinal detachment. b Transaxial constructive 
interference steady-state (TR/TE, 14/7 ms) image 
of bilateral etinoblastoma with secondary retinal 
detachment. Notice the shallow anterior chamber of 
the right eye, a sign of increased intraocular pressure
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declining [44, 58]. In the minimal requirements for diagnostic evaluation of retinoblastoma or 
mimicking lesions according to the consensus reached among members of the ERIC, the use of 
fat saturation in contrast-enhanced T1W sequences is no longer recommended. 
•   Transaxial or sagittal oblique T1W spin-echo helps detection of intraocular blood and 
subretinal fluid with high protein content. Retinoblastoma is slightly hyperintense with 
respect to the vitreous body. 
•   Transaxial or sagittal oblique heavily T2W spin-echo provides detailed information about 
the classic low signal intensity of retinoblastoma and presence of retinal detachment. 
•   Transaxial and sagittal oblique contrast-enhanced T1W spin-echo provides information 
about the enhancement of lesions, optic nerve- and ocular wall invasion, and anterior eye 
segment enhancement.
The recommended protocol for high-resolution MR imaging of the eye(s) and distal optic nerve(s) 
differs slightly between unilateral or bilateral disease (Table 1, Figs. 8-9). Incidence of metastatic 
risk factors is highly dependent on tumor location and tumor size. Therefore, a distinction is 
made between bilateral disease with only one eye strongly affected (high-resolution MRI can be 
performed in the worst affected eye only) and extensive disease in both eyes (high-resolution MRI 
of both eyes). 
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Fig. 7 Recommended slice positions. One T2-weighted section in the sagittal oblique plane and one in the 
transaxial plane should be precisely aligned at the middle of the optic disk and the distal (at least 1 cm) 
end of the optic nerve. a Correct alignment of transaxial sections. b Correct alignment of sagittal oblique 
sections. c Detailed view of the distal optic nerve (line segment: imaging axis; distal 1 cm of the optic nerve 
between red dots) 
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Fig. 8 In unilateral retinoblastoma (or bilateral disease with only one eye strongly affected), high-resolution 
MRI is done in the (most) affected eye only. Imaging example of a left unilateral lesion. a Sagittal oblique 
T2-weighted(TR/TE3,460/110ms)image. b Transaxial precontrast T1-weighted (TR/TE 360/13 ms) image. 
c Transaxial postcontrast T1-weighted (TR/TE 360/13 ms) image. Notice the inhomogeneous enhancement 
pattern, which is common in retinoblastoma
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Brain
The brain should always be imaged in retinoblastoma patients for analysis of midline structures 
in order to depict trilateral retinoblastoma (i.e. PNET located mainly in the pineal gland, or more 
rarely in suprasellar area) or leptomeningeal spread. For a patient presenting with leukocoria 
suspicious of having retinoblastoma or already diagnosed as retinoblastoma based on clinical 
findings and US, the baseline evaluation should include an MR imaging of the brain that meets 
the standardized protocol. Imaging of the brain is performed with (multi-channel) headcoil only 
and should at least include the following or similar types of sequences: 
•   Transaxial fast spin-echo T2W sequence (slice thickness, ≤ 4 mm). This sequence provides 
an overview of the brain anatomy and structural abnormalities (patients with 13q deletion 
syndrome). 
Fig. 9 MRI of bilateral retinoblastoma with extensive 
disease in both eyes should be performed with two 
surface coils. The field of view should be slightly 
increased to cover both eyes in the transaxial plane. 
Imaging example of bilateral lesions: a Precontrast 
transaxial T1-weighted (TR/TE, 360/13 ms) image. b 
Postcontrast transaxial T1-weighted (TR/TE, 360/13 
ms) image
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•   Transaxial or sagittal contrast-enhanced T1W sequence (2D spin-echo T1W with slice 
thickness ≤ 3  mm; or 3D gradient-echo with slice thickness ≤1  mm). This sequence 
provides information about enhancement of the pineal gland, presence of a midline PNET, 
leptomeningeal metastases and extensive optic nerve invasion. 
•   Coronal and sagittal high-resolution T2W sequence (slice thickness, 1.5  mm). These 
sequences are optional but should be added to the protocol in case of an atypical pineal 
gland (partially cystic, irregular, enlarged).
IMAGE ANALYSIS CHECKLIST FOR MR REPORTING (TABLE 2)
Table 2 Retinoblastoma: Checklist for MRI radiology reports
Parameters
Tumor characteristics
SI relative to the vitreous body; moderately high on T1-W and low on T2-W
Laterality
Growth Pattern
Tumor size and location; in contact with optic nerve 
Buphthalmia
Tumor extension
Optic nerve and meningeal sheath invasion
Ocular wall invasion (choroid and sclera)
Extraocular extension
Anterior eye segment 
Anterior chamber depth
Enhancement 
Tumor invasion; ciliary body 
Brain
Trilateral retinoblastoma; pineal gland and supra- or parasellar region
Leptomeningeal metastases
Malformations
SI signal intensity
Tumor size and location
Compared to the vitreous body, retinoblastoma has moderately higher signal intensity on 
T1W and lower on T2W images. Increased size of the globe, globe deformation and reduced 
anterior chamber depth are signs of increased intraocular pressure and are usually associated with 
buphtalmia (Fig. 10). These signs should be mentioned since they are associated with a higher 
risk of globe rupture and secondary orbital seeding during enucleation. Laterality and growth 
pattern should be mentioned as well as the location of the tumor, with respect to the equator of 
the eye (anterior, posterior or combined) and with respect to the papilla (the optic nerve disk) 
and the macula. One should in particular identify tumor close to the optic disk, because this may 
invade the nerve [22] (Fig. 11). 
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Fig. 11 Pre- (a) and postcontrast (b) transaxial T1-weighted (374/14) MR images show small nodular 
enhancement at the optic nerve disk (arrow), which represents superficial optic nerve invasion by intraocular 
tumor seeding (predilection site). c Abnormal contrastenhancement of the anterior eye segment combined 
with macroscopic tumor seedings (arrow)
Optic nerve and meningeal sheath invasion
In normal-size optic nerves, the direct radiological criterion used to diagnose postlaminar nerve 
invasion is the presence of abnormal contrast enhancement (enhancement ≥ 2 mm in diameter) in 
the distal nerve [21] (Fig. 12). Interruption of the normal linear enhancement at the optic nerve 
disk (choroidoretinal complex) supports a suggestion of optic nerve invasion [22]. Postlaminar 
optic nerve or optic nerve menigeal sheath invasion should raise suspicion of leptomeningeal 
metastases. In such situations, additional contrast-enhanced sagittal T1W imaging of the whole 
spine is recommended.
Fig. 10 Retinoblastoma with signs of increased 
intraocular pressure following subretinal hemorrhage 
(fluid–fluid levels). a Bilateral retinoblastoma with 
increased size of the left eye (buphthalmus) and 
a shallow anterior chamber (arrow) seen on T2-
weighted (TR/TE, 4,430/102 ms) image. b Bilateral 
retinoblastoma with focal bulging of the posterior eye 
segment (arrow) of the right eye and a shallow anterior 
chamber seen on T2-weighted (TR/TE, 4,430/102 ms) 
image
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Ocular wall invasion and extraocular extension
Discontinuity of the normal choroidal enhancement is the leading criterion for infiltration 
[22, 24] (Fig. 13). Massive choroidal invasion presents as focal choroidal thickening (Fig. 13). 
Increased enhancement and thickening of the entire uveal tract (choroid, ciliary body, iris) is 
a sign of uveitis, usually secondary to massive (sub) total tumor necrosis [22]. Protrusion of 
enhancing tissue through the thickened choroid into the (low signal-intensity) sclera or beyond 
is a sign of scleral invasion or extraocular extension, respectively.
Anterior eye segment
Anterior eye segment enhancement occurs frequently in retinoblastoma and is usually a sign of 
iris angiogenesis [27, 30]. Tumor invasion into the anterior eye segment (Fig. 11) is an infrequent 
finding, usually associated with anteriorly located retinoblastoma. Enhancement of the tumor 
extending into the ciliary body or beyond should raise suspicion of anterior eye segment invasion. 
Transaxial T2W images of both orbits can be used to depict a decreased anterior chamber depth 
(Fig. 10). 
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Fig. 12 Postcontrast transaxial T1-weighted (TR/TE, 374/14 ms) 
MRI. Abnormal enhancement of the distal optic nerve in continuity 
with tumor is a sign of postlaminar optic nerve invasion
Fig. 13 Postcontrast transaxial T1-weighted (TR/TE, 305/15 ms) MRI. 
Intraocular enhancing retinoblastoma combined with focal choroidal 
thickening and a discontinuity of the linear enhancement pattern of 
the choroid (arrowheads) adjacent to the tumor mass is suspicious for 
tumor invasion. Histopathological examination of this eye showed 
massive choroidal invasion
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Brain
Careful analysis of midline structures should be performed to depict trilateral retinoblastoma 
(i.e. PNET located mainly in the pineal gland, or rarely in the suprasellar area) (Fig.  14) or 
leptomeningeal spread (if patient shows extensive postlaminar optic nerve invasion enhancement). 
Congenital brain malformations occur mainly in patients with 13q- deletion syndrome [10]. 
Benign pineal cysts should not be misinterpreted as pineal PNET, even in children with 
retinoblastoma [10, 66]. Thin-section T2W and contrast-enhanced T1W slices are helpful for 
differential diagnoses. In doubtful cases, close follow-up with MRI is recommended.
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CONCLUSION
Together with US, high-resolution MR imaging has emerged as the most important imaging 
modality in the assessment of retinoblastoma—for diagnostic confirmation and for determination 
of local tumor extent and associated intracranial abnormalities. CT is no longer indicated in 
children with leukocoria because of (1) ionizing radiation and (2) no added diagnostic value. US 
combined with MRI using our suggested standardized retinoblastoma MRI protocol provides 
state-of-the-art pretreatment diagnostic evaluation in children with retinoblastoma. 
Fig. 14 Pineoblastoma in a patient with hereditary unilateral 
retinoblastoma. Postcontrast axial T1-weighted (TR/TE, 
650/10 ms) MRI shows a cystic enhancing mass of the 
pineal gland (arrow) suspicious for pineoblastoma (trilateral 
retinoblastoma)
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ABSTRACT 
BACKGROUND AND PURPOSE: Non-invasive evaluation of retinoblastoma treatment 
response has become more important due to increased use of eye-sparing treatment. We evaluate 
the relation between dynamic contrast-enhanced magnetic resonance imaging (DCE-MR 
imaging) and histopathological parameters to determine its value in assessing tumor angiogenesis 
and provide new radiologic prognostic indicators in retinoblastoma.
METHODS: Fifteen consecutive retinoblastoma patients (mean age 24 months, range 2-70 
months) and enucleation of the eye as primary treatment (15 eyes), were scanned at 1.5T using 
dedicated surface coils. Pre-treatment DCE-MR imaging of the most affected eye was evaluated 
by two observers using curve-pattern analysis. The first 5min of each curve and the full time series 
were described by κ5min and κ17min, respectively. Assessed histopathological and immunologic 
parameters included known metastatic risk factors (optic nerve invasion, choroid invasion and 
microvessel density (MVD)), tumor necrosis, and experession of vascular endothelial growth 
factor (VEGF) and its receptor, Flt-1. 
RESULTS: The median value of κ5min was 1.28 (range 0.87 – 2.07) and correlated positively 
with MVD (P = 0.008).The median value of κ17min was 1.33 (range 0.35 – 3.08), and correlated 
negatively with tumor necrosis (P = 0.002). Other (immuno)histopathological parameters did 
not correlate with DCE-MR imaging parameters. Interobserver agreement for κ5min was 0.53, 
and for κ17min a strong agreement of 0.91 was observed.
CONCLUSION: In retinoblastoma, the early phase of the DCE time curve positively correlates 
with MVD while the presence of late enhancement is correlated with necrosis. Thus, the potential 
for DCE-MR imaging to non-invasively assess tumor angiogenesis and necrosis in retinoblastoma 
tumors is promising and warrants further investigation. 
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INTRODUCTION 
In retinoblastoma, increasing eye preservation and tumor control has been achieved due to 
introduction of conservative treatment strategies. Especially the recent introduction of selective 
intra-arterial chemotherapy infusion via the ophthalmic artery as an effective treatment method 
for intraocular retinoblastoma will dramatically decrease the number of enucleations (1-3). In the 
near future more and more patients will be treated without histopathological confirmation of the 
diagnosis, leading to uncertainty about risk factors that can predict disease dissemination and 
prognosis. Histopathology is still the gold standard for detection of tumor spread and therefore 
prognosis of retinoblastoma (4). Currently, the risk for metastatic disease and the decision about 
the use of prophylactic therapy is based on the following characteristics; (i) tumor invasion in the 
optic nerve posterior to the lamina cribrosa, (ii) invasion in the anterior eye segment, and (iii) 
extensive invasion of the ocular coats (massive choroidal, scleral invasion). These characteristics 
can well be detected on histopathology, but detection by conventional magnetic resonance (MR) 
imaging is not optimal so far (5-13). Therefore, it is important to assess prospects of other MR 
imaging methods that could further optimize the tumor tissue characterization in vivo.
Tumor angiogenesis is a key element in the pathophysiology of tumor growth and metastases. 
It has been shown that tumor microvessel density (MVD) as marker for angiogenesis correlates 
statistically significant with both local invasive growth and presence of metastases in retinoblastoma 
(4;14). Thus, tumor angiogenesis in retinoblastoma is considered to be a metastatic risk factor. 
Currently, tumor angiogenesis can only be assessed in vitro on histopathological specimens by 
assessment of MVD and angiogenic growth factors such as vascular endothelial growth factor 
(VEGF) and its receptor (Flt-1). In addition to promoting angiogenesis these growth factors cause 
an increased vascular permeability in neovascular capillary beds. 
A noninvasive evaluation of tumor angiogenesis might be obtained with dynamic contrast-
enhanced MR (DCE-MR) imaging. Using a fast T1W MR imaging technique before, during 
and after intravenous bolus administration of a gadolinium contrast agent, the change of signal 
intensity (SI) over time reflects the delivery of the contrast into the tumor interstitial space. 
The rates of contrast washin and subsequent washout from the tumor are related to tissue 
vascularization and perfusion, capillary permeability and composition of the interstitial space 
(15-20). To our knowledge, the correlation between DCE-MR imaging and retinoblastoma 
microvasculature has not been described before. However, a noninvasive imaging biomarker for 
tumor angiogenesis in vivo could have potential value in patients treated with eye-preservation 
treatment strategies. 
The purpose of this study was to evaluate the relation between DCE-MR imaging and 
histopathological parameters to determine its value in assessing tumor angiogenesis and providing 
new radiologic prognostic indicators in retinoblastoma. 
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METHODS
Patient population
From May 2006 to September 2009 retinoblastoma patients, diagnosed with extensive fundoscopy 
and ultrasound under general anaesthesia, were included in this prospective study if they met the 
following criteria: (a) having undergone pretreatment DCE-MR imaging, (b) enucleation of the eye 
due to retinoblastoma as primary treatment and (c) availability of diagnostic-quality pathological 
material. Twenty-one patients with retinoblastoma had DCE-MR imaging before enucleation. 
Five patients were excluded because of insufficient histopathological material (3 patients) or 
inadequate DCE-MR images (2 patients) and one patient was treated with chemotherapy prior 
to enucleation. The final study population consisted of 15 patients (5 girls and 10 boys), with 
a mean age of 24 months (median 23 months, range 2-70 months). Five patients had bilateral 
disease of which only the most affected eye was enucleated. Clinical records were reviewed by one 
reviewer (F. R.) to assess age at diagnosis, days between MR and enucleation, laterality, presence 
of vitreous/ subretinal tumor seeding (yes/no), extra-ocular tumor recurrence and last known 
follow-up date. This study was performed in agreement with the recommendations of the local 
ethics committee, with waiver of informed consent.
MR Imaging
All MR imaging examinations were performed under general-anesthesia on a 1.5-T scanner 
(Siemens Sonata; Erlangen, Germany) using a dedicated surface coil focused on the (most) affected 
eye. MR imaging included transversal and sagittal spin-echo T1W images (repetition time/
echo time 420/13ms; 3 and 2 acquisitions respectively) and transversal spin-echo T2W images 
(2470/120ms; one acquisition). All conventional images had an in-plane resolution of 0.58 x 0.58 
mm2 and a slice thickness of 2 mm. Transverse DCE-MR images were obtained with 3D fast low-
angle shot (FLASH), 8.6/4.8ms; flip angle 25°; in-plane resolution of 0.66 x 0.66 mm2. One 3D 
volume consisted of 16 partitions of 3 mm thickness (acquisition time per volume 17s). A total 
of 20 consecutive volumes were acquired in 5min39s. During DCE-MR imaging an i.v. bolus 
injection of 0.2 mmol/L Gd-DTPA (Magnevist, Schering, Berlin, Germany) per kg body weight 
was administered after the first volume. To determine late enhancement, two short DCE series 
consisting of 3 volumes were acquired at t=13 min and t=17 min after contrast injection. After 
each DCE-MR imaging series fat-suppressed T1W spin-echo images were obtained (653/11ms; 
three acquisitions) in transverse, sagittal and coronal orientation. Thus, the three DCE series 
lasted less than 8 min in total and were acquired interleaved with the conventional sequences.
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Image Analysis 
a) Conventional MR imaging
Tumor volume measurements were performed by two observers in consensus (F.R. and P.d.G.) 
on post-contrast transverse T1W MR images with use of a computerized image analysis tool 
(Centricity Radiology RA 600; GE Medical Systems, Milwaukee, WI.). On every slice in which 
tumor was present, this structure was manually outlined as a region of interest (ROI). The ROI 
covered the whole tumor on each slice. Surfaces of the ROIs were calculated and tumor volume 
was obtained from the surfaces on consecutive slices multiplied by slice thickness and interslice 
gap. In addition, tumor enhancement was scored as either homogeneous or heterogeneous.
b) ROI placement for dynamic analysis
DCE-MR imaging data were analyzed using the time series of an ROI, which was placed by two 
observers independently (F.R. and P.d.G.). Both observers were blinded to histological findings. 
On a workstation (Leonardo, Siemens, Erlangen, Germany), ROIs were manually drawn on a 
volume at the end of the first DCE series. The ROI was positioned on one slice within the most 
enhancing part of the tumor. Care was taken to avoid areas with necrosis within the tumor on the 
basis of focal high SI on T2W images and absence of enhancement on postcontrast images. As 
some ROIs were small, it was verified that the position of the ROIs remained strictly within the 
tissue during the dynamic series, and was not influenced by minor motion (despite anaesthesia). 
For each ROI, SI as a function of time was extracted.
c) Dynamic analysis 
Preferably, quantitative analysis of DCE-MR imaging is performed to obtain values of the volume 
transfer constant Ktrans and the volume of extravascular extracellular, i.e. interstitial space per 
unit volume of tissue v
e
 (21). This, however, requires determination of both an arterial input 
function and pre-contrast T1 relaxation times, which were not included in the current protocol. 
Recently, Guo and Reddick (17) have proposed a curve pattern analysis based only on the dynamic 
measurements, yielding a value κ5 which showed a close correlation with the rate constant k
ep
, 
which is defined as k
ep 
=Ktrans/v
e
.
This curve pattern analysis was performed using Matlab (MathWorks, Natick, MA) (PJ.W.P. 
and J.P.A.K.) both for the first DCE time series (resulting in a κ−value for 5min) and for the 
full dataset (κ-value for 17min). The κ17min can therefore be considered as a parameter for late 
enhancement. The analysis was performed on smoothed curves through the actual time points. 
The smoothed SI of the first series (t = 0 - 5minutes 39 seconds) was estimated by an exponential 
fit of the form S(t)=S(0)exp(-k(t-∆t) in which ∆t incorporates the time delay of contrast injection. 
For each of the second and third series (at t = 13 min and t = 17 min) the SI of the three volumes 
within these series was simply averaged.
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Histopathological analyses and immunohistochemical staining
All included eyes were re-evaluated by one pathologist (P.v.d.V.) with 11-years of experience in 
ophthalmopathology, who was blinded to patients’ clinical records and MR imaging findings. 
Histopathologic evaluation, using hematoxylin-eosin (HE) staining, included the following: 
tumor necrosis (semi-quantitatively estimated according to the percentage of necrotic tumor area); 
involvement of choroid (inflammation; minimal or massive tumor invasion); optic nerve invasion 
((pre)laminar or postlaminar); tumordifferentiation (poor-, moderate- and well-differentiated). 
From all affected eyes, deparaffinized 4-μm sections were immunohistochemically stained 
by using the avidin-biotin-peroxidase complex and direct antibodies against CD-31 (DAKO, 
Glostrup, Denmark), VEGF (Santa Cruz Biotechnology, Santa Cruz, CA) and VEGF-receptor-1 
(Flt-1) (Santa Cruz Biotechnology). In representative parts of the tumor, in 5 high-power-fields 
(magnification, x20) the mean MVD of tumor was calculated on CD-31 stained specimens. 
Evaluation of VEGF and Flt-1 staining intensity in the tumor was graded as follows: negative, 
weak or strong staining. These methods have been described previously by De Graaf et al (9). 
Statistical analysis
Interobserver variability for κ5min and κ17min was analyzed by calculating the intraclass 
correlation coefficient (ICC). Subsequent analyses were performed using the average of the two 
observers. All statistical calculations were performed using SPSS, version 15.0 (SPSS, Chicago 
III). Spearman rank correlations were calculated to test the strength of the association between 
DCE-MR imaging parameters and histopathologic parameters. Only two-tailed tests were used. 
A P-value of less than .05 was considered statistically significant. 
RESULTS
Clinical findings
MR imaging was performed at a mean of 6 days (median, 6 days; range 1 – 13 days) before 
enucleation of the eye. In 6 out of 15 eyes, vitreous and/or subretinal seedings were observed. 
Mean follow-up time after enucleation was 35 months (range 10 - 54 months). No patients 
developed histological proven extra-ocular recurrences and all patients were still alive at the time 
of follow-up. 
Conventional and DCE-MR imaging parameters 
Results of all patients are summarized in Table 1. Mean tumor volume was 2513 mm3 (range 
288-4847 mm3). All 15 tumors showed heterogeneous enhancement, as for example shown in 
fig 1-3.
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Table 1: Dynamic MR imaging and histologic findings in retinoblastoma patients
Patient Tumorvol- κ5min κ17min  MVD VEGF-Rb Flt-1 Optic nerve Choroid Necrosis 
ume (mm3) invasion invasion (%)
1 1690 2.07 1.53 29 weak weak no no 5
2 4782 1.74 3.08 21 negative positive postlaminar no 10
3 656 1.01 0.35 21 negative negative (pre)laminar no 90
4 2927 0.93 0.69 10 weak negative (pre)laminar no 50
5 4727 1.26 0.61 14 positive negative postlaminar minimal 70
6 2664 0.93 1.49 11 weak weak no no 20
7 1955 1.44 2.50 37 positive negative (pre)laminar no 0
8 2153 0.87 0.85 11 positive negative no no 5
9 2333 0.97 1.06 11 weak negative no no 30
10 960 0.99 1.53 23 positive negative postlaminar no 10
11 1931 1.84 1.07 17 positive weak no no 10
12 4463 1.05 1.02 12 positive weak (pre)laminar no 50
13 1325 1.20 1.28 15 weak weak (pre)laminar no 15
14 288 1.80 2.30 16 weak negative no no 20
15 4847 1.12 0.62 27 positive negative (pre)laminar no 50
Note: MVD = micro vessel density
DCE-MR imaging parameters determined in all 15 patients by both observers resulted in an 
intraclass correlation coefficient of 0.53 for κ5min, and 0.91 for κ17min. A comparison between 
the two observers showed that one patient (patient 15) with a large and heterogeneous tumor was 
the main cause of disagreement. When disregarding this patient, and considering 14 out of 15 
patients, intraclass correlation coefficient for κ5min increased to 0.92, while intraclass correlation 
coefficient for κ17min did not change.
A large range was observed both for κ5min (mean 1.28; median 1.12; range 0.87 – 2.07) and 
κ17min (mean 1.33; median 1.06; range 0.35 – 3.08). Examples of the DCE curves of 3 patients 
as measured by one observer are shown in Fig. 1-3. Fig. 1c (patient 9) shows a slow initial uptake 
of contrast agent, resulting in a low value for κ5min of 0.76. Seventeen minutes after contrast 
injection, SI of tumor continues to increase slowly, resulting in an intermediate value for κ17min 
of 1.06. Fig. 2c (patient 2) shows another dynamic behaviour: a fast uptake of contrast agent with 
maximum SI reached already 3min after contrast injection, resulting in κ5min = 1.67. At later 
time points the SI remains similar, resulting in κ17min = 2.79. Generally, a steep slope and an 
early arrival at equilibrium lead to a higher κ-value, causing the high value of κ17min in this 
case. Instead, if the curve continues to increase during the 2nd and 3rd time series, κ5min and 
κ17min have more similar (and lower) values, as illustrated for patient 5 in Fig. 3. In our study, 
in none of the tumor ROIs a clear decrease of SI could be observed in the covered time frame of 
17 min. 
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Fig 1. Retinoblastoma tumor in the right eye 
(patient 9) with transverse T2-weighted spin-
echo (A) and transverse contrast-enhanced 
T1-weighted spin-echo (B) MR images. 
Curve-pattern analyses of the signal intensity 
curve of 1 observer (C) shows slow initial 
uptake of contrast (κ
5min
  = 0.76) and slow 
further rising of the curve (κ
17min
  = 1.06). 
Immunohistochemical staining with CD-
31 (original magnification ×10) (D) shows 
brown-stained microvessels on a background 
of blue tumor cells with a MVD of 11. 
Hematoxilin-eosin staining (E) illustrates 
30% necrotic areas (arrow).
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Fig 2. Retinoblastoma tumor in the right eye (patient 2) with transverse T2-weighted spin-echo (A) and 
transverse contrast-enhanced T1-weighted spin-echo (B) MR images. Curve-pattern analysis of the signal 
intensity curve of 1 observer (C) shows fast uptake of contrast agent (κ
5min
  = 1.67) and early arrival at 
equilibrium (κ
17min
 = 2.79). Immunohistochemical staining with CD-31 (original magnification ×10) (D) 
shows a high MVD of 21, and hematoxilin-eosin staining shows only 10% necrosis (arrow) (E).
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Fig 3. Retinoblastoma tumor in the right eye (patient 5) with transverse T2-weighted spin-echo (A) and 
transverse contrast-enhanced T1-weighted fat-suppressed spin-echo (B) MR images. Curve-pattern analysis 
of the signal intensity curve of 1 observer (C) shows a moderate uptake of contrast agent (κ
5min
 = 1.22) 
and a continuing increase leading to κ
17min
 = 0.84. Immunohistochemical staining with CD-31 (original 
magnification ×10) (D) shows an MVD of 14. Hematoxilin eosin staining (E) shows a large area of necrosis 
(70%) (arrow I) in vital tumor tissue (arrow II).
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Histopathologic and Immunohistochemical Findings
The mean amount of tumor necrosis was 29% (median 20%; range 0 – 90%), for example fig. 
1-3. Minimal tumor infiltration of the choroid occurred in 1 and inflammation in 2 of the 15 eyes. 
Massive invasion in choroid is a metastatic risk factor and did not occur in our patients. Post-
laminar optic nerve invasion is an important risk factor for extra-ocular recurrence and occurred 
in 3 eyes. (Pre)laminar optic nerve infiltration occurred in 6 out of 15 eyes. In 6 eyes no optic 
nerve infiltration was scored. In one patient the optic nerve was cut at surgery at the scleral surface 
without a stump. The tumor however reached the cut surface and was considered as positive for 
postlaminar optic nerve invasion. Ten out of 15 tumors were poor-, 4 moderate- and 1 well-
differentiated. 
The mean value of MVD was 18.4 per 20x field (range, 10 - 37). for example fig. 1-3. VEGF 
immunoreactivity was positive in 7, weak in 6 and negative in 2 patients. Flt-1 staining was 
determined as positive in 1 patient, weak in 5 and negative in 9 patients. 
Correlation between DCE-MR parameters and Histopathology /Immunohistochemistry
A positive correlation in retinoblastoma was found between κ5min and mean MVD (P = 0.008) 
(Fig.4a) and a negative association between κ17min and the percentage necrosis (P = 0.002) 
(Fig.4b). No statistically significant correlation between κ5min or κ17min was found with other 
clinical or histopathological data (choroid invasion; resp. P = 0.66 and P = 0.17, optic nerve 
invasion; resp. P = 0.27 and P = 0.90, VEGF; resp. P = 0.91 and P = 0.59 and Flt-1; resp. P = 
0.14 and P = 0.13). After disregarding patient 15 because of the interobserver disagreement in 
this patient, results remained similar. In fact, we found an additional positive correlation between 
κ17min and MVD (P = 0.03).
Fig 4. Graphs show the positive correlation (A) between κ
5min
and mean MVD (P = .008) and the negative 
correlation (B) between κ
17min
 (a measure for late enhancement) and tumor necrosis (P = .002).
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DISCUSSION 
Our study showed that DCE-MR imaging parameters correlated significantly with MVD and 
tumor necrosis. We observed a statistically significant correlation between mean MVD and 
κ5min. MVD is an important parameter to assess tumor angiogenesis in vitro, which has been 
associated with local invasive growth and hematogenous metastases in retinoblastoma (14). 
Highly vascularized tissue typically shows rapid enhancement after contrast injection. Indeed, 
tumors with a high MVD were described by a DCE MR imaging curve with a steep slope and 
therefore a high value of κ5min. The parameter κ obtained with curve pattern analysis has a 
strong correlation with the rate constant k
ep
 (17). And because k
ep
 has been shown sensitive to 
treatment in previous literature (22;23) this suggests a similar role for κ. 
In addition, we observed a negative correlation between the amount of tumor necrosis and 
κ17min, a parameter which represents the shape of the curve over a long time frame of 17 minutes. 
The occurrence of late enhancement is represented by a DCE MR imaging curve that gradually 
but steadily increases, resulting in a low value of κ17min. In literature, similar curves with late 
enhancement are associated with tumor necrosis (24;25). Using curve pattern analysis we can 
semi-quantitatively determine the occurrence of late enhancement, but we cannot differentiate 
between physiological factors such as vascularization, transfer rates, volume of the interstitial 
space, or a combination of these factors. Although clearly necrotic areas were not included in the 
ROIs, DCE MR imaging was sensitive enough to be negatively associated with the degree of 
necrosis, as also observed in some preclinical tumor models (26). In necrotic tumors, the central 
portions of the tumor become relatively hypovascular and eventually necrotic as the tumor grows 
(27). This regional hypoxia induces damage to vessels in the border zones adjacent to central 
necrosis (28). We assume that at a later stage, contrast may leak from the damaged vessels into 
the more vital parts of the tumor, causing late enhancement. 
Severe hypoxia, present in necrotic tumors, contributes to resistance to radiation therapy and 
decreases the efficacy of cytotoxic drugs including carboplatin and melphalan (29;30). These are 
both important chemotherapeutic agents in retinoblastoma treatment for chemoreduction and 
selective intra-arterial chemotherapy, respectively. Thus, evaluation of κ17min as a non-invasive 
marker for tumor necrosis could become a useful parameter in the choice of treatment or to 
monitor treatment response (31;32). Other treatment strategies, such as vascular targeting with 
antiangiogenic (anti-VEGF drugs) and angiostatic agents, are emerging as a possible treatment 
option for retinoblastoma (33-36). VEGF is correlated with tumor MVD in different tumors 
(37-39). Although we observed a correlation between κ5min and MVD, we did not find an 
association between DCE-MR imaging parameters and VEGF, possibly due to small sample size. 
Although not directly related to physiological parameters, curve pattern analysis could prove 
a stable measure for DCE-MR imaging analysis. The method has only recently been suggested, 
and has not yet been generally used. Application in retinoblastoma and the correlation with 
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MVD and necrosis suggest the applicability of this curve pattern analysis method, which does not 
require arterial input function or baseline T1 relaxation time measurements. 
Some limitations of our study should be addressed. The spatial alignment of MR imaging 
and histopathology is not perfect. Because of the poverty of clear landmarks it is difficult to 
get the same cross-section between MR imaging and histopathologic specimens. However, 
tumor angiogenesis influences all vital tumor tissue and not only the part in which the ROI 
was placed, as can be concluded from the convincing correlation between κ17min and mean 
MVD. In our study, the intraclass correlation coefficient of 0.53 for κ5min indicated only modest 
agreement. This low intraclass correlation coefficient was due to only one patient with a large 
and heterogeneous tumor, while for the other 14 patients the interobserver agreement of both 
κ-values was excellent. Especially in large heterogeneous tumors a localized comparison between 
histopathology and DCE-MR imaging will be useful. For instance, it may be expected that a 
voxel-wise evaluation of DCE-MR imaging data of the whole tumor will separately identify 
highly vascularized regions and regions near necrotic areas based on high κ5min in and low 
κ17min, respectively. In this respect, a higher field strength of 3T, possibly in combination with 
a multi-channel head coil, would be advantageous for voxel-wise evaluations, because of the 
higher signal-to-noise ratio. Another study limitation is the 17 minutes time frame of DCE-MR 
imaging after contrast injection. In this time frame we did not observe a decrease of SI which 
would be interpreted as washout of contrast agent. Although in other tumor types this curve 
pattern is common, and characteristic for a malignant tumor (40;41), it was not observed in these 
15 cases of retinoblastoma. Finally, because of the small size of our patient cohort our findings 
have to be considered preliminary and therefore the discriminatory value of DCE MR imaging 
in predicting aggressive in a single patient is not possible yet. Our results are the first in DCE 
MR imaging in retinoblastoma patients and need validation in a much larger group of patients, 
preferentially in a multicentric study. 
In conclusion, in retinoblastoma the early phase of the DCE time curve positively correlates 
with MVD, while the presence of late enhancement is correlated with necrosis. Thus, the potential 
for DCE-MR imaging to non-invasively assess angiogenesis and necrosis in retinoblastoma 
tumors is promising and warrants further investigation. 
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ABSTRACT
Background: Intratumoral calcifications are very important in the diagnosis of retinoblastoma. 
Although CT is considered to be superior in detecting calcification, the radiation hazard in 
especially hereditary retinoblastoma patients should be avoided. The purpose of our study is to 
validate the value of T2*WI for detection of calcifications in retinoblastoma with ex-vivo CT as 
gold standard. 
Materials and methods: Twenty-two consecutive patients with retinoblastoma (mean age, 21 
months, range 1-71 months) with enucleation as primary treatment were imaged with a 1.5 
T using a dedicated surface coil. Signal intensity void (SIV) indicating calcification on T2*WI 
were compared with ex-vivo high resolution CT (HRCT) and correlation was scored by two 
independent observers as poor, moderate or good correlation. Other parameters included shape 
and location of SIVs. In five tumors susceptibility-weighted images (SWI) were evaluated.
Results: All calcifications visible on HRCT could be matched with SIVs on T2*WI and correlation 
was scored as good in 17 (77%) and moderate in 5 (23%) eyes. In total, 93% (25/27) of the SIVs 
inside the tumor correlated with calcifications compared to none (0/8) of the SIVs outside the 
tumor. Areas of nodular shaped SIVs correlated with calcifications in 92% (24/26) and linear 
shaped SIVs correlated with hemorrhage in 67% (6/9) of the cases. The correlation between SIVs 
on SWI was better in 4 out of 5 tumors compared to T2*WI.
Conclusion: SIVs on in-vivo T2*WI correlates good with calcifications on ex-vivo HRCT 
in retinoblastoma. Gradient-echo sequences may be helpful in the differential diagnosis of 
retinoblastoma. Therefore the combination of fundoscopy, ultrasound and high-resolution MRI 
with gradient-echo sequences should become the standard diagnostic approach to diagnose 
retinoblastoma. 
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BACKGROUND 
Retinoblastoma is generally treated on basis of fundoscopic, ultrasound and imaging findings 
without prior histopathologic confirmation of diagnosis. Prevalence of calcifications is 
approximately 85%1, and is considered to be the key-finding in differentiating retinoblastoma 
from simulating lesions (Coats disease, persistent hyperplastic primary vitreous (PHPV) or 
toxocara endophthalmitis) in young children2. Only rare cases such as medulloepithelioma 
and retinocytoma, may also contain calcifications causing difficulty in clinical and radiological 
differentiation3. 
Ultrasound is the most commonly used imaging technique for evaluation of intraocular 
tumors. Combination of fundoscopy and ultrasound allows for the identification of calcifications 
in 91%-95% of patients4. However, sensitivity for depiction of small calcifications decreases in 
the presence of massive retinal detachment, vitreous hemorrhage and subretinal fluid, sometimes 
hampering confirmation of diagnosis. In these complicated eyes, CT is likely the method of 
choice for studying intraocular calcifications with reported sensitivities of 81%–96% 5. However, 
its diagnostic performance in staging retinoblastoma disease extent is limited and the theoretical 
increased risk of radiation induced cataract and fatal cancers in children who underwent CT 
should be considered6. Especially, since hereditary patients are at an even higher risk to develop 
radiation induced tumors compared to normal children. 
MRI is the non-invasive technique of choice for evaluation of retinoblastoma. The combination 
of ultrasound and MRI are considered to be the first-line diagnostic tools in the evaluation of 
children with suspected retinoblastoma, surpassing CT7. However, MRI does not allow facile 
identification of tumoral calcifications on routinely used clinical sequences. The lack of spatial 
resolution with standard clinical sequences provides an additional challenge for visualization of 
small punctate tumoral calcifications. Scarce data on high-resolution ocular MRI using surface 
coils show that various amounts of calcifications can be detected with reasonable diagnostic 
accuracy8.
Gradient-echo T2*-weighted imaging (T2*WI) sequences are sensitive to susceptibility 
differences among tissues that cause magnetic field inhomogeneity leading to signal loss and is used 
to depict blood products, deoxygenated venous blood in dilated vessels (venous congestion) and 
calcifications9;10. Previous work by Galluzzi et al showed that T2*WI can be a feasible technique 
to detect intraocular calcifications11. Calcified areas in retinoblastoma emerged as hypointense foci 
of signal intensity voids (SIVs) within the soft tissue mass. Most of the SIVs on T2*WI correlated 
to spots of intratumoral of calcifications on CT. However, it was not investigated if the shape and 
spatial arrangement of the intra-ocular SIVs on MR can all be matched with calcifications on CT. 
Especially, since additional SIVs can appear on high-resolution T2*WI, without a corresponding 
hyperintensity on CT. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
68  |  Chapter 4
The purpose of our study is to assess the ability of gradient echo T2*WI in visualization and 
morphologic evaluation of retinoblastoma calcifications and to compare T2*WI with ex-vivo CT 
scans of the enucleated eyes as gold standard. 
MATERIALS AND METHODS
Patient population
This study included patients from two European retinoblastoma reference centers and was 
performed in agreement with recommendations of both local ethics committees, with waiver of 
informed consent. From October 2009 to September 2011, retinoblastoma patients diagnosed 
with fundoscopy and ultrasound under general anesthesia, were included if: (a) adequate 
pretreatment T2*WI was available, (b) enucleation of the eye was the primary treatment for 
retinoblastoma and (c) high-resolution CT (HRCT) images of the enucleated eye were present. In 
patients with bilateral retinoblastoma, only the most affected eye was enucleated and included. 
Three patients were excluded because of inadequate T2*WI. Final study population included 22 
patients. Patient records were reviewed for age at retinoblastoma diagnosis. 
 
MR imaging
Pre-treatment MRI examinations were performed under general-anesthesia on 1.5T systems 
(Siemens Avanto or Sonata; Erlangen, Germany) using a dedicated surface coil (loop- or temporo-
mandibular coils featuring a diameter of 4 and 7 cm, respectively) focused on the (most) affected eye. 
Imaging was performed according to published guidelines7. In all patients, MR images included 
transverse and sagittal spin-echo T1W imaging (repetition time/echo time 300-420/13-15ms; 
slice thickness 2mm), transverse spin-echo T2WI (1200-2470/120-166ms; 2mm) and transverse 
2D T2*WI (300-650/15-25ms; 2mm). Additionally, 5 patients underwent susceptibility-
weighted imaging (SWI) (TR/TE 46/38ms, matrix 192×162, voxel size 0.4×0.6×1 mm3, no 
gap, 35 slices, averages = 2, flip angle 15°, acquisition time 7.34 min. SWI datasets included 
phase images and minimum intensity projection (minIP) images. 
Ex-vivo HRCT
HRCT was performed immediately after enucleation of the eye using either a BrightSpeed (GE 
Healthcare, Milwaukee, Wis.) or Sensation-64 (Siemens, Erlangen, Germany) system. Eyes were 
carefully positioned in a small cardboard tray supported with gauze and in the same orientation 
as the transverse plane of the MR images. Axial images were acquired with a section thickness of 
0.6mm, collimation of 0.5mm, pitch of 0.8, 120kV, 250 mAs, field of view 16cm and a 512x512 
matrix. From the raw data, individual data sets were reformatted into images of 0.6mm slice 
thickness in all 22 eyes. Raw data remained available for additional multi-planar reconstructions, 
which were made afterwards by one observer (FR) to provide accurate information of the obtained 
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data in the axial plane. Finally, two data sets of CT images were reconstructed and were available 
for all patients; one with slice thickness of 2mm (the same orientation and slice-thickness as 
T2*WI) and one with very thin slices (0.6mm).
Image analysis 
Retrospectively, two independent observers (P.G. and P.d.G., with 15 and 11-years of experience 
in ocular MRI, respectively), reviewed all T2*WI and HRCT images. Afterwards, differences 
in scoring were resolved in consensus. Both observers were blinded to results of clinical and 
histopathological findings. Ex-vivo HRCT was considered to be the gold standard for detecting 
calcifications. Presence or absence of calcifications on HRCT was assessed. Calcifications were 
defined as hyperdense foci within the tumor on HRCT images. MR images were independently 
reviewed by the same observers. After analyzing the MR images, detection of calcifications was 
confirmed in correlation with HRCT images by using anatomical landmarks so as to adjust for 
section thicknesses, angulation, and obliquity. Criteria used to define calcifications on MR were 
as follows: calcifications had to have the same morphologic pattern as on the HRCT (same shape 
and same spatial arrangement), and were considered to be localized foci of marked hypointense 
SIV on T2*WI. Correspondence between intraocular hyperdense areas on CT and intraocular SIV 
observed on MRI were scored as good, moderate or poor. Good correspondence was scored if all 
calcifications on HRCT perfectly matched with SIV on T2*WI, whether or not with the presence 
of evident artifacts or hemorrhage on MRI. Moderate correspondence was scored if there was an 
evident correlation between MRI and HRCT in some parts of the tumor, but additional SIVs on 
MRI were present without an evident explanation on basis of other MR sequences or hyperdense 
structures on CT. If no correlation could be observed at all, the correspondence was scored as poor. 
Location of SIVs in the tumor was categorized as central, peripheral or a combination of both. 
Shape of SIVs was categorized as nodular or linear. SIVs on T2*WI secondary to intravitreal or 
subretinal hemorrhage were considered if fluid-fluid levels (in correspondence with T2WI) or a 
smooth hypointense outlining of tumor or retina was present in the affected eye. Eyes with moderate 
or poor correlation based on (additional) SIVs without corresponding calcification on HRCT, or 
other explanation on conventional MR sequences were selected for additional correlation with 
histopathology. In 5 tumors SIVs in SWI images were evaluated and compared with the T2*WI 
and were scored as worse, equal or better correlation with calcifications on HRCT. Furthermore, 
feasibility of using phase images for detection of calcifications in retinoblastoma was studied. 
Calcium undergoes a positive phase shift (paramagnetic susceptibility) and is displayed as a high 
SI area on the phase image, whereas a negative phase shift (diamagnetic susceptibility) occurs for 
veins, iron, and hemorrhage, making them appear uniformly dark.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
70  |  Chapter 4
Histopathologic examination
Eyes were fixed in saline-buffered formalin, sampled, embedded in paraffin and sectioned in 
the same orientation as the axial plane of the MR images (thickness 4 µm) and stained with 
hematoxylin-eosin. Histopathological slices were only evaluated in tumors with additional SIVs 
on T2*WI without evident cause on other MR sequences or CT by two pathologists (P.v.d.V and 
P.T.). 
RESULTS
All 22-patients (22-eyes) in this study had histopathological proven retinoblastoma (mean age 
21-months; range, 1-73months). Mean time-interval between diagnosis and MRI was 5-days 
(range 0-8days). Mean time-interval between MRI and CT was 5-days (range 0-8days). Patient 
characteristics are summarized in table 1.
Table 1: Patient findings and correlation of CT with MRI in calcium detection
Patient (lat) Age Int. MR-En Corr. T2*WI-CT SWI Corr. T2*WI-SWI
1 (U) 1 1 moderate no NA
2 (U) 4 8 moderate no NA
3 (U) 46 6 moderate no NA
4 (U) 3 0 moderate no NA
5 (U) 26 6 moderate no NA
6 (U) 73 1 well no NA
7 (B) 8 4 well no NA
8 (U) 11 5 well no NA
9 (U) 8 1 well no NA
10 (U) 16 1 well no NA
11 (U) 3 8 well no NA
12 (B) 12 8 well no NA
13 (B) 35 8 well no NA
14 (U) 29 1 well nn NA
15 (B) 29 8 well no NA
16 (B) 13 6 well no NA
17 (U) 45 8 well no NA
18 (U) 5 8 well yes equal
19 (U) 9 7 well yes better
20 (U) 38 1 well yes better
21 (U) 5 8 well yes better
22 (U) 37 5 well yes better
lat= tumor laterality, int. MR-En= interval MRI and enucleation, Corr = correlation, T2*WI= T2*weighted 
imaging, SWI= susceptibility weighted imaging
median age 12,5
mean age 20,73
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Areas of calcification were present on HRCT in the tumors of all 22-eyes. Furthermore, all 
eyes showed foci of SIVs on T2*WI. A total of 35 areas of SIVs were depicted; 27 areas of SIVs 
inside the tumor and 8 areas outside the tumor. Shape was classified as nodular (n=26) and linear 
(n=9). Nodular SIVs were predominantly located within the tumor (25 out of 26 SIVs; 96 %) and 
19 (76%) in the tumor center, whereas linear shaped SIVs were predominantly located outside 
the tumor (7 out of 9 SIVs; 78%). Of the two linear SIVs, one was located at the periphery of the 
tumor while the other was located centrally within the tumor.
Correlation between calcifications on CT and areas SIVs on T2*WI was scored as good in 
17 (77%) and moderate in 5 (23%) eyes. Poor correlations were not observed. Of 27 areas of 
SIVs located inside the tumor, 25 areas (93%) correlated with calcifications, 1 with intratumoral 
hemorrhage and 1 with dilated venous vessel (venous congestion). Of the 8 areas of SIVs located 
outside the tumor, 6 (75%) correlated with hemorrhage (5 subretinal and 1 intratumoral) and 
2 with susceptibility artifacts secondary to air-tissue interface. Areas of nodular shaped SIVs 
correlated to calcifications in 92% (24/26) and linear shaped SIVs correlated to hemorrhage in 
67% (6/9). 
The 17 good-corresponding eyes showed evident matching (same shape and same spatial 
arrangement) between hyperdense structures on CT and areas of SIVs on T2*WI (Fig.1). 
Additional SIVs in good-corresponding tumors were mostly located outside the tumor with a 
linear aspect corresponding with artifacts or hemorrhage (Fig. 2). In 3 good-corresponding tumors 
additional SIVs were observed on T2*WI, and did not have any corresponding hyperdensity on 
HRCT. However, on histopatholgy, these SIVs did correlate with spots of calcifications (Fig. 3). 1 
In 5 moderately-corresponding eyes, the hypointense areas on MRI could only be correlated 
in part with hyperdense areas on CT. Additional SIVs were all located outside the tumor and 
correlated with hemorrhage and venous congestion. 
Discrepancies between observers occurred in two good-corresponding cases. In one case a 
linear hypointense structure which indicated hemorrhage caused confusion. In the other case 
more SIVs were observed on MRI compared to the poor resolution of CT. The spots of calcification 
on CT however matched well with T2*WI.
In 5 patients SWI datasets were available and all eyes were good-corresponding. In 4 eyes the 
correlation between SIVs on SWI images and the calcifications on HRCT was better compared 
to the T2*WI images (Fig. 4) and in 1 eye the correlation showed no difference between the two 
gradient-echo techniques. In two patients the quality of the phase images was diminished due to 
image distortions. Phase images showed hyperintense SI of calcification in the other 3 eyes, which 
was confirmed on the HRCT. None of these eyes showed intraocular or intratumoral hemorrhage 
clinically or on histopathology. 
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Fig. 1: Excellent-matching hyperdense calcifications on ex-vivo high-resolution CT (left column) with 
signal intensity void spots on gradient-echo T2*-weighted MR images (right column) in patient 12 [a], 16 
[b], 18 [c], 19[d], 14 [e].
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Fig. 2: Examples of additional signal intensity voids on T2*-weighted MR images without correspondence 
with ex-vivo high resolution CT. 
Patient 13 shows a hypo-intense nodular structure (a) in the anterior part of the eye (arrow) on T2*-
weighted imaging without corresponding hyperdensity on ex-vivo high-resolution CT (b). Histopathology 
demonstrated a hemorrhage (arrow) precisely matching this additional SIV (c). Adjacent to this hemorrhage 
multiple linear-arranged spots matched with hyperdense spots on CT. 
In patient 11 (d) a linear band of SIV on T2*WI is shown outside the tumor along the detached retina 
(white arrow) as well as in the iris (black arrow). The grey arrowhead is pointing to the lens which is 
dislocated. Histology (e, f) showed necrotic tumor with dilated vessels (venous congestion) (white arrow) 
and hemorrhagic necrosis of the iris also combined with venous congestion (black arrow). The anterior 
chamber is infiltrated by neoplastic cells and cellular debris.
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Fig. 3: Extra signal intensity void spots in the anterior part of the eye on gradient echo T2*-weighted 
images (arrow) (a) were observed in patient 21 with excellent correspondence with HRCT (b). However, a 
band of additional signal intensity void spots were present in the anterior part of the tumor on gradient-echo 
T2*-weighted MR image (arrow) without correspondence on ex-vivo high-resolution CT. Histopathologic 
correlation (c) showed multiple foci of calcifications in the anterior part of the tumor (arrow).
Fig. 4: Value of phase imaging in identifying calcification in retinoblastoma (patient 22). Signal intensity 
void spots can be seen on T2*-weighted (a) and SWI minIP image (b). Phase image (c) shows high signal 
intensity centrally identifying calcification, confirmed on the ex-vivo high resolution CT image (d).
DISCUSSION
T2*WI allows for accurate identification of calcified areas in retinoblastoma. In our study, all 
calcifications seen on ex-vivo HRCT could be matched with SIVs on T2*WI and this technique 
even depicted small SIVs better than HRCT. SIVs located in the tumor center are more likely to 
be calcification whereas peripheral SIVs and other intraocular SIVs can also indicate hemorrhage, 
slow flowing blood in venous congestion or artifact. 
Detection of calcifications is critical for the differential diagnosis of retinoblastoma. After 
fundoscopy, the first-line diagnostic tool is always ocular ultrasound. In experienced hands, 
ophthalmologists demonstrate calcifications in the majority of patients. When calcifications are 
not detected, cross-sectional imaging studies can be used as a problem solving technique12;13. 
MRI is the technique of choice for evaluation of intraocular pathology, especially in children 
presenting with leukocoria.
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The guidelines for imaging retinoblastoma by de Graaf et al serves as a checklist for minimal 
requirements for pretreatment diagnostic evaluation of retinoblastoma or mimicking leasions7. 
They concluded that together with ultrasound, high resolution MRI is the most important imaging 
modality for retinoblastoma diagnosis and evaluation of associated intracranial abnormalities. CT 
was highly discouraged in retinoblastoma children because of ionizing radiation and no added 
diagnostic value. 
Historically MRI is considered to be an inferior technique for detection of calcifications 
compared to CT. However, accuracy to successfully depict small foci of calcifications by T2*WI 
was already reported in other studies14;15. Galluzzi et al showed that T2*WI is a feasible technique 
to detect calcifications in retinoblastoma (8). In their study all SIVs matched with calcifications. 
SIVs on T2*WI could however also represent other pathology than calcifications. In our study we 
further characterize SIVs based on calcifications, hemorrhage or artefact by discussing different 
accompanying patterns. 
We were able to confirm the capability of this sequence for calcification detection. In some 
tumors T2*WI was even more sensitive in depicting small intraocular calcifications in-vivo 
compared to HRCT ex-vivo. It must be stressed that the HRCT protocol in this study is considered 
to be more sensitive for detection of small punctate calcification compared to commonly used 
clinical protocols for pediatric orbital CT. 
Additional hypointense areas however on MRI can cause confusion. Intratumoral hemorrhage 
is the most important cause of false-positive SIVs16. Hemorrhage is more likely to appear in large 
necrotic tumors and can cause extensive intraocular complications such as massive subretinal or 
intravitreal haemorrhage with subsequent increase in intraocular pressure. Smooth and linear SIVs 
in retinoblastoma on T2*WI are indicative for intratumoral haemorrhage and are predominantly 
located in the tumor periphery, whereas calcifications more frequently present as hypointense 
SIVs in the tumor center. Massive subretinal or intravitreal haemorrhage can easily be diagnosed 
on conventional T2WI with fluid-fluid (sedimentation) levels. We considered smooth and linear 
SIVs on T2*WI indicative for intraocular hemorrhage. They are predominantly on the surface of 
the tumors or aligning with the (usually) detached retina. Close correlation with findings during 
fundoscopy and ultrasound might further help in interpretation of SIVs on tumor surface. 
Advanced disease with massive tumor necrosis can also present with secondary neovascular 
glaucoma, uveitis and/or aseptic orbital cellulitis. These conditions are associated with venous 
congestion, i.e. extremely dilated intraocular venous structures. Susceptibility effects in 
venous blood is caused by the presence of deoxyhemoglobin and becomes more pronounced in 
venous congestion with increased intravascular space and slow flowing venous blood (Fig 4)17. 
Susceptibility artifacts due to air beneath the eyelid or within the paranasal sinuses can also cause 
SIVs on T2*WI. These artifacts can be distinguished from calcifications by the linear aspect 
and location. Susceptibility artifacts caused by air are usually located in or near the anterior eye 
segment. 
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SWI was available for review in a small subset of patients, which allowed us to explore for 
the first time the potential value of this sequence in retinoblastoma. This technique showed 
to be more sensitive than T2*WI in detecting (micro)calcifications and differentiating them 
from intratumoral (micro)hemorrhage, necrosis and artifacts in oligodendroglioma, vestibular 
schwannoma and diffuse infiltrating pontine gliom10;18;19. In contrast to T2*WI, SWI is based on 
a long echo time, high-resolution, flow-compensated three-dimensional gradient-echo imaging 
technique with filtered phase information in each voxel. The combination of magnitude- and 
phase-data creates an enhanced contrast magnitude image that is particularly sensitive to 
hemorrhage, calcium, iron storage and slow flowing venous blood, therefore allowing a significant 
improvement in sensitivity and specificity compared to T2*WI18;20. Preliminary results in our 
study showed that correlations between SWI and HRCT in retinoblastoma are equal to or 
even better compared to T2*WI. Therefore, further studies with more patients are required to 
determine diagnostic accuracy of SWI in detection of microcalcifications in retinoblastoma.
Our study has some limitations. First, we did not perform histopathologic correlation 
to confirm presence of calcifications in all eyes, but only of SIVs for which a corresponding 
hyperdensity on HRCT was lacking. However, accuracy of CT in depicting calcifications in soft-
tissues is well accepted, and this technique has been used as a reference in several studies in the 
past5;11;21. Second, the lesions studied were all retinoblastomas, without a number of simulating 
lesions for comparison. It is thus impossible to determine whether the (theoretical) absence of 
SIVs on T2*WI or SWI in simulating diseases can be a reliable parameter to narrow down 
the differential diagnosis. Third, all included patients required enucleation, which resulted in 
selection bias, since small tumors are usually treated with conservative (eye-sparing) treatment 
options. The amount of calcifications might be higher in larger tumors, which makes detection of 
calcification by CT and MRI easier. A potential reduction in sensitivity might become apparent 
for both techniques by adding smaller tumors. We recommend further research on this topic, in 
which retinoblastoma as well as simulating lesions are studied with T2*WI or SWI to evaluate 
presence of SIVs in these diseases. Ideally, these studies should include close correlation with 
histopathology to explore possible false-positive findings in simulating lesions. The small sample 
size of SWI studies in retinoblastoma is another limitation in our study. However, these initial 
positive findings are the first described in literature and warrants further research, especially since 
SWI including information provided by the phase-images harbors the potential to be a sensitive 
as well as a specific technique to detect or exclude calcifications in retinoblastoma. 
CONCLUSION
Our study shows a good correlation between SIVs as detected on in-vivo T2*WI or SWI sequences 
and calcifications on ex-vivo HRCT in retinoblastoma. Gradient-echo sequences may be helpful 
in suggesting the diagnosis of retinoblastoma. In retinoblastoma patients it is important to 
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always avoid radiation hazards, especially from CT. The combination of fundoscopy, ultrasound 
and high-resolution MRI with gradient-echo sequences should become the standard diagnostic 
approach to diagnose retinoblastoma and removes potentially harmful ionizing radiation from 
the study protocol. 
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ABSTRACT
Background and purpose. Although pineoblastoma is the main brain abnormality associated 
with hereditary retinoblastoma, recent studies suggest an association with pineal cysts. This 
association is important because some pineoblastomas mimic pineal cysts. If there is a relationship, 
then radiologists should be aware of it because diagnostic confusion is possible. Mental 
retardation and congenital brain anomalies are also reported in patients with retinoblastoma, 
mostly in combination with 13q deletion syndrome. In this retrospective study, the presence of 
brain abnormalities on MR images in a large group of consecutive patients with retinoblastoma 
is evaluated. 
Materials and Methods. Brain MR images of 168 patients with retinoblastoma from 1989 
to 2009 were evaluated by 2 radiologists for tumors, structural anomalies, myelinization, and 
coincidental findings. Clinical records were reviewed for laterality, heredity, and the presence of 
the 13q deletion syndrome. 
Results. The hereditary group (patients with bilateral and unilateral proved RB1-germline 
mutation) included 90 (54%) of 168 patients. Seven patients had 13q deletion syndrome. 
Normal findings on brain MR images were seen in 150 (89%) patients. Five pineoblastomas 
were detected, all in patients with hereditary retinoblastoma (5.5% in the hereditary subgroup). 
Nine pineal cysts were detected (2.2% in the hereditary subgroup). Corpus callosum agenesis 
was found in 1 patient and a Dandy-Walker variant in 1 patient, both in combination with 13q 
deletion syndrome. 
Conclusions. Pineoblastoma is associated with hereditary retinoblastoma, and structural brain 
abnormalities are restricted to patients with the 13q deletion syndrome. The incidence of pineal 
cysts in patients with retinoblastomas is similar to that in healthy children and is not associated 
with hereditary retinoblastoma.
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INTRODUCTION
Retinoblastoma is the most common intraocular tumor in early childhood, occurring in 1/17,000 
live births (1). Retinoblastoma cells contain a mutation or deletion of the retinoblastoma gene 
(RB1 gene), a tumor-suppressor gene, located on chromosome 13q14 (2,3). Approximately 40% 
of patients with retinoblastoma have hereditary disease (mostly bilateral tumors), while the 
remainder (60%) have unilateral nonhereditary disease. A minority is due to a cytogenetically 
detectable interstitial deletion of variable size with a minimal overlapping region in band 13q14 
(4). It is reported that midline intracranial neuroblastic tumors of either the suprasellar or the 
pineal region (pineoblastoma) are present in approximately 5%–15% of patients with hereditary 
retinoblastoma (5).
Besides midline malignant tumors, benign intracranial abnormalities are also reported in 
the retinoblastoma population, in particular the presence of pineal cysts. In the literature, an 
association between hereditary retinoblastoma and pineal cysts is suggested. Popovic et al (6) 
reported an incidence of pineal lesions (cysts and pineoblastoma) of 6.4% in their retinoblastoma 
population. All pineal lesions were present in the bilaterally affected hereditary patients. In 
this subgroup, they found an equal incidence of 5.3% for both pineal cysts and pineoblastoma. 
The combination of retinoblastoma, suprasellar tumor, and pineal cystis is also reported, 
which, according to Popovic et al,(7) further adds to a possible relationship between hereditary 
retinoblastoma and pineal lesions. Karatza et al.(8) reported 11 patients with retinoblastoma with 
pineal cysts simulating pineoblastoma. They recommended that clinicians should be aware of the 
presence of this benign lesion when performing routine neuroimaging, especially in patients with 
bilateral disease. 
However, pineal cysts are quite common in the general population. In postmortem cases, 
pineal cysts are encountered in 25%–40% of people of all ages (9,10). In recent literature, an 
incidence of 0.4%–2.2% on MR images in the general pediatric population between 0 and 5 
years of age has been reported (11). It is already known that pineoblastoma is associated with 
retinoblastoma. If the same is true for pineal cysts, then radiologists should be aware of the 
association. Distinct imaging criteria in distinguishing pineoblastomas from pineal cysts should 
be evaluated to avoid diagnostic and therapeutic confusion. 
Retinoblastoma may occur in the presence of 13q deletion syndrome. The risk of 
retinoblastoma development in patients with this syndrome is approximately 80% (3,4) Besides 
retinoblastoma, this syndrome has a spectrum of clinical features, including moderate-to-severe 
developmental delay. Baud et al (4) reported a variable degree of mental retardation in patients 
with retinoblastoma with associated 13q cytogenic abnormalities. Only in case reports, describing 
patients with 13q deletion syndrome or in combination with retinoblastoma, are congenital brain 
abnormalities or brain disorders indicative of cognitive symptoms reported (4,7,12–24). Ballarati 
et al.(25) reported central nervous system anomalies such as Dandy-Walker malformation, 
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cerebellar hypoplasia, cortical dysplasia, and agenesis of the corpus callosum in patients with 13q 
deletion. Although one can assume that these symptoms are due to 13q deletion syndrome, it 
is interesting to evaluate whether (structural) brain abnormalities are involved in patients with 
retinoblastoma. To our knowledge, no large correlative study has been performed on the presence 
of retinoblastoma and brain abnormalities on MR imaging. 
The purpose of this retrospective study was to evaluate the presence of brain abnormalities on 
MR images in a large group of consecutive patients with retinoblastoma. 
MATERIALS AND METHODS
Patients
Patients eligible for this retrospective study were those at our institution with retinoblastoma 
who had undergone MR imaging of the brain that enabled adequate image interpretation between 
1989 and 2009. To avoid alteration in the brain due to aging, we only evaluated patients younger 
than 5 years of age. The diagnosis of retinoblastoma was confirmed in all patients with extensive 
funduscopy, sonography, and MR imaging. In case of enucleation, the diagnosis was confirmed by 
histopathology. In this period, we identified 245 patients with retinoblastoma, and all patients 
had undergone MR imaging. However, in 77 patients, brain imaging studies were absent or 
incomplete and, therefore, excluded. The total number of included patients was 168. The need 
for informed consent was waived because of the retrospective nature of the study. 
Clinical records were reviewed by 1 reviewer for the patient’s sex, age at first MR imaging, 
laterality, heredity, and the presence of 13q deletion syndrome. In patients with brain 
abnormalities, the evaluation of pre- or posttreatment MR imaging had to exclude treatment-
induced brain abnormalities. 
Patients with bilateral disease or a positive family history of retinoblastoma or a defect in 
the RB1 gene found in chromosomal/deoxyribonucleic acid analysis were classified as having 
hereditary disease. All other patients were classified as having nonhereditary disease (1). 
MR Imaging
MR imaging was performed at 1T (Magnetom Impact Expert; Siemens, Erlangen, Germany) and 
1.5T (Magnetom Vision and Sonata, Siemens). Within the past 20 years, MR imaging protocols 
for retinoblastoma have changed. In the beginning, whole-brain MR imaging sequences were 
more common in retinoblastoma MR imaging protocols in combination with a standard-
quadrature head coil. Due to technologic developments and improved coil design, attention 
shifted to small-FOV imaging of the orbits by using surface coils. MR imaging protocols did not 
differ between unilaterally and bilaterally affected patients. Postcontrast axial T1W MR images 
covering the whole brain were available in all included patients. In only 48 of 168 patients were 
axial T2W MR images of the brain available. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Brain Abnormalities on MR Imaging in Patients with Retinoblastoma  |  83
Image Analysis
MR imaging examinations were individually reviewed by 2 radiologists with, respectively, 4 and 
9 years of experience in pediatric neuroradiology. Disagreement was resolved by consensus. The 
parameters evaluated on MR imaging were selected on the basis of literature study (4,7,12–24) 
and were divided into the following categories: benign or malignant tumor (tumor of the pineal 
gland, pineal cyst, or other); structural anomalies (corpus callosum agenesis, holoprosencephaly, 
encephalocele, Dandy-Walker malformation or a variant, hypoplasia of the basic pontis, 
microcephaly and polymicrogyria, or other); and degree of myelinization, ventriculomegaly, or 
coincidental findings. Special attention was paid to myelinization to clarify possible cognitive 
symptoms. The diagnosis of a pineal tumor was made if the pineal gland was enlarged, solid, and 
isointense to gray matter on T1W images with homogeneous and intense contrast enhancement.6 
A pineal cyst was diagnosed if the pineal gland was enlarged and had a central region hypointense 
with respect to white matter on T1W images and isointense with respect to CSF on T2W images 
and a thin wall of 2 mm with discrete rim enhancement after gadolinium injection.6 The 
diameters of pineal cysts and pineoblastomas were measured. 
RESULTS
Clinical Findings
The mean age at first MR imaging of the 168 patients was 17 months (range, 0–59 months). 
Bilateral retinoblastoma was present in 78 patients (46%) and unilateral disease in 90 patients 
(54%). Seventy-nine patients with retinoblastoma were female (47%) (41 bilateral, 38 unilateral) 
and 89 (53%) were male (36 bilateral, 53 unilateral). The hereditary group consisted of 90 patients 
and the nonhereditary group of 78 patients. Seven hereditary patients (8%) were diagnosed with 
13q deletion syndrome. 
MR Imaging Findings
Brain MR imaging showed no abnormalities in 150 (89%) patients. Brain abnormalities were 
found in 18 patients (11%), with the pineal gland as the most commonly affected site (14 
patients, 78%) (Table). Pineoblastoma was found in 5 patients at a mean age of 20 months 
(range, 1–39 months), all with hereditary retinoblastoma (3.0% overall incidence, and 5.5% 
in the hereditary group). The mean interval between diagnosis of ocular and intracranial tumor 
was 16.4 months. In 1 patient (10 months of age), the pineoblastoma was detected with the 
diagnosis of retinoblastoma (synchronous tumors). In the other 4 patients, the pineoblastoma 
was discovered at a later stage; 6, 15, 25, and 37 months after the diagnosis of retinoblastoma 
(metachronous tumors). In patients 6, 8, and 9, the tumor presented as a solid mass isointense 
with respect to gray matter on precontrast T1W images and showed a homogeneous intense 
contrast enhancement in the pineal region (diameters respectively, 55, 16, and 49 mm) (Table). 
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Table 1: MR imaging findings in retinoblastoma patients
Patient (age/sex) Heredity Pre-t. MRI MRI findings (side) Size (mm)
1 (1/ M) Y Yes DV (temporal and atrium)
2 (13/ M) Y Yes Dandywalker variant with DV
3 (4/ F) Y Yes CCA (corpus/splenum), vermishypoplasia, DV
4 (10/ M) Y Yes trignocephalia, DV
5 (10/ M) Y Yes pineoblastoma 15
6 (39/ F) Y Yes pineoblastoma 55
7 (5/ F) Y Yes pineoblastoma 59
8 (1/ M) Y Yes pineoblastoma 16
9 (37/ F) Y Yes pineoblastoma 49
10 (34/ M) N Yes pineal cyst 7
11 (16/ F) N Yes pineal cyst 6
12 (31/ M) N Yes pineal cyst 6
13 (15/ F) Y Yes pineal cyst 5
14 (0/ F) N Yes pineal cyst 4
15 (23/ F) N Yes pineal cyst 3
16 (9/ F) Y Yes pineal cyst 3
17 (10/ M) N Yes pineal cyst 4
18 (18/ M) N Yes pineal cyst 3
Note: age in months. Pre-t MRI= pre-treatment MRI, DV=dilatated ventricles, CCA= corpus callosum 
agenesis
In patients 5 and 7, the tumor consisted of a heterogeneous mass with intense contrast enhancement 
and areas with low signal intensity on T1W images and high signal intensity on T2W images, 
suspicious for central necrosis. In patient 5, the configuration of the lesion mimicked a pineal cyst 
(Fig 1). On axial images however, the diagnosis of pineoblastoma was more evident because there 
was an asymmetric nodular thickening of the enhancing wall. The thickness of the enhancing 
wall varied from 3 to 7 mm. Histopathology revealed a pineoblastoma with central necrosis. 
The total incidence of pineal cysts in our study was 5.4% (9 patients), with an incidence of 9.0% 
in the nonhereditary group (7 patients; mean age, 20 months; range, 10–34 months) and 2.2% 
in the hereditary group (2 patients; mean age, 9 months; range, 9–10 months) (Fig 2). The 
mean size of the cysts in the nonhereditary group was 4.8 mm (range, 3–7 mm) and 4 mm in 
the hereditary group (range, 3–5 mm). In 2 patients, follow-up MR imaging was available and 
showed no change in the pineal cysts.
Besides pineoblastoma and pineal cysts, a diversity of brain abnormalities was found. Corpus 
callosum agenesis occurred in 1 patient with hereditary retinoblastoma (Fig 3), and in another 
patient, a hereditary Dandy-Walker variant occurred. Both were known to have a 13q deletion 
syndrome. In the other 5 patients (71%) with 13q deletion syndrome, no brain abnormalities 
were present. One patient with hereditary retinoblastoma showed DV. 
Evaluation of white matter abnormalities was only possible in 48 patients because of 
incomplete series of T2W images of the brain in 120 patients. In this subgroup, no white matter 
abnormalities were observed and all patients with retinoblastoma showed normal myelinization. 
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Fig 1. Patient 5, a 10-month-old with hereditary retinoblastoma and pineoblastoma. A, Sagittal T1-
weighted postgadolinium MR image shows a cystic mass in the pineal gland. B, Axial T1-weighted image 
shows an asymmetric nodular thickening of the tumor wall. The thickness of the enhancing wall varies from 
3 to 7 mm, suspicious for pineoblastoma.
Fig 2. Patient 10. Contrast-enhanced T1-weighted MR image of a 
34-month-old patient with nonhereditary retinoblastoma with a pineal 
cyst, with a diameter of 7 mm.
Fig 3. Patient 3. Sagittal T1-weighted image of a 4-month-old with 
13q deletion syndrome and bilateral retinoblastoma shows agenesis of 
the splenium of the corpus callosum.
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DISCUSSION
In this study, we present an overview of brain abnormalities in a large group of patients with 
retinoblastoma. Pineoblastoma is the most well-known brain pathology associated with 
retinoblastoma, a combination known as trilateral retinoblastoma, occurring in 1.5%–5% of all 
patients and in 5%–15% in the hereditary subgroup (5,22). Besides the pineal region, tumors 
may also occur in the suprasellar or parasellar region. Our study showed similar results, with an 
incidence of 3.0% in the whole study group and 5.5% concerning only the hereditary group.
Three of 5 pineoblastomas showed a typical imaging pattern: a solid homogeneous lobulated 
enlarged pineal gland, isointense with gray matter on T1W images with intense homogeneous 
contrast-enhancement. In the other 2 pineoblastomas, low signal intensity on T1W images and 
high signal intensity on T2W images with heterogeneous enhancement areas were present. One 
pineoblastoma even mimicked a pineal cyst due to a large central area of histopathologically 
proved necrosis. The thickness of this cyst wall (7 mm), however, did not correspond with the 
criteria of pineal cyst (thickness, 2 mm). This finding can cause confusion in the diagnosis of 
pineoblastoma, and it could have been erroneously diagnosed as a pineal cyst, with severe clinical 
consequences (8). This has been reported only once before. Sugiyama et al.(26) reported a case 
of a pineoblastoma with a large central cyst, histopathologically due to central necrosis. In our 
patient, the pineoblastoma was discovered in an early stage synchronously with the intraocular 
tumor on baseline MR imaging without clinical symptoms due to pineoblastoma. 
Central necrosis can be present in large and small pineoblastomas, and especially small 
pineoblastomas with central necrosis can mimic a pineal cyst. In our experience, the thickness and 
appearance of the cyst wall before and after contrast administration on MR imaging are indeed 
important to differentiate a pineal cyst and pineoblastoma. Pineal cysts show a thin wall (<2 
mm) with discrete enhancement, whereas pineoblastomas with central necrosis show a nodular 
thickened wall with homogeneous wall enhancement. 
In our screening for brain abnormalities in 168 patients with retinoblastoma, pineal cysts 
were detected in 5.4% of the patients. Sener (10) performed a review of MR imaging in 500 
children and 500 adults and found no pineal cysts in children younger than 12 years of age. 
The sensitivity of this study, however, could have been limited by using 0.5T MR imaging in 
evaluation. Sawamura et al.(27) found 79 cysts in 6023 patients but none in children younger 
than 10 years of age. However, only MR images in 73 children of 10 years of age and younger 
were evaluated. 
The study of Al-Holou et al.(11) was the only one in which the incidence of pineal cysts on 
MR imaging was examined in healthy children younger than 5 years of age. They reported an 
incidence of 2.0%, almost similar to that in our hereditary group. In this study, the pineal cyst 
population was compared with an age- and sex-matched control population. Popovic et al.(6,7) 
also reported almost the same incidence as in our overall study group (5.3%). They found cysts 
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in patients with bilateral hereditary retinoblastoma, but no pineal cysts in the patients with 
nonhereditary retinoblastoma. These previously mentioned studies included only pineal cysts of 
>5 mm. In our study of patients with retinoblastoma younger than 5 years of age, 5 of the 9 cysts 
were <5 mm (4 of the 5 pineal cysts in the nonhereditary group). 
A follow-up study in a matched control group would be necessary to examine the high 
incidence of pineal cysts in the patients with nonhereditary compared with hereditary 
retinoblastoma with the same criteria used in our study. In previous studies, only Karatza et 
al.(8) reported the occurrence of pineal cysts in patients with nonhereditary retinoblastoma. They 
reviewed 1400 medical records of patients with retinoblastoma and found 3 pineal cysts (0.2%) 
in patients with unilateral and 8 pineal cysts (0.6%) in patients with bilateral retinoblastoma. 
These low incidences are probably due to screening for pineal cysts in medical records instead of 
re-evaluation of MR images. In our experience, these cysts are not always described in medical 
records as a finding. However, for assessing the association between retinoblastoma and pineal 
cysts, the incidence of pineal cysts in the hereditary group is interesting. Given the incidence 
of 2.2% in the hereditary group, which is similar to the incidence in the healthy population 
(11) there is no association between hereditary retinoblastoma and pineal cysts. Although it is 
important to be aware of pineoblastomas mimicking a pineal cyst, there is no evidence that pineal 
cysts occur more often in patients with retinoblastoma compared with the healthy pediatric 
population. 
In our study group, larger structural brain abnormalities occurred only in combination 
with a 13q deletion syndrome. One patient with 13q deletion syndrome had a corpus callosum 
agenesis and another patient showed a Dandy-Walker variant with DV. This brain abnormality 
is also described in previous case reports. Alanay et al.(28) reported a patient with a thin corpus 
callosum and a Dandy-Walker malformation.
CONCLUSION
In conclusion, pineoblastoma is associated with hereditary retinoblastoma, and structural brain 
abnormalities are restricted to the patients with 13q deletion syndrome. The incidence of pineal 
cysts in retinoblastoma is similar to that in healthy children and is not associated with hereditary 
retinoblastoma. 
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ABSTRACT
BACKGROUND: Trilateral retinoblastoma (TRb) is a rare disease associating intraocular 
retinoblastoma with intracranial primitive neuroectodermal tumor. Treatment is difficult 
and prognosis is poor. This multicenter study evaluates clinical findings and MR imaging 
characteristics of associated intracranial tumors in Rb-patients. 
METHODS: Clinical data of 17 patients (16 TRb- and 1 quadrilateral Rb-patients) included 
time-intervals between Rb- and TRb-diagnosis and presence of baseline brain-imaging (BBI). 
Two reviewers reviewed all images individually and one reviewer per center evaluated their 
images. Consensus was reached during a joint scoring session. Studies were reviewed for tumor 
location, size and imaging characteristics (signal intensity (SI) on T1W- and T2W images, 
enhancement pattern and cystic appearance). 
RESULTS: Of 18 intracranial tumors, 78% were located in the pineal gland and 22% suprasellar. 
All tumors showed well-defined borders with mostly heterogenous enhancement (72%) and 
isointense SI on T1W (78%) and T2W images (72%) compared to grey matter. The majority of 
pineal TRbs showed a cystic component (57%). TRb detected synchronously with the intraocular 
tumors on BBI (n=7) were significantly smaller (P= 0.02), and mainly asymptomatic than TRb 
detected later on (n=10). Overall 5-year-survival of TRb patients detected on BBI was 67% 
(95%-confidence interval 29%-100%) compared to 11% (95%-confidence interval 0%-32%) for 
the group with delayed diagnosis.
CONCLUSIONS: TRb mainly develops in the pineal gland and frequently presents with a 
cystic appearance that could be misinterpreted as benign pineal cysts. Routine BBI in all newly 
diagnosed Rb-patients can detect TRb in a subclinical stage.
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INTRODUCTION 
Trilateral retinoblastoma (TRb) is a disease associating unilateral or bilateral retinoblastoma (Rb) 
with an intracranial midline primitive neuroectodermal tumor (PNET) which usually arises in 
the pineal gland (PG) (77%) (1). In hereditary Rb patients, the neural ectoderm destined to 
form both retinal and pineal tissue is prone to develop multifocal neoplasms. This results in 
histological similar but separate located tumors (2). The risk of developing TRb in Rb patients, is 
less than 0.5% for sporadic unilateral disease (3), 5-13% in sporadic bilateral disease and 5-15% 
in familial bilateral Rb (1). Patients with TRb frequently present with signs of intracranial 
hypertension (3-7). Few long-term survivors are reported and especially in symptomatic patients 
prognosis is poor (1;3;8-10).
Previous studies on TRb detection, neuroimaging screening and prognosis all focused on 
time intervals between detection of Rb and TRb (metachronous tumor development) (1;10-13). 
Reported median time between Rb and TRb diagnosis is 21 months (1;3;9;10). However, Kivela 
et al reported that with inclusion of brain MR screening during first MRI examination for Rb 
(i.e., baseline brain imaging; BBI) approximately 50% of TRb cases can potentially be found (1). 
These are considered synchronous tumors, detected on baseline MRI. Approximately another 
25% of TRbs can be found during the first year after Rb detection. However, recent literature 
states that TRb is rarely present at diagnosis of Rb (14). We hypothesize that the exact prevalence 
of synchronous occurrence of TRb and Rb in literature is underestimated. In most studies, it 
remains unclear whether BBI was performed at Rb diagnosis, at some time-point during follow-
up or only in a later stage for detection of symptomatic TRb; and if imaging was performed with 
CT or MR. This complicates the evaluation of “true” synchronous TRb in literature.
Only few radiological articles on TRb have been reported, and these were mainly individual 
case reports. To our knowledge, only two studies described radiologic findings on MRI in 
trilateral retinoblastoma, both within small groups of patients (10;15). Because of these modest 
study populations, it is relevant to identify specific MRI characteristics of TRb in a larger group 
of patients. 
The primary purpose of this multicenter study was to evaluate clinical findings and MRI 
characteristics of associated intracranial tumors in Rb patients. The secondary purpose was to 
assess clinical, radiological and prognostic differences between TRb depicted on BBI and those 
depicted later on.
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MATERIALS AND METHODS
Patient population 
This retrospective study was performed in agreement with the recommendations of the local 
ethics committees within a European multicenter partnership (ERIC) with five participating Rb-
centers. Review of clinical records between 1991 and 2010, revealed 17 Rb-patients with MRI 
and intracranial tumors. TRb was diagnosed on basis of histopathological confirmation (surgery 
or presence of tumor cells in cerebrospinal fluid [CSF]) or clinical disease progression during 
follow-up MRI. TRb was defined as a mass lesion in the PG or suprasellar region in Rb patients. 
Tumor in both PG and suprasellar regions in combination with bilateral Rb was classified as a 
quadrilateral Rb (QRb). 
Record Review
Clinical records were reviewed for tumor laterality, family history for Rb, age of Rb-diagnosis, 
time-interval from Rb- to TRb-diagnosis and TRb-diagnosis to death or last follow-up date. 
Symptoms at first presentation of TRb and treatment received for Rb and TRb were recorded. 
Laboratory records were analyzed for tumor  cells in CSF acquired by lumbar puncture (LP) 
performed either at diagnosis or during follow-up. Particular attention was paid to the presence 
of BBI, which is necessary to evaluate the simultaneous occurrence of TRb at Rb-diagnosis. TRbs 
were categorized in synchronous or metachronous tumors to the intraocular tumor. Patients with 
bilateral retinoblastoma, a positive family history of retinoblastoma or mutations in the RB1 
gene found in chromosomal/DNA analysis were classified as hereditary. Disease progression was 
defined as either tumor recurrence, intracranial or intraspinal leptomeningeal spread or distant 
metastases.
Image Review
Patients underwent various imaging protocols for the assessment of TRb. MRI sequences varied 
in different institutions. Brain MRI protocols at least included either sagittal or transverse 
unenhanced T1W images or T2W images in 14 patients. Post-contrast T1W images of TRb 
were available in 16 patients.
Two observers (J.C. and P.d.G.) with respectively 22 and 10 years experience individually 
reviewed all MRI examinations and one radiologist from each participating center (H.J.B., P.G., 
P.M. and S.G.) evaluated their images. Agreement was reached during a joint scoring session. MR 
images were evaluated for mass lesions in the PG and suprasellar regions and for leptomeningeal 
tumor dissemination. Regarding the TRb, maximal axial diameter (MAD) at diagnosis, tumor 
border, presence of tumor necrosis, tumor aspect (solid; solid with cystic component; or complete 
cystic), SI on T1W and T2W images compared to grey matter, aspect of contrast enhancement, 
presence of vessel encasement, hydrocephalus and leptomeningeal metastases were scored. 
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Statistics
Statistical calculations were performed using SPSS, version 15.0 (SPSS, Chicago III). BBI and 
MAD were analyzed by using the Mann-Whitney test. Difference in mean MAD between 
pineoblastomas and suprasellar tumors was analyzed using an independent t-test. Associations 
between other clinical dichotomous parameters and BBI were assessed using Fisher exact tests. A 
95%-confidence interval for 5-year survival was calculated based upon the Kaplan-Meier survival 
function. A P-value of less than 0.05 was considered statistically significant. 
RESULTS
Clinical findings 
Clinical data of part of this study were previously reported (Table 1) (1). Ten patients had familial 
Rb (59%) and 11 patients also a positive RB1-gene mutation (65%). Sixteen patients (94%) were 
classified as hereditary Rb. Mean age of Rb-diagnosis was 9 months (median age 5 months) and 
of TRb 26 months (median age, 23 months). Mean time-interval between detection of Rb and 
TRb was 18 months (median, 14 months). In none of the patients, TRb was found before Rb.
Nine patients had signs of intracranial hypertension, whereas the other 8 patients were 
asymptomatic at detection. LP at baseline were performed in 7 patients (positive for tumor 
cells in 5 patients) and during follow-up in 11 patients (positive in 5 additional patients). 
Histopathologic specimen was available in 4 TRbs and were classified as PNETs. Rb was treated 
with external beam radiotherapy (EBRT) (mean age 10 months, median 5 months) in 3 out of 10 
metachronous patients. These patients developed TRb after a mean interval of 19 months (range 
5-37 months). Rb was treated with chemotherapy in 2 out of 10 metachronous TRb patients 
(mean interval 35 months; range 30-40 months). Treatment for TRb was initiated in 13 patients. 
Two patients received palliative treatment because of tumor spread, one patient was not treated 
because of parental refusal, and one patient was lost of follow-up. 
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MRI characteristics of TRb
MRI characteristics are summarized in Table 2. In our group of 17 patients, 18 intracranial 
tumors were detected. 
Of the 14 pineoblastomas, 6 (42%) showed a completely solid aspect (fig 1a), 4 (29%) solid 
with cystic component (fig. 2) and 4 (29%) were completely cystic with an irregularly thickened 
rim (fig. 3). Pineoblastomas mimicking pineal cysts, showed an irregular (patient 6, fig 3a) or 
thickened (patient 16, fig. 3c) cyst wall, sometimes with tiny nodules. Follow-up imaging in 
patient 6 showed progression of the pineal lesion into a solid tumor with diffuse leptomeningeal 
metastases 14 months after refusal of treatment (Fig 3b). Patient 16 showed an obvious solid 
tumor part on the axial MR images (fig. 3d). Secondary hydrocephalus occurred in 8 patients 
(57%) with pineoblastoma (fig 1 b, 2b) and leptomeningeal metastases in 3 patients (21%) (fig. 
1d, 2b). One suprasellar tumor showed a homogenous solid aspect with a cystic component (fig 
2a).
Overall, the mean MAD was 30mm (range 9 – 59mm). 
Fig. 1 Solid pineoblastoma with hydrocephalus and extensive leptomeningeal metastases. Sagittal T1-
weighted (a), axial T2-weighted (b), contrast-enhanced sagittal T1-weighted images of the brain (c) and 
spine (d) of patient 13. Pineoblastoma showed mostly isointense SI on both T1-weighted (a) and T2-
weighted (b)MR images with respect to gray matter and homogenous contrastenhancement (c). The large 
tumor mass (33 mm) showed compression on the brainstem (mesencephalon) and cerebral aquaduct (a, 
c) with secondary hydrocephalus (b). Multiple nodular leptomeningeal tumor seedings are present in the 
spinal canal (d)
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Fig. 2 Suprasellar and pineal gland trilateral retinoblastoma. Contrast-enhanced axial T1-weighted images 
showing solid tumor masses with cystic components in both the suprasellar region (patient 15) (a) and 
pineal gland (patient 7) (b). The pineal gland mass causes a secondary hydrocephalus because of brainstem 
compression (b)
Fig. 3 Pineoblastoma presenting as suspicious cyst. Contrastenhanced sagittal (a–c) and axial (d) T1-weighted 
images of the brain in patient 6 (a, b) and patient 16 (c, d). The pineal gland in a shows an irregular cyst wall 
with tiny nodules, which progressed into a solid tumor with diffuse (nodular) leptomeningeal metastases 14 
months later after treatment refusal (b). The pineal gland in patient 16 mimics a pineal cyst on the sagittal 
image (c), but shows a solid part of the lesion on the axial image (d), suspicious for pineoblastoma
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Clinical and radiological patterns according to time of diagnosis
BBI was available in 7 cases and in all Rb and TRb were diagnosed simultaneously (mean age 
15 months, median 12 months; range 3- 38 months). These 7 patients did not have any signs of 
intracranial hypertension at first presentation.
In the remaining 10 patients without BBI, mean interval between Rb and TRb diagnosis was 
27 months (median 24 months; range 5 – 54 months). Symptoms of intracranial hypertension 
occurred in 8 patients. A significant difference was observed in tumorsize (P= 0.02) and 
hydrocephalus (P= 0.002) in favour of patients with BBI. In 1 patient with TRb no symptoms 
occurred, and in 1 QRb patient symptoms could not be retrieved from the clinical records. 
Furthermore, other differences were observed in the patients with BBI compared to patients 
without BBI. Tumor size was significantly smaller in patients with BBI (mean MAD 18mm 
[range 9-34mm]) compared to patients without BBI (mean MAD 35mm [range 11-59mm]) 
(P = 0.02). Hydrocephalus (P = 0.002) occurred more often in patients without BBI and thus in 
larger tumors. Lumbar puncture in patients with BBI was positive in 29% of the cases and 70% 
in patients without BBI (P = 0.15). 
In addition, more synchronous tumors were detected after the year 2000 as illustrated in 
Table 1, because BBI was more routinely included in current imaging protocols. 
Survival
One out of 17 patients was lost to follow-up and excluded from survival analysis. One out of these 
16 patients was treated with chemotherapy and lost to follow-up after 3 months with progressive 
disease and one died from intoxicity after intensive chemotherapy. 
Five out of 16 patients (33%) are still alive (mean survival, 67 months; median 63 months, 
range, 50 – 93 months). Four of these 5 patients (80%), presented with synchronous TRb 
detected on BBI and were free of disease (mean survival, 61 months; range 50- 74 months). The 
other survivor was diagnosed with a pineoblastoma of 51 mm (54 months after RB-diagnosis 
without BBI). This patient had local tumor recurrences but is still in second complete remission, 
93 months after complete resection of the pineoblastoma and intensive chemotherapy. 
The remaining 10 patients died after a mean interval of 24 months. Eight presented with 
metachronous TRb and without BBI. Cause of death in these 10 patients included local spread of 
the initial TRb (3 patients), leptomeningeal metastases (4 patients), tumor recurrence (2 patients) 
and side effects of intensive chemotherapy (1 patient).
Difference in survival of PNET early detected with BBI compared to those with delayed 
diagnosis was not significant (P = 0.064). The overall 5-year-survival of PNET detected on BBI 
was 67% (95% confidence interval 29%-100%) compared to 11% (95% confidence interval 0%-
32%) for the group without BBI.
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DISCUSSION
Most important imaging finding of this retrospective analysis is that the majority of the 
pineoblastomas in our study were partially or totally cystic. Other main findings are that 
TRbs detected synchronously with the Rb on BBI were significantly smaller, more frequently 
asymptomatic and could have a better prognosis compared to TRbs found after diagnosis of Rb 
(metachronous TRBs). 
In literature, the simultanous occurrence of Rb and intracranial tumor is rare (14;16). Kivela 
et al. reported that intracranial tumors were detected before Rb-diagnosis in 3% of the cases, 14% 
simultaneously with Rb and 83% after Rb-diagnosis. However, the incidence of synchronous 
TRb is probably underestimated, as historically little documentation about the presence of BBI 
at Rb-diagnosis is available. Most TRbs described are diagnosed after first presentation with 
symptoms and signs of intracranial hypertension. Diagnosis and treatment for retinoblastoma is 
usually completed by then (3-7). In our study, in all patients with synchronous tumors detected 
on BBI, significantly smaller TRbs were detected compared to metachronous TRb. Furthermore, 
70% of patients with metachronous tumors presented with symptoms due to intracranial 
hypertension and 80% died due to their intracranial tumor. This indicates that the majority 
of metachronous tumors could have been detected in an earlier stage if BBI would have been 
performed. Remarkably, the majority of synchronous tumors were detected in TRb-patients after 
the year 2000, as cerebral imaging was performed more frequently in our centers. We found a 
lower median time-interval of 14 months in our group compared to a median time-interval of 21 
months mentioned in literature (1;13). In these studies however, the majority of the TRbs (83% 
and 62% respectively) were detected after diagnosis and treatment for Rb, while in our study a 
higher rate of synchronous tumors (41%) were present.
Pineoblastomas and suprasellar tumors presented as typically well-defined lesions with 
relatively isointense SI on T1W and T2W images compared to grey matter. Contrast enhancement 
in these tumors was mostly heterogenous due to cystic components or tumor necrosis. Similar 
SIs on T1W images were reported in 4 and 8 patients respectively on MRI (10;15), but diverse 
enhancement patterns and SIs on T2W images were described (13;15;17;18). Hydrocephalus was 
a typical complication of large pineoblastomas. Therefore, we stress the need for BBI to detect 
smaller TRbs. 
The majority of the pineoblastomas in our study were partially or totally cystic. Pineal cysts 
have been reported in Rb patients but not associated with hereditary Rb (19). The presence 
of suspicious pineal cystic tumors however, are a point of discussion (19-24). Because of life-
threatening side effects that may be related with curative aggressive treatment in TRb patients 
(25), it is important that cysts are not misinterpreted as tumor. Pineal cysts are diagnosed if a) 
an enlarged PG is present, b) with a hypointense central region with respect to white matter on 
T1W images and isointense with respect to CSF on T2W images and c) a thin wall of 2 mm or 
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less with discrete rim enhancement after gadolinium injection (20). Although these criteria are 
formulated, pineal lesions in retinoblastoma are causing radiological dilemmas, especially if the 
cyst wall is irregularly thickened (> 2 mm) or shows a fine nodular aspect of the wall (19;20). In 
our study, only 6 out of 14 pineoblastomas were completely solid, whereas 29% (4 tumors) had 
both a cystic and solid component and 4 tumors mimicked a pineal cyst. Hence, the need for 
imaging characteristics of early stage (cystic) pineoblastoma and follow-up scheme in suspicious 
cystic lesions of the PG is necessary to these from benign pineal cysts. Identification of such criteria 
is only possible in a large group of suspicious cystic PGs in Rb patients. Because these tumors are 
rare, a multicentric prospective study is necessary to define evident criteria for detection of early 
stage (cystic) pineoblastoma. Meanwhile, we recommend that pineal cystic lesions depicted on 
BBI should be classified into three groups: (1)“probably benign pineal cyst”, (2)“obvious cystic 
pineoblastoma”, or (3)“suspicious pineal cyst”. The first group contains patients with a cystic PG 
with discrete rim enhancement and a thin smooth wall; we recommend repeating MRI once after 
6 months and if stable; no further follow-up. The latest group requires close MR follow-up after 
3 months. As currently MRI of every new Rb patient is performed routinely in most centers, 
screening could easily be obtained by performing at least one brain MR sequence (26). This 
screening could be achieved by a post-contrast 3D T1W sequence with 1 mm slice thickness, 
and if a cystic portion is detected in the PG, an additional 2 mm T2W sequence can further 
characterize the lesion. 
In our series, a trend was observed for a better survival of patients who had PNET early detected 
with BBI. However, due to the small sample size, this difference did not reach significance. 
Several studies advise brain imaging screening in Rb-patients in order to detect TRb in an early 
stage (1;9;27). Although improvement of prognosis in TRb patients is important, caution with 
screening programs should be considered. First, prognosis of TRb patients detected by screening 
compared to patients with symptomatic disease should be evaluated. Duncan et al were the first 
to evaluate screening for TRb with CT at baseline and additional brain MRI every 6 months 
in 83 hereditary Rb patients (12). No improved outcome was observed despite early diagnosis. 
Kivela et al (1), discovered that screening identified TRb in an earlier stage, but without better 
survival. This indicates that longer survival was due to lead-time bias. A disadvantage of early 
detection without better outcome is severe treatment-related morbidity and distress in these 
children leading to lower quality of life. In recent literature however, high-dose chemotherapy has 
successfully been introduced for TRb, gradually leading to an increase in survival time (14;28). 
Especially TRb detected in an early stage could benefit from these new treatment strategies, 
since reported survivors are almost inevitably the synchronous or early metachronous patients. 
These early metachronous patients (TRb diagnosed a few months after Rb-diagnosis) should be 
classified as “missed synchronous” rather than “early metachronous”. Therefore we stress the need 
for routine brain MRI in every single newly diagnosed retinoblastoma patient on admission, 
which is a potentially simple and (cost-)effective screening method for early TRb detection. The 
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value of extending brain MRI screening after BBI is under discussion and therefore sporadically 
applied in European retinoblastoma referral centers. 
The rare incidence of TRb in all participating Rb-centers in Europe is in agreement with the 
observed declining incidence of TRb over the last decades (29-31) and is still a matter of debate. 
An increasing use of neoadjuvant chemotherapy for intraocular retinoblastoma (chemoreduction) 
preventing development of TRb has been suggested by Shields et al. who registered fewer TRb 
since the introduction of chemoreduction as primary treatment for Rb (31). However, cases of 
TRb are reported even after an intensive scheme of chemoreduction therapy in advance (32). In 
our study, two out of 10 metachronous TRb patients received chemotherapy and still developed 
TRb. The decreasing incidence of TRb could be due to the declining use of EBRT in patients 
with hereditary retinoblastoma (33). In three patients, intraocular Rb was treated with EBRT and 
these patients developed metachronous pineoblastomas.
A limitation of this study is the absence of BBI in all included metachronous TRbs. Therefore, 
the true incidence of metachronous TRb is likely to be still overestimated. Also, the small size of 
our patient cohort was a study limitation for statistical analysis.
In conclusion, TRb mainly develops in the PG and frequently presents with a cystic 
appearance that may be misleading. We recommend a three-group classification of pineal cystic 
lesions depicted in Rb patients. Routine BBI in all newly diagnosed Rb is strongly recommended 
as it may detect TRb in a subclinical and potentially curable stage. 
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ABSTRACT 
INTRODUCTION: Hereditary retinoblastoma survivors have an increased risk for cranio-facial 
second primary tumours (SPT), especially after treatment with external beam radiotherapy 
(EBRT). This multicentre study evaluates the clinical and imaging characteristics and outcomes 
of cranio-facial SPTs in irradiated retinoblastoma survivors.
PATIENTS AND METHODS: Clinical and radiological data of 42 retinoblastoma patients with 
44 second and third malignancies were reviewed. Radiological data included anatomic location 
and CT and MR characteristics. Cox regression and likelihood ratio chi-square test were used to 
evaluate differences in patients’ survival rates.
RESULTS: Cranio-facial SPTs were diagnosed at a median age of 13 years. Histological types 
included osteosarcomas (43%), rhabdomyosarcomas (20%) (57% embryonal, 43% alveolar) and 
a variety of other types of SPT (37%). Predilection sites were: temporal fossa (39%), ethmoid 
sinus (23%), orbit (18%), maxillary sinus (16%) and intracranial dura mater (4%). Most of the 
osteosarcomas (78%) and rhabdomyosarcomas (80%) occurred in patients treated with EBRT in 
the first year-of-life. Treatment of SPTs with a microscopically complete surgical resection led to 
a significantly better 5-year overall survival (OS) (P= 0.017) and event-free survival (EFS) (P= 
0.012) compared to patients treated without surgery or incomplete resection (OS: 83% versus 
52%; EFS: 80% versus 47%).
CONCLUSIONS: Osteosarcomas and rhabomyosarcomas are the most common cranio-facial 
SPTs in irradiated hereditary retinoblastoma survivors, which develop in specific locations and 
occur predominantly in patients irradiated in their first year-of-life. Microscopically complete 
surgical resection of SPTs is a major prognostic factor, suggesting the potential benefit of early 
detection by imaging. 
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INTRODUCTION 
Hereditary Rb survivors are at greater risk of developing second primary tumors (SPTs) (1) 
because of RB1-gene germline mutation. In developed countries, SPTs are the leading cause of 
death in patients with hereditary Rb (2-6).
The incidence of SPTs in hereditary Rb is 8.4% at 18-years and 36% at 50-years after 
diagnosis (3,4,6–9). External beam radiotherapy (EBRT) increases the risk for subsequent 
malignant neoplasms, as up to 70% of SPTs in Rb patients develop inside or at boundaries of the 
irradiation field (3,4,6,10–14). The age of Rb-diagnosis and subsequent age of irradiation is an 
additional risk factor: patients irradiated during the first year of- their-life develop two to eight 
times more SPTs than patients irradiated after one year (15–17). The combination of EBRT and 
chemotherapy in hereditary Rb patients also slightly increases the risk for SPT development 
compared to EBRT alone (4). Most common histological types of SPT in irradiation fields are 
osteosarcoma, rhabdomyosarcoma, leiomyosarcoma, other soft tissue sarcomas, meningioma 
(12,13,18,19) and rarely carcinomas (8,9).
Prognosis of cranio-facial SPTs in Rb survivors is poor despite aggressive treatment. One 
major prognostic factor of these tumors is the feasability of complete resection of the SPT (20) 
and therefore early diagnosis is crucial. 
Compu ted tomogr aphy (CT)- and magnetic resonance (MR) imaging features of Rb are well 
documented. To our knowledge however, except for case reports (18,19), there is only one study 
(16) describing the spectrum of imaging characteristics of cranio-facial SPTs in Rb survivors. 
This multicenter study evaluates the clinical and imaging characteristics and outcomes of 
cranio-facial SPTs in irradiated hereditary retinoblastoma survivors.
PATIENTS AND METHODS 
Study population
This retrospective study originated from an international partnership of five Rb-reference centers 
(ERIC),from Amsterdam, Essen, Lausanne, Paris and Siena in agreement with the recommendations 
of each local ethics committee or institutional review board. Patient records from 1989 and 2010 
were reviewed and SPTs were included by both ophthalmologists and oncologists from the Rb-
reference centers. The following inclusion criteria were set: (1) a cranio-facial second or third 
malignancies in a retinoblastoma (confirmed by ocular funduscopy, imaging or histopathology) 
patient, (2) EBRT for retinoblastoma, (3) availability of adequate CT or MRI of the SPT. Patients 
with either metastatic tumor, retinoblastoma recurrence or trilateral retinoblastoma were not 
included in the present study. Fourty-four second and third malignancies in 42 patients were 
included in this retrospective study. In the majority of patients the EBRT planning designs 
could not be retrieved from the medical records and were not digitally available, therefore a clear 
definition of the radiation fields and bounderies is lacking.
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Clinical data and primary retinoblastoma treatment
Clinical records were evaluated for patients’ age (at time of Rb-diagnosis, EBRT treatment 
and SPT-diagnosis), presence of RB1-mutation, treatment of Rb and radiation dose. Patients 
with bilateral Rb, a positive family history of Rb or a RB1-gene mutation were classified as 
“hereditary”. Symptoms associated with SPT at first presentation, histopathological type of SPT 
and treatment for SPT were also recorded. Delay of SPT diagnosis was calculated as the time 
elapsed from onset of symptoms to confirmation of SPT diagnosis (imaging or biopsy). Surgical 
treatment was categorized as complete or incomplete microscopic resection. The definition 
of microscopic complete resection was based on both pathological and surgical information. 
Microscopic complete resection was defined as if (macroscopically) the whole tumor was resected, 
with free resection margins at histopathology without macroscopic residual tumor on follow-up 
imaging. Time-intervals were calculated from EBRT to SPT-diagnosis, and SPT-diagnosis to 
death or last follow-up date. Clinical data of part of this patient-cohort were previously reported 
(4,6).
Imaging data and analysis
Only pre-treatment images of SPTs were assessed to avoid treatment effects. Thirty-three MR 
scans were available for review including unenhanced T1W images in all patients and post-
contrast T1-weighted images and T2W images. In addition, 22 CT scans were available for 
review including 18 contrast-enhanced CT-examinations. In 11 out of 44 tumors both MR and 
CT was available.
Images were scored for location of SPT and involvement of bones and muscles in the cranio-
facial area. Tumor location was afterwards categorized in predilection sites. which were based 
on the presumed origin of the SPTs; an anatomical compartment or structure which contained 
the majority of the tumor mass. Additional parameters included regarding tumor spread into 
neighboring anatomical compartments and structures (e.g. spread into the paranasal sinuses, 
orbit, intracranial, cavernous sinus and pterygopalatine fossa), perineural spread, invasion through 
the skullbase and vessel encasement or invasion. 
MRI and CT characteristics for SPTs included tumor border (ill- or well-defined), enhancement 
(homo- or heterogeneous) and necrosis (yes/no). SPTs on MRI were also evaluated for signal 
intensity (SI) as compared to normal muscles on T1W and T2W images (hypo-, iso- and 
hyperintense) and on CT (hypo-, iso- and hyperdense) for calcifications and density of the tumor.
Statistics
All data were statistically analyzed using SPSS, version 15.0 (SPSS, Chicago III). Meningiomas 
were excluded from the survival analysis. For eventfree survival analysis (EFS), an event was 
considered as if a relapse of the SPT (local recurrence or metastases) or cranio-facial third primary 
tumor occurred. Cox regression was used to evaluate differences in EFS and overall survival (OS) 
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in patients treated with or without complete microscopic tumor resection by the likelihood 
ratio chi-square test. The 95% confidence intervals at 5-year survival were calculated for the 
EFS and OS. The association between complete microscopic tumor resection and complete 
disease remission was analyzed by the likelihood ratio chi-square test. Differences between 
histopathological subtypes and age at SPT diagnosis were analyzed using analysis of variance. 
RESULTS 
Clinical characteristics 
Patient and treatment characteristics are described in Table 1. All patients had hereditary retino-
blastoma. EBRT was performed at a mean age of 11 months, and before 1-year of age in 69% of 
patients. Data regarding EBRT dose were available in all but 2 patients. A mean dose of 45 Gy 
(range 40–50Gy) was delivered in 15 to 25 fractions of 2 or 3 Gy. Fourteen patiens (33%) also 
received chemotherapy. Chemotherapy regimen included cyclophosphamide in 10, vincristin in 
11, actinomycin in 4, carboplatin in 2, etoposide in 2 and cisplatin in 2 patients. In one patient 
chemotherapy data could not be retrieved.
Table 1: Patient characteristics of retinoblastoma patients with SPT
Characteristic No. patients (n= 42)
Hereditary retinoblastoma 42
Median age Rb-diagnosis in M (mean, range) 8 (10, 0 - 36)
Median age EBRT in M (mean, range) 10 (11, 1-37)
Median age SPT in Y (mean, range) 13 (15, 3 - 38)
Sex
male 19
female 23
Positive RB1-gene mutation 35
Treatment Rb
Enucleation eye 28
EBRT 42
unilateral 28
bilateral 14
Chemotherapy 14
EBRT in 1st year of life 29
Rb= retinoblastoma, M= months, Y= years EBRT= external beam radiation therapy
SPTs were diagnosed at a median age of 13 years (range, 3–38 years). TPT (2 patients) oc-
curred at a median age of 15 years. Mean time-interval from EBRT to development of SPT was 
15 years with a range of 3 to 37 years. In our study population, EBRT performed within the first 
year-of -life led to SPTs after a mean interval of 14 years compared to 17 years when performed 
after the first year-of-life.
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Delay of diagnosis between onset of symptoms to confirmation of SPT was 56 days (mean 
256 days, range 6-707 days). The most frequent presenting symptom was local swelling (60%). 
Other symptoms included: local pain (14%), headache (19%), sinus symptoms (epistaxis [7%] 
and persisting rhinorrhoea [5%]), not-fitting eye-prothesis (10%), symptoms of intracranial hy-
pertension (5%) and ptosis (5%).
Treatment of SPTs
Forty patients underwent treatment for SPT which included chemotherapy in 35 patients (88%), 
surgery in 25 patients (64%) (out of which only 7 patients showed a microscopic complete tu-
mor resection), EBRT in 4 patients (10%) and brachytherapy in 3 patients (8%). Two patients 
received only palliative care because of extensive tumor spread.
Clinical and radiological characteristics according to histopathological subtypes
The 44 craniofacial SPTs and TPTs were categorized in the following five groups: osteosarcomas 
(17 SPTs and 2 TPTs), rhabdomyosarcomas (9 SPTs), other sarcomas, carcinomas and miscellaneous 
tumors (16 SPTs) (Table 2). Imaging characteristics for osteosarcomas and rhabdomyosarcomas 
are summarized in Table 3.
Table 2: Histopathology and age at diagnosis of 44 second and third primary tumors
Histopathological subgroups Number Median age in years (mean, range)
Osteosarcoma 19 13 (14, 5 - 20)
Rhabdomyosarcoma 9 11 (11, 5 - 22)
Other sarcomas 8 22 (23, 15 - 36)
Leiomyosarcoma 2
Undifferentiated sarcoma 5
Liposarcoma 1
Carcinomas 5 16 (19, 7 - 38)
Sebaceous gland carcinoma 1
Undifferentiated spindle cell carcinoma 3
Sinonasal neuroendocrine carcinoma 1
Miscellaneous 3 11 (14, 3 - 28)
Meningeoma 2
Esthesioneuroblastoma 1
More osteosarcomas and rhabdomyosarcomas were found in Rb survivors treated with 
EBRT within the first year-of-life compared to EBRT after the first year-of-life although this 
difference was not significant (P = 0.07). The median age of occurrence of SPT was significantly 
younger for the two major histological types (P = 0.008 for osteosarcomas and P = 0.003 for 
rhabomyosarcomas) than for the others. In the subgroup of 14 patients treated with a combination 
of EBRT and chemotherapy, no significant correlations were found regarding histopathology, age 
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at presentation or predilection sites of SPTs compared to patients treated for Rb with EBRT 
alone. 
Tumor origin was subdivided into five predilection sites; temporal fossa (39%), ethmoid sinus 
(23%), orbit (18%), superior maxillary (16%) and intracranial dura mater (4%).
Table 3: CT and MR imaging characteristics of osteosarcoma and rhabdomyosarcoma in %
Osteosarcoma Rhabdomyosarcoma
MR (n= 14); CT (n= 12) MR (n= 8); CT (n= 2)
Mean TV in cm3(range) 107 (0.4-411) 91 (12-330)
Border
well-defined 88 (23) 100 (10)
ill-defined 12 (3) 0
Necrosis
yes 65 (17) 50 (5)
no 27 (7) 50 (5)
NA 8 (2) 0
EP
homogeneous 4 (1) 15 (2)
heterogeneous 86 (22) 75 (7)
NA 12 (3) 10 (1)
SI T1-W (MR)
hypointense 21 (3) 0
isointense  71 (10) 100 (8)
hyperintense 7 (1) 0
SI T2-W (MR)
hypointense 21 (3) 0
isointense 7 (1) 25 (2)
hyperintense 64 (9) 75 (6)
NA 7 (1) 0
Density (CT)
hypodense 17 (2) 50 (1)
isodense 17 (2) 50 (1)
hyperdense 25 (3) 0
NA 42 (5) 0
Calcifications (CT)
yes 50 (6) 50 (1)
no 33 (4) 50 (1)
NA 17 (2) 0
TV= tumorvolume, EP= enhancement pattern, SI T1-W= signal intensity on T1-weighted images
SI T2-W= signal intensity on T2-weighted images, (absolute values in brackets)
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Osteosarcoma
Osteosarcoma was the most frequent histologic subtype (43%, 19/44), including 2 TPTs. 
Fourteen osteosarcoma (78%) developed in patients treated with EBRT within the first year-of-
life. Median age for osteosarcoma diagnosis was 13 years (range, 5 – 20 years). The orbit (36%) 
(Fig 2) and temporal fossa (36%) were the predilection sites in this group, Fig 1. In patients 
with osteosarcomas with EBRT after the 1st year-of-life, the temporal fossa (50%) was mostly 
affected. All osteosarcomas in the maxillary sinus and 83% in the orbit were also present in this 
group. Nine out of 18 patients (50%) with osteosarcoma died (mean interval, 65 months) and 10 
patients are currently in complete remission (mean follow-up of 87 months). 
Fig. 1. Typical location of osteosarcom a originating from the lateral orbital wall (greater wing of the 
sphenoid) and temporal bone with extension into the temporal fossa in a 12 years-old girl with bilateral 
retinoblas toma. The tumour was treated with chemotherap y only after parental refusal for surgery. This 
girl died 3 years after diagnosis due to local disease progression.
Rhabdomyosarcoma
Rhabdomyosarcoma was the second most common SPT (20%, 9/44) including 4 embryonal and 
3 alveolar subtypes (data not available for 2 patients). Median age of rhabdomyosarcoma was 
11 years (range 5 – 22 years). Eight out of 9 rhabdomyosarcomas were detected in patients 
irradiated in the first year-of-life, with the ethmoid (50%) (Fig. 2a, b) and temporal fossa (38%) 
as predominantly affected sites. Only 1 tumor developed in a patient irradiated after the first year; 
tumor occurred in the temporal fossa. In total, 4 out of 9 rhabdomyosarcoma patients died after a 
mean follow-up of 77 months (range 5-154). Three patients died due to disease progression and 
1 patient died 154 months after SPT diagnosis from a TPT (osteosarcoma) occuring 6 years after 
rhabdomyosarcoma. Five patients are still in complete remission (mean follow-up, 68 months). 
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Fig. 2. A 13-year-o ld girl presenting with a second and third primary tumour after bilateral EBRT at 
2 months of age. An embryonal rhabdomyosa rcoma of the right ethmoid sinus (a and b) occurred at 13 
years of age, which was treated with chemotherap y, surgery and brachytherap y. During follow-up for this 
second primar y tumour, the patient complained about a painful swelling under the left eye and magnetic 
resonance imagin g (MRI) demonstrated an osteosarcoma originati ng from the orbital floor with soft-tissue 
invasion (small arrow) (e). Retrospect ively, this tumour could be observed 6 months and 2 months earlier 
without soft-tissue invasio n (c and d). This third primary tumour was treated with chemother apy, extensive 
surgery and brachytherapy. Both tumours were completely resected and this girl is still in second complete 
remission.
Other second primary tumors
A variety of other types of SPTs after irradiation were divided in; other sarcomas, carcinomas 
and miscellaneous tumors (Table 2). In 8 patients with EBRT in the 1st year-of-life, 5 (63%) 
were other sarcomas, 2 (25%) carcinomas and 1 (12%) miscellaneous tumors. The temporal fossa 
(40%) and ethmoid sinus (40%) were the predilection sites for patients irradiated within their 
1st year-of-life.
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Survival
At the study time point, 20 patients were still alive (mean interval, 82months; median, 73months; 
range, 17–168months) since SPT-diagnosis. Among these 20 patients, 19 were in complete re-
mission (including 3 patients in second complete remission). One patient was disease free and 
lost to follow-up 1 month after complete microscopic tumor resection. Twenty-two patients died 
from disease progression (mean interval, 51 months; median, 32 months; range, 6 days–244 
months) from diagnosis. 
A significant better 5-year OS (P= 0.017) (Fig 3a) and EFS (P= 0.012) (Fig 3b) was observed 
in patients with complete microscopic tumorresection and 5-year OS and EFS were respectively 
83% (95%CI 54%-100%) and 80% (95%CI 45%-100%). Complete microscopic tumorresection 
also showed a statistically significant correlation with complete disease remission (P = 0.036) 
(Fig. 4). In patients with incomplete resection, the 5-year OS and EFS were 52% (95% CI 34%-
70%) and 47% (95% CI 29%-64%) respectively. Tumor location (P = 0.38), histopathological 
subtype (P = 0.33) and age of EBRT (< 1 year; > 1 year) (P = 0.53) were not associated with a 
significant difference in survival. 
Fig. 3. Overall survival curve (P = 0.017) (a) and event-free survival curve (P = 0.012) (b) showin g the 
effects of comple te (n = 7, dotted line) and incomplete (n = 33, solid line) microscopic tumour resection in 
40 retinoblas toma patients with second primary cranio-facia l tumours.
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Fig. 4. Second primary tumours with complete (a and c) versus incomplete (b and d) microscopic tumour 
resection in the orbital region. Sebaceous gland carcinoma (a and c) in a 38 year old woman with invasion 
in intra-orb ital fat treated with surgery and still under comple te remission. Liposarc oma (b and d) in a 28 
year old woman treated with chemother apy and radiatio n therapy with tumour progression and death 3 
years after diagnosis.
DISCUSSION 
Osteosarcoma and rhabdomyosarcoma are the most common histopathological subtypes of cra-
niofacial SPTs in irradiated hereditary retinoblastoma patients, accounting for 64% of all SPTs 
in our study. Most osteosarcomas are primarily located in the orbit or temporal fossa and rhabdo-
myosarcomas in the ethmoid sinus or temporal fossa. Hereditary Rb-patients irradiated in their 
first year-of-life have a higher risk of SPTs since 79% of osteosarcomas, 89% of rhabdomyosarco-
mas and 63% of the other sarcomas develop in this group of children (21). 
In our study, the majority of the patients complained about a local swelling, sometimes 
combined with local pain as previously described (20). Physicians should realise that otherwise 
innocent symptoms, such as a combination of chronic headache and sinus symptoms, may be 
potentially indicative for craniofacial SPTs (8). These (chronic) symptoms in irradiated hereditary 
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Rb-patients should alert physicians to perform imaging without delay in order to detect SPTs at 
a potentially curative stage.
Radiologists should realise that cranio-facial SPTs in these patients occur in specific predi-
lection sites. Most SPTs develop in the temporal fossa (39%), especially in patients treated with 
EBRT before 1 year-of-age. In the subgroup of 14 patients treated with a combination of EBRT 
and chemotherapy, no significant correlation was observed regarding histopathology, age at pre-
sentation or predilection sites of SPTs compared to patients treated for Rb with EBRT alone. 
Osteosarcomas frequently originated from the orbit and rhabdomyosarcomas from the ethmoid. 
Signal intensity or density are nonspecific for a specific histological type, although calcifications 
are present in at least 50% of osteosarcomas. Tateishi et al. (16) reported imaging characteristics 
(MRI or CT) of SPTs in the irradiated field in 15 patients, and only for osteosarcomas central cal-
cification was found as important finding on CT. Therefore, any solid tissue mass should prompt 
to perform a biopsy for tumor identification without delay. 
Prognosis of Rb patients with SPTs depends on possible treatment strategies. SPTs in the 
irradiated area, treated by a radical surgical approach in combination with chemotherapy and/or 
re-irradiation, show a better survival compared to cases without combined aggressive treatment 
(22). Re-irradiation however, has an increased risk of complications due to post-radiation effects 
and might further increase the risk for a third or fourth primary tumor (23). Therefore, in cases of 
small and resectable tumors in a previously irradiated area, surgery remains the modality of choice 
(24) and complete resection is important for an optimal outcome (25). In some cases however, it 
is difficult to achieve clear surgical margins in this region (20). Our study confirmed a significant 
better 5-year EFS (83%) and OS (80%) in patients treated with complete microscopic tumor 
resection. In this group, we saw significantly more patients with complete disease remission 
with a mean interval of 82 months. This stresses the need of early detection of SPTs in a stage 
where complete resection is possible. Additional pre-operative chemotherapy in combination 
with radical resection may increase the survival rate of patients treated for SPTs occurring after 
hereditary retinoblastoma (20).
A diagnostic protocol based on clinical symptoms is impor tant in Rb patients previously ir-
radiated and specific infor mation regarding these symptoms should be provided as warning signs 
for the patient of interest. However, symptoms are usually nonspecific and the most common is 
soft tissue swelling which may occur quite late in tumor development. For the same reason, a 
clinical depiction based on regular ENT examination would also probably be unsufficient. In 
order to detect SPTs at an early and potentially resectable stage, an imaging screening program 
could be suggested. According to our data, we would recommend to screen the population of all 
retinoblastoma patients treated with EBRT from an age of 5 years to approximately 20 years. 
Frequency of imaging is dependent of different factors including age and associated treatments, 
growth-rate of sarcomas, patients comfort and costs of imaging examinations. Although there is 
currently no consensus about the repetition time, a one year interval could be suggested. Because 
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hereditary retinoblastoma patients are extra vulnerable for radiation damage to the DNA, CT-
scans should be avoided, and MRI should be preferred. 
The benefit of such an MR depiction program in terms of survival is currently not evi-
dence-based. Early diagnosis of SPTs should be balanced against patients’ discomfort and anxiety 
related to repeated MRI examinations, and against potential false positive MR findings leading 
to unecessary biopsies. Such a screening should only be performed through a scientific multi-
center research protocol including informed consent and should assess screenings-intervals, exact 
radiation dose at the tumor site, survival, and the accuracy, benefit, costs and tolerability of the 
method. 
Precise comparison of the SPT location with the radiation fields was not possible in this study 
with the consequence that the exact dose at the tumor site could not be calculated. Furthermore, 
the small size of our patient cohort was a study limitation for statistical issues. 
In conclusion, osteosarcomas and rhabomyosarcomas are the major cranio-facial SPTs in 
irradiated retinoblastoma patients developing in specific locations, particularly in patients with 
EBRT in their first year-of-life. As complete surgical resection is a major prognostic factor, the 
diagnosis of SPT should be obtained as early as possible. Therefore, awareness about the risk 
factors and associated revealing symptoms,typical location and radiological patterns is important. 
An MRI-based screening program could also prove value in detecting these tumors in an early 
and resectable stage to improve survival.
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Retinoblastoma has evolved from a deadly childhood cancer to a largely curable disease within 
the past 100 years. Current treatment strategies are firstly focused on survival and secondly on 
salvaging the eye, providing the best visual outcome as possible. Despite the clear advantages, 
the drawback of this development is that histopathological confirmation of diagnosis and 
analysis of prognostic factors will be decreasingly available in the future. Histopathology is the 
golden standard in evaluating tumor spread and therefore in predicting disease dissemination 
and prognosis of retinoblastoma. These parameters influence treatment options of a child with 
retinoblastoma. Therefore, non-invasive evaluation of prognostic risk factors and treatment 
response become increasingly important. 
Hereditary retinoblastoma survivors have a greater risk to develop associated neoplasms. 
Hereditary retinoblastoma is associated with trilateral retinoblastoma (TRB) and second primary 
tumors (SPT). These co-morbidities have great consequences as most patients have a poor 
prognosis. It is important to understand the pattern of development of both TRB and SPT in 
retinoblastoma patients to detect these tumors in an early and potentially curable stage. 
The first part of this thesis reports on novel diagnostic imaging techniques applied for ocular 
MR imaging to differentiate between retinoblastoma and simulating lesions. The capability 
of advanced imaging techniques to evaluate prognostic factors and treatment response such as 
angiogenesis and tumor necrosis are studied. The second part of this thesis focuses on imaging 
patterns of associated abnormalities and more specifically TRB and cranio-facial second primary 
tumors in irradiated hereditary retinoblastoma survivors. 
Minimal required protocol for retinoblastoma imaging 
Chapter 2 presents an overview of the minimum requirements for diagnostic evaluation of 
retinoblastoma or mimicking lesions according to the consensus reached among members of the 
European Retinoblastoma Imaging Collaboration (ERIC)1. The value of MRI is mostly reliant on 
the protocol used2. The combination of ultrasound with high resolution MRI is recommended 
as most useful imaging modalities. Together with fundoscopy, ultrasound is mainly responsible 
for diagnosis of retinoblastoma and detects the specific calcifications in retinoblastoma. High 
resolution MRI is mainly necessary for determination of tumor extent (optic nerve, choroid, 
sclera and anterior eye segment) and associated morbidity as TRB and (during follow-up) 
SPT. Only in complicated eyes MRI may play a role in tumor diagnosis itself. The minimal 
required protocol explicitly excludes CT scans because it poses a significant radiation risk to 
(especially hereditary) retinoblastoma patients. The main advantage of MRI compared to CT 
includes the lack of radiation exposure, better soft tissue discrimination and higher soft tissue 
contrast. Standardization of imaging protocols world-wide is necessary to perform multicenter 
international studies for further tumor characterization and implementation of novel imaging 
techniques in retinoblastoma. New non-invasive imaging parameters to assess tumor response 
and prognostic factors are essential in the future of retinoblastoma treatment. 
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Value of novel techniques for ocular MRI in retinoblastoma diagnosis
Ultrasound remains the most economical, rapid and safest imaging modality for confirmation 
of diagnosis and has a high diagnostic accuracy. Even in difficult cases ultrasound is able to 
differentiate between benign and malignant intraocular childhood lesions by analysis of tumor 
morphology and by depicting calcifications which are characteristic for retinoblastoma1. 
If clinical diagnosis is uncertain, the combination of ultrasound and MRI is necessary to 
differentiate between intraocular abnormalities. Confusion in diagnosis sometimes may be 
the case when persistent hyperplastic primary vitreous and Coats disease are considered in the 
differential diagnosis. These diseases have a close resemblance with retinoblastoma and can be 
differentiated by subtle additional MRI information such as eye size, morphology of mass-lesions 
and enhancement patterns. Because of the increasing use of conservative strategies in treatment 
of retinoblastoma, novel imaging techniques become more important for noninvasive diagnosis. 
Especially in complicated eyes, for example in cases when opaque media occurs such as cataract or 
bleeding in the anterior segment or vitreous, ultrasound and even the standard MRI techniques 
could become insufficient to confirm the diagnosis of retinoblastoma. Worldwide CT has been 
the method of choice to detect calcifications and confirm retinoblastoma diagnosis for years3;4.
In chapter 3 we show that retinoblastoma imaging nowadays can be safer and more valuable 
without exposing the patients to the radiation hazards of CT. The use of T2*WI in depicting 
calcifications in retinoblastoma demonstrated to be as good as ex-vivo high resolution and 
high dosis CT-scans. Diagnostic value of T2*WI thereby surpasses the commonly used in vivo 
standard pediatric orbital CT, which is usualy acquired with lower resolution and lower dosis. 
We were able to confirm and reproduce a study of Galluzzi et al which showed a good correlation 
between calcifications on CT and signal intensity voids on T2* weighted imaging5. In addition 
we showed MRI characteristics which could differentiate between other causes of signal intensity 
void spots on T2*WI and calcifications. In ocular MR imaging these additional void spots 
could indicate intratumoral hemorrhage, which mainly has a smooth and linear aspect and is 
predominantly located in the tumor periphery. Linear signal intensity voids could also be the 
effect of susceptibility artifacts causing magnetic field inhomogeneities at the air-tissue interface, 
such as under the eye lid and is primarily located close to the anterior eye segment. At last we 
described signal intensity voids due to venous congestion, which is a result of susceptibility effects 
in venous blood caused by the presence of deoxyhemoglobin, increased intravascular space and 
slow flowing venous blood. Another promising MRI technique we used to detect calcifications 
and differentiate them between intratumoral hemorrhage, necrosis and artifacts is susceptibility 
weighted imaging. Our study suggest that this technique has the potential to be more sensitive 
than T2*WI. 
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Value of novel MRI techniques in evaluation of prognostic factors and treatment response
In chapter 4 we describe the potential of dynamic contrast enhanced MRI (DCE-MRI) for 
assessment of tumor angiogenesis and tumor vitality in retinoblastoma. Microvessel density is an 
important parameter for tumor angiogenesis in vitro and is associated with local invasive growth 
and hematogenous metastases in retinoblastoma6. 
In DCE-MRI, non-invasive evaluation of tumor angiogenesis is acquired by analysis of a set 
of T1W images, which are obtained consecutively before, during and after injection of a bolus of 
gadolinium contrast material. This technique supplies information on the uptake and eventually 
washout of gadolinium from the tissue in the first few minutes after injection Highly vascularized 
tissue with a high MVD typically shows rapid signal enhancement after contrast injection, 
corresponding to a DCE-MRI curve with a steep slope. This curve provides information about 
blood flow, capillary leakage and related physiological parameters. This technique is increasingly 
being used in improving clinical diagnostic imaging and in assessing microvascular changes 
after treatment7. A variety of quantitive values associated with DCE-MRI has been analyzed 
in previous literature in which the same quantities appear with a different name or symbol so 
that comparison of work from different groups is difficult8. Ktrans for example is a frequently 
used parameter representing the volume transfer constant but requires determination of both 
an arterial input function (AIF) and adequate precontrast datasets to calculate the baseline T1 
relaxation time. In retinoblastoma imaging however this parameter is not easily applicable 
because of several reasons. First, in retinoblastoma imaging the estimation of an AIF for sampling 
is difficult because the lack of a large arterial vessel near the tumor. Secondly, a baseline T1 
measurement is usually required for generating the contrast concentration curve from the signal 
curve. This T1 measurement requires additional acquisition time, and has not yet been applied 
and validated in orbital imaging9. In our study we used the parameter κ obtained with curve 
pattern analysis. We showed that the early phase of the curve κ(5min), which represents the initial 
phase of the curve, is positively correlated with tumor MVD (p= 0.008)10. This parameter could 
be a predictor of tumor extent since MVD as a marker correlates with both local invasive growth 
and the presence of metastasis in retinoblastoma. It could also be a useful follow-up parameter for 
evaluation of angiogenesis in tumors treated with vascular targeting (antiangiogenic) drugs (anti-
VEGF drugs). Although, we observed no significant correlation between DCE-MRI parameters 
and VEGF in our small study population, it would be interesting to evaluate this in a large 
retinoblastoma population in the future. 
The parameter obtained from the full time series, κ(17min), negatively correlated with 
the degree of tumor necrosis (p= 0.002). The κ(17min) could be a predictor for the success of 
conservative treatment of retinoblastoma because severe hypoxia, which is present in necrotic 
tumors, has a negative influence on the outcome of radiation and chemotherapy. A limitation of 
our study is the lack of clear landmarks to obtain the same cross section between MRI and the 
histopathology slice which is especially difficult in heterogenous tumors. We used the classical 
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region of interest (ROI) approach where the time intensity curves in a ROI are averaged. These 
curves reflect the status of the tissue and capillary integrity. In breast cancer it has been used 
as indicator of suspected malignancy11;12. There is however still no general consensus on the 
real ability of this analysis to correctly grade tumors or exclude malignancy13;14. Although we 
included the most enhancing part of the tumor, in heterogeneous tumors this technique is not 
accurate enough. In the future, pixel-by-pixel analysis could optimize DCE-MRI parameters 
by considering the heterogeneity of the tumor. Previous literature demonstrated that where the 
ROI approach fails to show the presence of highly vascularized areas, the pixel-by-pixel approach 
reveals co-existence of a heterogeneous pattern of signal intensity curves15. This technique 
could be valuable in the future for response prediction in conservative treatment strategies for 
retinoblastoma.
Follow-up imaging of associated morbidity
Hereditary retinoblastoma is associated with both malignant and benign brain abnormalities. 
First, the midline primitive neuroectodermal tumor in the pineal and suprasellar region 
(known as trilateral retinoblastoma [TRB]) occurs in 5-15% of this population16;17. Structural 
brain abnormalities are reported in retinoblastoma patients with 13q deletion syndrome18. In 
chapter 5 we provide an overview of brain abnormalities that were found in a large group of 
168 retinoblastoma patients of which 7 patients were diagnosed with 13q deletion syndrome. 
In this study population, structural brain abnormalities occurred only in combination with a 
13q deletion syndrome. One patient showed a corpus callosum agenesis and another patient a 
Dandy-walker variant with dilated ventricles which has been described once before in literature19. 
In 5.5% of the hereditary retinoblastoma patients pineoblastoma was detected on MRI in 
accordance with previous literature16;17. The total incidence of pineal cysts in our study was 5.4%, 
with an incidence of 9.0% in the non-hereditary group and 2.2% in the hereditary group. The 
incidence in the group of hereditary retinoblastoma is similar to that in healthy younger children 
and is therefore not associated with retinoblastoma. However, radiologists should realize that 
small pineoblastomas can have a cystic appearance which could be confusing when analyzing the 
pineal gland in hereditary retinoblastoma patients. This issue is further discussed in chapter 6. 
Some studies indicate that in the future the incidence of pineoblastoma may decrease due to the 
protective effect of chemoreduction therapy and/or the lack of external beam radiation therapy 
(EBRT)20-22. It is likely that this decrease is a consequence of the latter because the vast majority 
of pineoblastomas are detected at baseline, even before intravenous chemoreduction therapy 
could have been applied. Furthermore, in the future it will be of interest to know if incidence of 
pineoblastoma remains the same after the introduction of selective intra-arterial chemotherapy 
applied to the affected eye via the ophthalmic artery. 
In chapter 6 imaging parameters of TRB are further characterized. These intracranial primitive 
neuroectodermal tumors are most commonly located in the pineal gland (77% of the cases)23. 
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Pineoblastomas and suprasellar tumors present as typically well-defined lesions with relatively 
isointense signal intensity on T1W images compared to gray matter, in agreement with previous 
literature17, and isointense signal intensity on T2-W images. These tumors show heterogenous 
contrast enhancement because of cystic components or tumor necrosis. A possible association 
between benign pineal cysts and retinoblastoma which could be an indication for pineoblastoma 
development is also suggested24. The majority of the pineoblastomas in our study are partially 
cystic with a solid part (29%) or totally cystic (29%). Benign pineal cysts occur in 0.4% - 2.2% 
of the general pediatric population in accordance with the incidence of pineal cysts in hereditary 
retinoblastoma25;26 In hereditary retinoblastoma patients it is important that these cystic pineal 
glands based on early stage pineoblastomas are detected in time and not misinterpreted with 
benign pineal lesions so that treatment can be focused on curation. Benign pineal cysts are 
defined as (1) the presence of an enlarged pineal gland, (2) with a hypointense central region 
with respect to white matter on T1W images and isointense with respect to cerebral spinal 
fluid on T2W images, and (3) a thin wall of 2 mm or less with discrete rim enhancement after 
gadolinium injection27. Despite these criteria, pineal lesions in retinoblastoma causes dilemmas, 
especially if the cyst wall is irregularly thickened (> 2mm) or shows a fine nodular aspect of the 
wall28. Therefore identification of imaging criteria concerning early stage (cystic) pineoblastoma 
and follow-up of suspicious cystic pineal lesions are necessary in future prospective multicenter 
studies. In the meantime we recommend to classify cystic pineal lesions into three categories (1- 
“probably benign pineal cyst”, 2- “obvious cystic pineoblastoma”, or 3- “suspicious pineal cyst”) 
with different clinical approaches to detect pineoblastoma at an early stage. If the lesion follows 
the criteria regarding benign pineal cysts (category 1), we recommend repeating MRI after 6 
months, if stable no further follow-up imaging will be necessary. The third category however 
needs close MR follow-up after three months. Screening of the pineal gland in retinoblastoma 
patients could be achieved by a post-contrast 3D T1W sequence with 1 mm slice thickness. If a 
cystic lesion is detected in the pineal gland, an additional 2 mm T2W sequence or thin slice 3D 
T2/CISS can be performed to characterize the lesion. 
Primitive neuroectodermal tumors in the pineal gland or suprasellar location associated 
with retinoblastoma (known as trilateral retinoblastoma) has been lethal in virtually all cases 
previously reported. However, intensive treatment with high-dose chemotherapy protocols and 
stem cell reinfusion possibly combined with surgery may potentially be curative29. This thesis 
demonstrates that TRB detected synchronous with retinoblastoma on first MRI examination 
(baseline brain imaging, BBI) are significantly smaller than metachronous tumors (18mm versus 
35mm, P= 0.002). Patients with BBI also have lesser symptoms and tend to have a better 
prognosis compared with TRB detected after retinoblastoma diagnosis (metachronous tumors). 
Previous literature suggests that the occurrence of retinoblastoma and a simultaneous intracranial 
tumor is rare30. However this incidence is probably underestimated as in most reported cases of 
TRB BBI is not present. The majority of our patients who did not survive TRB, presented usually 
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with large and mainly metachronous tumors. Kivela detected that mainly children with tumors 
that were 15 mm or less in size had a better prognosis than children with larger ones (p = .020). 
Screening should be focused on detection of these small tumors. The incidence of synchronous 
tumors is increased since the year 2000 when brain imaging was routinely performed in the 
ERIC-centers. Only in patients with BBI there is a possibility to detect these small tumors 
and potential cure the patient. Therefore standard BBI in retinoblastoma is important in every 
newly diagnosed retinoblastoma patient and is therefore recommended in the ERIC guidelines. 
Although in this thesis the value of BBI is stressed, standard follow-up brain MRI screening in 
hereditary retinoblastoma patient is not recommended. In a previous study, screening led to a 
longer median survival time, but the age of TRB detection was earlier while the age of death did 
not differ. This means that screening led to lead time bias with more risk for severe treatment 
related morbidity and distress in children. 
Second primary tumors (SPT) are responsible for a significant proportion of the mortality 
in hereditary retinoblastoma survivors31;32. External beam radiation therapy (EBRT) increases 
the risk for (radiation induced) bone cancers and soft tissue sarcomas. Seventy percent of these 
sarcomas develop within the head and face32. Our study shows that craniofacial SPTs in irradiated 
retinoblastoma patients are diagnosed at a median age of 13 years (range 3 – 38 years) and a 
median time-interval between EBRT to SPT development of 15 years (range: 3–37). Age of EBRT 
is a risk factor for SPT development in retinoblastoma with development of considerably more 
SPTs in patients irradiated during their first year of life compared to irradiation after one year33;34. 
This might in part be explained by the fact that hereditary retinoblastoma patients develop 
their disease at a younger age and therefore treated earlier. SPTs are usually symptomatic at 
diagnosis with local swelling (60%), local pain (14%), headache (19%), epistaxis (7%), persistent 
rhinorrhea (5%), not-fitting ocular prothesis (10 %), symptoms of intracranial hypertension 
(5%), and ptosis (5%) as most frequent symptoms. These symptoms appear innocent, but when 
persistent it could indicate the presence of an SPT. When SPTs present with late stage disease 
with a bulky tumor mass, a complete resection is not possible anymore, which diminish the 
change of survival. Histopathological subtypes of SPT predominantly includes osteosarcomas 
and rhabdomyosarcomas (together 64% of all cranio-facial second primary tumors in irradiated 
retinoblastoma patients) and with a lower prevalence leiomyosarcoma, undifferentiated 
sarcomas, meningiomas, and carcinomas. Predilection sites for SPT development in irradiated 
retinoblastoma survivors are the ipsilateral irradiated orbit and temporal fossa for osteosarcomas, 
and the ethmoid and temporal fossa for rhabdomyosarcomas. The overall prognosis of SPTs in 
the craniofacial area in previously irradiated retinoblastoma patients is generally poor, despite 
intensive treatment based on chemotherapy and surgery. 35;36Prognosis depends on feasibility of 
complete microscopic tumor resection of the SPT which has a significantly better overall and 
event free survival compared to incomplete resection. 
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CLINICAL IMPLICATIONS AND FUTURE PERSPECTIVE
Retinoblastoma diagnosis
In daily clinic practice, the combination of fundoscopy, ultrasound and MRI detects retinoblastoma 
in almost all cases5. Presence of calcifications is critical for retinoblastoma diagnosis and is 
difficult to evaluate by fundoscopy if unclear ocular medium is present. The most common 
mimickers of retinoblastoma in eyes with leukocoria include persistent hyperplastic primary 
vitreous and Coats disease. In contrast to retinoblastoma, both of these do not show calcifications. 
T2*WI shows to be a feasible technique to detect calcifications. It is possible to distinguish 
between calcifications and other causes of signal intensity void spots on MR (hemorrhage, venous 
congestion) by analyzing the shape and location of signal intensity voids. In patients with still 
confusion regarding diagnosis after fundoscopy and ultrasound, T2*WI could be added to the 
imaging protocol for further differentiation. Susceptibility weighted imaging has the potential 
to differentiate between hemorrhage and calcifications by using the phase information in the 
phase image, and could therefore be an even more specific technique for retinoblastoma diagnosis. 
Future research should focus on diagnostic accuracy of susceptibility weighted imaging in 
detection of calcifications and secondarily, the accuracy to differentiate between retinoblastoma 
and simulating lesions.
Conservative treatment and response evaluation
Super-selective administration of chemotherapy to the affected eye (i.e. intra- arterial and intra-
vitreal chemotherapy) leads to globe salvage in more and more patients by avoiding enucleation 
or EBRT and minimizing side effects of systemic intravenous chemotherapy and late sequelae 
of EBRT. These conservative treatment strategies require an accurate pretreatment non-invasive 
staging of the disease. Furthermore, functional MRI techniques might provide parameters 
to support the ophthalmologists in treatment selection and early prediction of response to 
conservative treatment. Dynamic contrast enhanced MRI can be a feasible technique to non-
invasively characterize the intraocular mass for tumor angiogenesis and tumor necrosis, which 
respectively is considered as a risk factor for disseminated disease and treatment response. This 
technique could even become more accurate with pixel-by-pixel analysis identifying separate 
regions of high vascularization and necrosis in one tumor. With increasing technical options 
for DCE-MRI, future applications of T1 relaxation time calculations and AIF measurements 
for quantitative modeling might further enhance the options for tumor characterization and 
treatment response prediction. Before this technique can be applied in daily clinical practice, 
prospective studies for response evaluation and standardization of imaging analysis methods 
between retinoblastoma centers should be achieved. 
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Imaging of associated morbidity
In every retinoblastoma patient the brain should be imaged during the first MRI examination as 
most trilateral retinoblastomas are detected at BBI. It is important that complex cystic lesions in 
the pineal gland are discovered in time, since small pineoblastomas can present as cystic lesions. 
If the lesion resembles a benign pineal cyst MRI should be repeated after 6 months, and if stable 
no further follow-up imaging will be necessary. In cases of irregularly thickened or fine nodular 
aspect of the wall occurs, close MR follow-up after three months should be performed. Larger 
prospective multicenter studies are necessary to evaluate the benefits of screening. 
Most common cause of death in retinoblastoma survivors are development of second primary 
tumors, especially after external beam radiation therapy for retinoblastoma. Detection of these 
tumors in an early stage is crucial and therefore a screening program for craniofacial SPTs in 
hereditary retinoblastoma patients who were initially treated with EBRT could be beneficial. 
In the future a prospective non-invasive study (preferably part of a larger multicenter study) 
is necessary to investigate whether screening for SPTs in irradiated hereditary retinoblastoma 
survivors with MRI is effective for early tumor detection and results in a reduction of mortality. 
Screening could potentially be related to associated anxiety, but also to reassurance. Besides 
evaluation of the ability of MRI to detect these tumors in time, a future study should also focus 
on psychological burden.
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NEDERLANDSE SAMENVATTING
Retinoblastoom is in de afgelopen 100 jaar veranderd van een fatale vorm van kinderkanker tot 
een grotendeels geneesbare ziekte. De huidige behandelstrategieën zijn in de eerste plaats gericht 
op overleving en daarnaast behoud van het oog met optimale visus. Door deze ontwikkelingen 
zal er in de toekomst steeds minder vaak weefsel beschikbaar zijn waardoor histopathologische 
bevestiging van de diagnose en analyse van histopathologisch prognostische factoren beperkt 
wordt. Histopathologie is de gouden standaard in de evaluatie van tumor uitbreiding en prognose 
van retinoblastoom. In de toekomst wordt het daarom belangrijk om technieken te ontwikkelen 
die een niet-invasieve evaluatie van prognostische risicofactoren en behandelrespons mogelijk 
maken.
Patiënten met de erfelijke vorm van retinoblastoom hebben een groter risico op het 
ontwikkelen van geassocieerde vormen van kanker, zoals het trilaterale retinoblastoom (TRB) en 
tweede primaire tumoren (TPT), met een slechte prognose tot gevolg. Het is belangrijk om het 
ontwikkelingspatroon van deze tumoren in kaart te brengen, zodat behandeling in een vroeg en 
mogelijk curabel stadium kan plaatsvinden.
Het eerste deel van dit proefschrift richt zich op nieuwe beeldvormende technieken 
die worden toegepast bij MRI van het oog om onderscheid te maken tussen retinoblastoom 
en simulerende laesies. Tevens worden de mogelijkheden van geavanceerde beeldvormende 
technieken geanalyseerd om factoren die de prognose en respons op behandeling beïnvloeden, 
zoals angiogenese en tumor necrose, te identificeren. Het tweede deel van dit proefschrift richt 
zich op MRI karakteristieken van geassocieerde afwijkingen in het hoofd en aangezicht , in het 
bijzonder TRB en TPT. 
Beeldvormend onderzoek bij retinoblastoom
Wereldwijd worden verschillende MRI technieken gebruikt voor de diagnostiek van retinoblastoom. 
Hoofdstuk 2 geeft een overzicht van de huidige toepassingen en beperkingen van beeldvormende 
technieken voor retinoblastoom en bevat een MRI protocol voor een hoogwaardige diagnostische 
evaluatie van retinoblastoompatiënten volgens consensus van de European Retinoblastoma 
Imaging Collaboration (ERIC), een samenwerkingsverband tussen radiologen uit Europese 
retinoblastoom-gespecialiseerde centra. Hoge resolutie MRI is noodzakelijk voor nauwkeurige 
evaluatie van tumoruitbreiding en daarnaast screening op geassocieerde maligniteiten zoals TRB 
en (tijdens de follow-up) TPT. Slechts in gecompliceerde gevallen speelt MRI een rol bij de 
diagnostiek van de primaire tumor. CT scans worden in dit protocol afgeraden vanwege de hoge 
stralingsbelasting in deze reeds erfelijk belaste groep patiënten. Afgezien hiervan is er bij MRI een 
beter onderscheid tussen weke delen doordat er een hoger weke-delen contrast is. Standaardisatie 
van MRI protocollen wereldwijd is belangrijk om internationale multicentrische studies uit te 
voeren voor verdere toepassing van nieuwe beeldvormende technieken bij retinoblastoom en 
daarmee een hoog niveau van beeldvorming na te streven.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
138  |  Chapter 9
Waarde van MRI voor differentiaal diagnose 
Echografie blijft de meest praktische beeldvormende techniek voor bevestiging van de diagnose 
retinoblastoom en heeft een hoge diagnostische nauwkeurigheid. Zelfs in gecompliceerde 
gevallen is echografie in staat om onderscheid te maken tussen goedaardige en kwaadaardige 
intraoculaire laesies bij kinderen. Bij twijfel is de combinatie van MRI en echografie aangewezen 
om te differentiëren tussen maligne en benigne intraoculaire afwijkingen, zoals persisterende 
foetale vasculatuur en de ziekte van Coats. In gevallen met opake media zoals bij cataract of een 
bloeding in het voorste segment of glasvocht, kunnen echografie en zelfs de standaard MRI-
technieken onvoldoende zijn om de diagnose  retinoblastoom te bevestigen.
In hoofdstuk 3 wordt een T2* gewogen MRI techniek in de diagnostiek van retinoblastoom 
besproken. Het gebruik van T2* gewogen opnamen om karakteristieke verkalkingen in 
retinoblastoom aan te tonen bleek net zo nauwkeurig te zijn als ex-vivo hoge resolutie CT-scans. De 
MRI techniek is echter veiliger vanwege de afwezigheid van additionele stralingsrisico’s zoals die 
bij CT wel aanwezig zijn. In vergelijking met de doorgaans lage resolutie CT scans die standaard 
bij kinderen wordt verricht, blijkt de diagnostische waarde van T2* gewogen beeldvorming 
beter. In onze studie bevestigen wij de goede correlatie tussen verkalkingen aangetoond op CT 
en hypointense laesies op de T2* gewogen opnames zoals eerder aangetoond door Galluzzi. 
Daarnaast formuleerden wij MRI kenmerken die kunnen differentiëren tussen verkalkingen 
en andere oorzaken van hypointense laesies op T2* gewogen beeldvorming bij retinoblastoom. 
Een bloeding in het oog kan zich bijvoorbeeld presenteren als een hypointense laesie. Het kan 
worden onderscheiden van verkalkingen door het aspect van de bloeding, namelijk glad met een 
lineair aspect en voornamelijk gelegen in de periferie van de tumor. Lineaire hypointense laesies 
kunnen echter ook het gevolg zijn van artefacten. Ook veneuze stuwing veroorzaakt hypointense 
laesies op T2* gewogen opnames door de aanwezigheid van deoxyhemoglobine, een gedilateerde 
veneuze vaten en langzaam stromend veneus bloed. Susceptibility weighted imaging lijkt een 
andere veelbelovende MRI techniek om verkalkingen te differentiëren van bloedingen, necrose 
en artefacten. Uit onze studie blijkt dat deze techniek mogelijk gevoeliger is dan T2* gewogen 
beeldvorming.
Waarde van dynamische MRI voor prognostische factoren en respons op behandeling
In hoofdstuk 4 beschrijven we de mogelijkheden van dynamische MRI (DMRI) voor de 
beoordeling van vaatnieuwgroei (angiogenese) in de tumor en vitaliteit van het tumor weefsel in 
een groep van 15 retinoblastoom patiënten. Dynamische MRI is een techniek waarbij een serie 
MRI beelden voor, tijdens en na contrasttoediening wordt vervaardigd. Deze techniek biedt de 
mogelijkheid van kwantitatieve evaluatie van de fysiologische eigenschappen van tumorweefsel. 
Analyse van contrastaankleuring van de tumor wordt gedaan met behulp van de “curve pattern 
analysis” methode. Microvasculaire dichtheid is een belangrijke histopathologische parameter 
voor tumorangiogenese in vitro en is gecorreleerd met invasieve groei en hematogene metastasen. 
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Karakteristiek voor zeer gevasculariseerd weefsel met een hoge microvasculaire dichtheid is 
snelle signaalversterking na contrastinjectie, overeenkomend met een DMRI curve met een steile 
helling. Deze curve geeft informatie over de doorbloeding, capillaire lekkage en gerelateerde 
fysiologische parameters. Deze techniek wordt steeds vaker gebruikt bij het verbeteren van 
klinisch diagnostische beeldvorming en bij de beoordeling van microvasculaire veranderingen na 
behandeling. In onze studie hebben we de fysiologische parameter κ gebruikt, verkregen met curve 
pattern analyse. We toonden aan dat de vroege fase van de curve κ(5 min), welke representatief is 
voor de eerste fase, positief gecorreleerd is met de microvasculaire dichtheid van retinoblastoom 
(p = 0.008). Dit kan mogelijk in de toekomst een belangrijke parameter vormen bij de follow-
up van retinoblastoom patiënten die behandeld worden met anti-angiogene geneesmiddelen. 
De κ(17min) vertegenwoordigd de volledige tijdscurve en is negatief gecorreleerd met de mate 
van tumornecrose (p = 0.002). De κ(17min) zou een geschikte parameter kunnen zijn om het 
succes van conservatieve behandeling van retinoblastoom te evalueren. In necrotische tumoren 
is namelijk sprake van ernstige hypoxie, wat het effect van behandeling middels bestraling en 
chemotherapie negatief beïnvloedt. Er bleek geen significante relatie te bestaan tussen kinetische 
gegevens van DMRI en de aanwezigheid van risicofactoren voor het optreden van metastasen 
(oogzenuw en choroidea invasie) of de aanwezigheid van groeifactoren voor vaatnieuwgroei 
(vascular endothelial growth factor; VEGF) in de tumor.
Follow- up beeldvorming van geassocieerde hersenafwijkingen of maligniteiten
Erfelijk retinoblastoom is geassocieerd met zowel kwaadaardige als goedaardige hersenafwijkingen. 
De meest bekende is het trilaterale retinoblastoom (ontogenetisch ontstaan uit hetzelfde weefsel 
als de retina, met lokalisatie in de pijnappelklier [pineoblastoom] en supra- of parasellaire regio) 
bij 5-15% van de retinoblastoom patiënten. Daarnaast zijn er ook structurele hersenafwijkingen 
gerapporteerd bij kinderen met het 13q deletie syndroom. In hoofdstuk 5 geven we een overzicht 
van de hersenen afwijkingen die werden gevonden in een grote groep van 168 retinoblastoom 
patiënten waarvan 7 patiënten werden gediagnosticeerd met het 13q deletie syndroom. In onze 
studie werden structurele hersenafwijkingen alleen in combinatie met dit syndroom gevonden. 
Eén patiënt toonde een corpus callosum agenesie en een andere patiënt een Dandy-Walker 
variant met verwijde ventrikels. Daarnaast vonden wij in 5.5% van de erfelijke retinoblastoom 
patiënten een trilateraal retinoblastoom, in overeenstemming met eerdere literatuur. De totale 
incidentie van pinealiscysten was 5.4 %( 9.0 % in de niet-erfelijke groep en 2.2 % in de erfelijke 
groep). De incidentie in de groep van erfelijk retinoblastoom is gelijk aan die bij gezonde jonge 
kinderen en derhalve niet geassocieerd met retinoblastoom. Belangrijk voor radiologen is dat 
kleine pineoblastomen een cysteus aspect kunnen hebben wat verwarring kan veroorzaken in 
de differentiatie met benigne pinealis cysten. Dit wordt besproken in hoofdstuk 6. Sommige 
studies geven aan dat de incidentie van het trilateraal retinoblastoom in de toekomst zal afnemen 
als gevolg van de beschermende werking van chemoreductie therapie en/of het ontbreken van 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
140  |  Chapter 9
uitwendige bestraling voor de behandeling van het retinoblastoom. Het is het meest aannemelijk 
dat deze afname het gevolg zal zijn van dit laatste aspect, omdat de overgrote meerderheid van 
pineoblastomen wordt gedetecteerd reeds vóór intraveneuze chemoreductie behandeling. Verder 
is het interessant om te evalueren of in de toekomst de incidentie van het pineoblastoom hetzelfde 
blijft na de invoering van selectieve intra-arteriële chemotherapie via lokale toediening in de 
arteria ophthalmica van het getroffen oog.
In hoofdstuk 6 worden karakteristieke MRI parameters van TRB vastgesteld. Deze 
intracraniële tumoren zijn meestal gelokaliseerd in de glandula pinealis (77% van de 
gevallen) of in de suprasellaire regio. Pineoblastomen en suprasellaire tumoren hebben een 
relatief isointense signaalintensiteit op T1-gewogen beelden ten opzichte van grijze stof en 
isointense signaalintensiteit op T2-gewogen beelden. Deze tumoren hebben een heterogeen 
aankleuringspatroon na contrasttoediening door met name cysteuze componenten in de tumor 
of tumornecrose. In de literatuur wordt een mogelijk verband gesuggereerd tussen goedaardige 
pinealiscysten en retinoblastoom, welke zich zouden kunnen ontwikkelen tot een pineoblastoom. 
De meeste pineoblastomen in onze studie zijn gedeeltelijk cysteus met een solide deel (29 
%) of helemaal cysteus (29 %). Goedaardige pinealiscysten treden op in 0.4% - 2.2% van 
de algehele pediatrische populatie overeenkomend met de incidentie van pinealiscysten in 
erfelijke retinoblastoom patiënten. Bij erfelijke retinoblastoompatiënten is het belangrijk om 
de cysteuze glandula pinealis die gebaseerd is op een pineoblastoom vroegtijdig te herkennen, 
zodat behandeling, gericht op curatie, zo vroeg mogelijk ingezet kan worden. Goedaardige 
pinealiscysten worden gedefinieerd als (1) de aanwezigheid van een vergrote glandula pinealis, 
(2) met een hypointens centraal gebied in vergelijking met witte stof op T1 gewogen beelden 
en isointens ten opzichte van liquor op T2 -gewogen beelden en (3) een dunne wand van 2 mm 
of minder met discrete en regelmatige randaankleuring na contrasttoediening. Ondanks deze 
criteria kunnen laesies in de glandula pinealis dilemma’s veroorzaken, vooral als de wand van de 
cyste onregelmatig verdikt is ( > 2 mm) of een fijn nodulair aspect heeft. In de toekomst is het van 
belang om prospectieve multicenter studies op te zetten om beeldvormende criteria te formuleren 
gericht op het identificeren van pineoblastoom in een vroeg stadium (mogelijk cysteus) en follow- 
up van verdachte pinealiscysten. In de tussentijd raden we aan om pinealiscysten in te delen in drie 
categorieën (1 - “waarschijnlijk goedaardige pinealiscyste” , 2 - “duidelijk cysteus pineoblastoom” 
, of 3 - “verdachte pinealiscyste”) met verschillende klinische benaderingen. Indien er duidelijk 
sprake is van een goedaardige pinealiscyste (categorie 1), dan raden wij aan de MRI na 6 maanden 
te herhalen. Indien de cyste stabiel blijft is er geen verdere follow-up beeldvorming noodzakelijk. 
In de derde categorie is echter strikte follow-up na drie maanden noodzakelijk. Screening van de 
glandula pinealis in retinoblastoom patiënten dient plaats te vinden middels een post-contrast 
3D T1 gewogen sequentie met 1 mm plakdikte. Als er tevens sprake is van een cysteuze laesie in 
de glandula pinealis, dan dient er additioneel een 2 mm T2 - gewogen sequentie of 3D T2/CISS 
sequentie uitgevoerd te worden om de laesie (met name de wand) te karakteriseren.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Summary in Dutch/Nederlandse samenvatting  |  141
Trilateraal retinoblastoom was dodelijk in vrijwel alle eerder gerapporteerde gevallen in 
de literatuur. Intensieve behandeling met hoge doses chemotherapie en stamceltransplantatie, 
eventueel in combinatie met chirurgie blijken potentieel curatief. Dit proefschrift toont aan dat 
als het TRB synchroon met retinoblastoom (hersentumor tegelijkertijd met de oogtumor) tijdens 
het eerste MRI-onderzoek vastgesteld wordt (baseline beeldvorming van de hersenen, BBI), de 
grootte aanzienlijk kleiner is dan metachrone (hersentumor vastgesteld na BBI) tumoren (18mm 
versus 35mm, P = 0.002). Patiënten met BBI hebben tevens minder symptomen en neigen tot 
een  betere prognose in vergelijking met TRB ontdekt na retinoblastoom diagnose (metachrone 
tumoren). In de ERIC richtlijn wordt geadviseerd om BBI bij iedere nieuw gediagnosticeerde 
retinoblastoom patiënt te verrichten. Hoewel in dit proefschrift de waarde van BBI wordt 
benadrukt, wordt standaard herhaaldelijke follow-up van de hersenen middels MRI bij erfelijk 
retinoblastoom patiënten niet aanbevolen. In een eerdere studie bleek screening namelijk te leiden 
tot een langere mediane overlevingstijd doordat de leeftijd van TRB detectie eerder was, terwijl 
de leeftijd van overlijden niet verschilde. Dit betekent dat het onderzoek leidde tot lead time 
bias en snellere behandeling, waardoor meer kans op ernstige behandelrisico’s en gerelateerde 
morbiditeit en stress bij kinderen.
Erfelijk retinoblastoom patiënten hebben een verhoogd risico op het ontstaan van tumoren 
elders in het lichaam. Deze zogenaamde tweede primaire tumoren (TPT) zijn verantwoordelijk 
voor een aanzienlijk deel van de sterfte van erfelijk retinoblastoom patiënten. Uitwendige 
bestraling geeft een verdere verhoging van het bestaande risico op botkanker en weke delen 
sarcomen. Daarvan ontwikkelt zich 70% in het hoofd en aangezicht; voormalig bestralingsveld 
voor de oogtumoren. Onze Europese studie toont aan dat craniofaciale tweede primaire tumoren 
in bestraalde retinoblastoom patiënten worden gediagnosticeerd op een mediane leeftijd van 
13 jaar (range 3-38 jaar). De mediane tijd tussen bestraling en ontwikkeling van SPT is 15 
jaar (range 3-37 ). Leeftijd van bestraling is een risicofactor voor de ontwikkeling van TPT 
in retinoblastoompatiënten. Patiënten bestraald tijdens hun eerste levensjaar ontwikkelen 
aanzienlijk meer TPT in vergelijking met bestraling na het eerste levensjaar. Dit zou deels 
verklaard kunnen worden door het feit dat erfelijk retinoblastoom patiënten hun ziekte op een 
jongere leeftijd ontwikkelen en dus eerder behandeld worden. TPT presenteren zich bij diagnose 
met de volgende klachten; plaatselijke zwelling (60 %), lokale pijn (14 %), hoofdpijn (19 %), 
epistaxis (7 %), persistente rhinorroe (5 %), niet-passend oculaire prothese (10 %), symptomen 
van intracraniale hypertensie (5 %) en ptosis (5%). Sommige van deze symptomen lijken 
onschuldig en aspecifiek, maar bij aanhoudende klachten kunnen deze symptomen duiden op een 
TPT. Wanneer TPT zich presenteren in een laat stadium van de ziekte met een grote tumormassa, 
is er vaak geen complete tumorresectie meer mogelijk wat de kans op uiteindelijke overleving 
verkleint. Histopathologische subtypen van TPT bestaan voornamelijk uit osteosarcomen en 
rhabdomyosarcomen (samen 64 % van alle craniofaciale tweede primaire tumoren bij bestraalde 
retinoblastoom patiënten) en in mindere mate leiomyosarcomen, ongedifferentieerde sarcomen, 
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meningiomen, en carcinomen. Voorkeurslokalisaties voor TPT in bestraalde retinoblastoom 
patiënten bestaan uit de ipsilateraal bestraalde orbita en fossa temporalis voor het osteosarcoom; 
en het ethmoid en fossa temporalis voor het rhabdomyosarcoom. De algehele prognose van 
bestraalde retinoblastoom patiënten met TPT in het craniofaciale gebied is over het algemeen 
slecht, ondanks intensieve behandeling op basis van chemotherapie en chirurgie. De prognose 
is afhankelijk van de haalbaarheid van een volledige microscopische tumor resectie van de TPT. 
Dit heeft een significant betere overall en event-free overleving in vergelijking met incomplete 
tumorresectie.
Klinische implicaties en toekomstperspectief
Selectieve toediening van chemotherapie aan het aangetaste oog (d.w.z. intra-arteriële en intra-
vitreale chemotherapie) leidt tot behoud van het oog en voorkomt enucleatie en bestraling 
in de meerderheid van de patiënten. Dit heeft als gevolg dat bijwerkingen door systemische 
intraveneuze chemotherapie en tevens late gevolgen van bestraling voorkomen worden. Deze 
conservatieve behandelingsstrategieën vereisen een nauwkeurige niet-invasieve evaluatie van het 
retinoblastoom voordat er gestart wordt met therapie voor verdere vervolg van de ziekte. Met 
behulp van functionele MRI-technieken kunnen ook parameters vastgesteld worden die de oogarts 
in een vroeg stadium kunnen helpen in het voorspellen van respons op conservatieve behandeling. 
Door middel van dynamische MRI kan niet-invasief de tumor angiogenese activiteit en necrose 
van de tumor in het oog geëvalueerd worden, wat respectievelijk beschouwd wordt als een 
risicofactor voor gedissemineerde ziekte en behandelrespons. In de toekomst kan deze techniek 
geoptimaliseerd worden door “pixel-by-pixel analyse” waarbij afzonderlijke gebieden van hoge 
vascularisatie en necrose in een tumor vastgesteld kan worden. Voordat de DMRI in de dagelijkse 
klinische praktijk kan worden toegepast, dienen toekomstige studies voor standaardisatie van 
analysemethoden te zorgen tussen retinoblastoom expertise centra.
Beeldvorming van morbiditeit
Bij elke retinoblastoom patiënt moeten de hersenen worden afgebeeld in het eerste MRI-
onderzoek, omdat de meeste trilaterale retinoblastomen worden vastgesteld bij BBI. Omdat 
kleine pineoblastomen zich als cysteuze laesies kunnen presenteren, is het belangrijk dat complexe 
cysteuze laesies in de pijnappelklier tijdig worden ontdekt. Indien de laesie een goedaardige 
pinealiscyste op MRI lijkt te zijn, dan wordt de MRI herhaald na 6 maanden en is er indien stabiel, 
geen verdere follow-up beeldvorming noodzakelijk. Indien er sprake is van een onregelmatig 
verdikte fijn nodulair aspect van de wand, dan is follow-up beeldvorming middels MRI na drie 
maanden aanbevolen. In de toekomst is multicentrisch onderzoek in een grote patiëntenpopulatie 
nodig om de voordelen van screening te evalueren.
De meeste voorkomende oorzaak waaraan retinoblastoom overlevenden sterven is de 
ontwikkeling van een tweede primaire tumor, vooral als de patiënt uitwendig is bestraald voor het 
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retinoblastoom. Het vaststellen van deze tumoren in een vroeg stadium is derhalve cruciaal. Een 
screeningsprogramma voor craniofaciale TPT in erfelijk retinoblastoom patiënten die aanvankelijk 
werden behandeld met bestraling kan gunstig zijn. In de toekomst is een multicentrische 
studie noodzakelijk om te evalueren of screening middels MRI op TPT in bestraalde erfelijke 
retinoblastoom overlevenden effectief is om vroegtijdige tumoren te ontdekken en met name of 
door het eerder vaststellen van de TPT de mortaliteit ook afneemt. Screening zou kunnen leiden 
tot angst, maar ook geruststelling. Een toekomstige studie zou zich daarom ook moeten richten 
op psychische belasting.
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DANKWOORD
Heerlijk, het is zover! De periode dat ik aan dit proefschrift heb gewerkt, eindigt met dit 
dankwoord. Zonder de betrokkenheid van velen was dit proefschrift niet tot stand gekomen. Ik 
wil daarom graag op deze manier iedereen bedanken die direct of indirect heeft bijgedragen aan 
mijn onderzoek. 
Allereerst wil ik mijn bewondering uitspreken voor alle kinderen met retinoblastoom en hun 
ouders die samen zo ongelofelijk dapper omgaan met deze ziekte en de MRI onderzoeken onder 
narcose ondergaan. Respect hiervoor!
Mijn promotoren Prof. dr. J.A. Castelijns en Prof. dr. A. C. Moll en co-promotor dr. P. de Graaf 
wil ik graag bedanken voor hun begeleiding in alle fasen van het onderzoek. In de praktijk bleek 
de combinatie van jullie kwaliteiten goed te werken.
Beste Jonas. Bedankt voor de geboden ruimte en het vertrouwen dat je mij gaf om als onderzoeker 
onder jouw begeleiding te promoveren en het inmiddels succesvolle Europese retinoblastoom-
netwerk (ERIC) te coördineren. Hieruit zijn een aantal mooie multicentrische studies 
voortgevloeid. Het begon tijdens mijn wetenschappelijke stage waarbij jij veel tijd en energie 
hebt geïnvesteerd in het mij wegwijs maken in de wereld van de hoofdhals MRI. Dit heeft mijn 
enthousiasme aangewakkerd om meer onderzoek te doen onder jouw supervisie. Met name je 
persoonlijke begeleiding en betrokkenheid heb ik zeer gewaardeerd. Jouw deur stond altijd open 
voor overleg. Tijdens mijn promotie heb ik een grote persoonlijke tegenslag moeten verwerken. 
Hierbij kon ik voor 100% op jou rekenen. Ik zal jou hiervoor altijd dankbaar blijven!
Beste Annette. Dank voor de regelmatige gesprekken over mijn onderzoek, waarbij jouw blik 
vanuit de kliniek een verrijking was. Hierdoor is de inhoud van mijn proefschrift enorm verbeterd. 
Als je promoveert binnen een vakgebied waarin met name naar beelden wordt gekeken, dan 
schuilt het gevaar om het contact met patiënten te verliezen. Ik vond het fijn dat je mij de 
mogelijkheid gaf om met het retinoblastoomspreekuur mee te lopen om zo een goede indruk te 
krijgen van de impact die deze ziekte heeft. Fijn dat je mijn tweede promotor bent geworden!
Beste Pim, ik ben jou heel veel dank verschuldigd voor de tijd en energie die je hebt gestoken 
in dit proefschrift, ondanks je drukke werkzaamheden (afronding promotie, ERIC, opleiding 
tot radioloog, begeleiding promovendi, gezin). Ik heb hier veel bewondering voor! Jij tilde elk 
artikel naar een hoger niveau door jouw zeer kritische en verhelderende feedback. Op inhoudelijk 
vlak kon ik mij geen betere begeleider wensen. En zonder jou was dit proefschrift er zeker niet 
geweest! Het onderzoek naar beeldvorming van retinoblastoom is bij jou in zeer goede handen.
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The members of the European retinoblastoma imaging collaboration, dr. H. Brisse, dr. P. 
Galluzzi, dr. P. Maeder and dr. S. Göricke, thank you for your co-operation in the “marathon” 
MRI examination sessions. This collaboration resulted in some great articles. I was very grateful 
for your hospitality and the opportunity to visit your hospital for data collection and I enjoyed 
your company during the ERIC dinners! 
Ik wil alle co-auteurs bedanken voor hun onmiskenbare bijdrage op verschillende gebieden.
I would like to express special thanks to dr. Brisse. Dear Hervé. I really enjoyed working with 
you. Thank you for your always quick and constructive feedback regarding our European studies. 
It is an honour that you agreed to join the reading committee. I loved to visit your beautiful Paris!
Dr. P.J.W. Pouwels, beste Petra, dank voor je intensieve begeleiding en hulp bij het testen, 
implementeren en analyseren van data m.b.t. de dynamische MRI studie. Zonder jouw duidelijke 
uitleg en bereidheid om dit enkele keren te herhalen, was ik waarschijnlijk verdronken in deze 
materie. Je was mijn rots in de branding! 
Dr. D. L. Knol, beste Dirk, voor de statistiek van mijn onderzoeken kon ik volledig op jou 
bouwen. Dank voor de heldere uitleg en de tijd die je voor mij uitgetrokken hebt. 
Prof. dr. P van der Valk, beste Paul, dank dat je ondanks jouw drukke agenda altijd wel tijd 
kon vrijmaken voor het tijdrovende werk van het vinden (!) en daarna het beoordelen van alle 
histopathologische coupes voor de MRI/CT- PA correlatiestudies. 
Prof. dr. S. Imhof, beste Saskia, ik voel mij vereerd dat jij deel wilt uitmaken van mijn 
leescommissie. Ondanks het feit dat we slechts kort met elkaar hebben samengewerkt, voordat jij 
hoogleraar werd in Utrecht, heb ik onze samenwerking altijd erg prettig gevonden. Dank voor je 
enthousiasme en deskundigheid!
Drs. E. Sanchez en drs. J.I.L.M. Verbeke, beste Ester en Jonathan. Dank dat jullie bereid waren 
om de vele MRI beelden te beoordelen. Dankzij jullie was dit gezellig en leerzaam. 
De betrokken verpleegkundigen, artsen en onderzoekers van het multidisciplinaire retinoblastoom 
team van het VUmc wil ik bedanken voor hun samenwerking en gezelligheid tijdens mijn 
promotietraject. Jennifer en Tamara, dank jullie wel voor de fijne gesprekken waarbij we het wel 
en wee van onderzoek doen met elkaar konden delen. 
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Graag wil ik de leden van de leescommissie bedanken voor het zorgvuldig lezen van mijn 
proefschrift en de bereidheid om hierover van gedachten te wisselen tijdens de verdediging: mw. 
prof. dr. S. M. Imhof, prof. dr. F. Barkhof, dr. H. Brisse, prof dr. P. van der Valk, prof. dr. G. J. L. 
Kaspers en prof. dr. G. P. M. Luyten.
Mijn ex-kamergenoten Iris Kilsdonk en Wolter de Graaf wil ik bedanken voor de ontzettend 
gezellige tijd waarin we veel lief en leed hebben gedeeld. Iris, dank voor alle momenten dat ik me 
kapot heb gelachen met jou en ook voor je steun tijdens de moeilijke periodes. Aan deze promotie 
heb ik een goede vriendin overgehouden en ik zou dan ook niemand anders als paranimf naast 
mij willen op deze belangrijke dag! Ik ben blij dat jij je plek hebt gevonden bij de radiologie. 
Met jouw skills wordt je een fantastische radioloog en wetenschapper. Wolter, dank dat jij als een 
soort redder in nood altijd klaar stond om mij uit de brand te helpen (met name de computer-
problemen en de muizen…!). Fijn dat je inmiddels je plek hebt gevonden.
Maja en Milou wil ik danken voor de koffiemomenten waarbij de belangrijkste actualiteiten de 
revu passeerden. Jammer dat deze intervisiemomenten nu schaars zijn geworden, maar we gaan 
hier zeker verandering in brengen als we zometeen alle 3 gepromoveerd zijn.
Martijn, jou wil ik in het bijzonder bedanken voor het prachtige coverdesign van mijn boekje! En 
dit was slechts een van de vele momenten waarop je mij en ook anderen geholpen hebt. Tijdens 
mijn promotie kwam ik regelmatig buurten in de kamer die jij deelde met Gijs en Veronica. 
Jullie waren een hilarisch trio!
Alle mede-onderzoekers van verschillende afdelingen wil ik bedanken voor hun collegialiteit: 
Veronica, Gijs, Oliver, Bastiaan, Ivo, Stefan, Jasper, Marieke, Marcus en Daan. In het bijzonder 
Marloes, mijn beste studiemaatje!
De ondersteuning van de secretaresses was goud waard. Sandra, Angelique, Karlijn, Letty, Regina 
en Lydia, dank jullie wel!
Bij het opzetten van multicentrische studies, waarbij veel data verstuurd en opgeslagen moet 
worden, is de ICT essentieel! Dennis en Freek, dank dat jullie hierbij een belangrijke rol hebben 
gespeeld.
Hesdy zonder jou had ik geen enkele MRI kunnen beoordelen of een letter digitaal “op papier” 
kunnen krijgen, aangezien mijn computer op de een of andere manier regelmatig crashte. Bedankt 
dat je hier altijd een oplossing voor wist te vinden. Kees, dank voor je ondersteuning hierbij ;).
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Van het ene warme bad naar het andere. Ik wil graag al mijn collega arts-assistenten en specialisten 
van het Slotervaartziekenhuis bedanken voor de gezelligheid en collegialiteit die ik tot op de dag 
van vandaag enorm waardeer. Prof. Dr. D. Brandjes en dr. J. W. Mulder, dank voor de kans die 
ik heb gekregen om in opleiding tot internist te komen. Ik voel me helemaal op mijn plek bij de 
interne geneeskunde!
Lieve vrienden en (schoon)familie, dank voor jullie interesse in mijn onderzoek en alle gezelligheid 
naast het harde werken!
Mijn broer en zusjes wil ik bedanken voor het feit dat we altijd op elkaar kunnen rekenen. 
Als het er echt op aankomt, dan staan we voor elkaar klaar. Ashwad, fijn dat jij door je rust en 
kalmte vaak de relativerende factor bent in ons kippenhok. Soheilah, dank voor jouw eeuwige 
enthousiasme en gezelligheid. Ik ben blij dat jij mijn paranimf bent. Zonder jou zou ik hier niet 
rustig kunnen staan. Faaïzah, ik bewonder jouw standvastigheid en idealen. Onze gesprekken 
zijn altijd erg motiverend voor mij geweest. Mijn baby-zusje Sadia, ik ben trots op de vrouw die 
jij geworden bent! Dank dat je ons gezinnetje het afgelopen jaar geholpen hebt om de ballen in 
de lucht te houden waardoor het mede mogelijk is geworden dit proefschrift af te ronden.
Mijn nanie (oma) wil ik bedanken voor het feit dat haar deur altijd voor ons open staat. De weg 
naar Zwolle weten we ook zeker te vinden!
Dan de twee grootste liefdes in mijn leven (de echte mannen!). Daniël Jorna, mijn allerliefste 
Ziaul, jij staat altijd voor mij klaar en geeft mij de kans om mijn dromen te realiseren. Ik had dit 
nooit voor elkaar kunnen krijgen zonder jouw onbeperkte liefde, steun en geduld. Met jou aan 
mijn zijde weet ik dat ik de hele wereld aan kan. Ik hou van jou! 
Lieve Kamiel, hemaar baby, jij bent het allermooiste wat me ooit is overkomen! Mijn grootste 
motivatie om dit boekje af te ronden, ben jij. Met jouw lachebekkie sleep jij me door alle moeilijke 
momenten heen en breng jij ongelofelijk veel blijdschap in mijn leven. 
Tenslotte wil ik mijn moeder bedanken. Helaas ben je niet meer bij ons, een gemis wat ik nog 
steeds elke dag voel. Alles wat ik in mijn leven bereikt heb, komt door jouw onvoorwaardelijke 
liefde, vertrouwen en de kansen die jij voor mij gecreëerd hebt! Mama, dit proefschrift draag ik 
op aan jou.
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